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Schizophrenia is a chronic psychotic illness affecting ~21 million people globally. Currently 
available antipsychotic agents act through a dopamine D2 receptor mechanism, and produce 
extrapyramidal or metabolic side effects. Hence, there is a need for novel targets and agents. 
The mGlu2/5-HT2A receptor heteromer has been implicated in the action of antipsychotic 
agents, and represents a novel and attractive therapeutic target for the treatment of 
  
schizophrenia. A long-term goal of this project is to synthesize bivalent ligands where a 5-
HT2A receptor antagonist is tethered to an mGlu2 PAM via a linker. 
 
The goals of the investigation were to study the SAR of risperidone (an atypical 
antipsychotic agent) at 5-HT2A receptors using a “deconstruction-reconstruction-
elaboration” approach to determine the minimal structural features of risperidone that 
contribute to its 5-HT2A receptor affinity and antagonism, and to determine where on the 
“minimized risperidone” structure an mGlu2 PAM can be introduced. Additional goals 
included studying the binding modes of various mGlu2 PAMs and identifying where on an 
mGlu2 PAM a risperidone “partial” structure could be introduced. 
 
Biological studies of deconstructed/elaborated analogs of risperidone suggest that the entire 
structure of risperidone is not necessary for 5-HT2A receptor affinity and antagonism, and 
that a fluoro group contributes to 5-HT2A binding. 6-Fluoro-3-(4-piperidinyl)-1,2-
benz[d]isoxazole that has only half the structural features of risperidone retains 5-HT2A 
receptor affinity and antagonist activity, and represents the “minimized risperidone” 
structure with the piperidine nitrogen atom representing a potential linker site for eventual 
construction of bivalent ligands. Molecular modeling studies at 5-HT2A receptors suggest 
that risperidone and its analogs have more than one binding mode.  
 
Modeling studies to evaluate binding modes of various PAMs at mGlu2 receptors, coupled 
with known SAR information, were used to identify a PAM (JNJ-40411813), and the 
  
pyridone nitrogen atom of JNJ-40411813 as a potential linker site. Additionally, potential 
synthetic routes for JNJ-40411813 were explored that might be of value in the synthesis of 
bivalent ligands. 
 
Based on the structural features of 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole, a new 
pharmacophore for 5-HT2A receptor antagonists, consisting of one aromatic region, a basic 
protonated amine and hydrogen bond acceptors, has been proposed. 
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I. INTRODUCTION 
 
 
 
 
Schizophrenia is a chronic, recurring psychotic illness with an enigmatic etiology that remains a 
significant health problem and affects ~1% of the global population.1,2 There is emerging evidence 
to show that schizophrenia might be a part of a larger group of disorders called “schizophrenia 
spectrum disorder” that is prevalent in ~6% of the general population.1,2 The clinical symptoms of 
schizophrenia can be classified into positive symptoms such as hallucinations and delusions, 
negative symptoms that include anhedonia and apathy, and cognitive deficits that are related to 
working memory, and attention.1,3,4 
 
Several hypotheses have been proposed to link altered brain function and schizophrenia and there 
could be abnormalities in dopamine (DA), serotonin (5-HT), glutamate (GLU), γ-aminobutyric 
acid (GABA), and acetylcholine (ACh) receptor pathways.4–6 However, most clinically available 
antipsychotic agents act through a dopamine D2 receptor mechanism.
7 
 
The introduction of chlorpromazine (a “typical” antipsychotic agent) in 1952 marked a new era of 
drug treatment in psychiatry.8,9 Chlorpromazine is a dopamine D2 receptor antagonist that is 
effective against the positive symptoms of schizophrenia;10 however, extrapyramidal symptoms 
(EPS) are a common side effect of chlorpromazine therapy.11
  2 
 
The introduction of clozapine in 1990 was a hallmark in antipsychotic therapy.12 Clozapine can 
ameliorate both the positive and negative attributes of schizophrenia with a lower propensity to 
cause EPS.12 The introduction of clozapine led to the development of the concept of “atypical” 
antipsychotics, and its clinical success prompted the development of other atypical antipsychotic 
agents such as risperidone.13  
 
Risperidone is effective in treating the positive and negative symptoms of schizophrenia and has 
a lower propensity to cause EPS.14 It is a dopamine D2 receptor (Ki = 3.1 nM) and 5-HT2A receptor 
(Ki = 0.16 nM) antagonist.
15 Moderate D2 receptor occupancy, and  predominantly 5-HT2A receptor 
occupancy, might be the mechanism for its effectiveness against the positive, and negative 
symptoms of schizophrenia, with reduced side effects.14 Even though risperidone has a much lower 
tendency to cause EPS than typical antipsychotic agents, therapy with risperidone is associated 
with other side effects such as hyperprolactinemia, and weight gain.13,16,17  
 
Nearly all currently available antipsychotic agents act through a dopamine D2 receptor mechanism, 
and cause either extrapyramidal or metabolic side effects.7 Hence, there is a pressing need for 
novel therapeutic targets and agents.  
 
 Literature precedent exists for the formation of a functional 5-HT2A/mGlu2 receptor 
heterocomplex18–21 that has been implicated in the mechanism of action of antipsychotic agents.22 
Roles for the 5-HT2A receptor and the mGlu2 receptor in the pathophysiology of schizophrenia 
  3 
have been well established.14,23 5-HT2A receptor antagonists/inverse agonists, and mGlu2 receptor 
orthosteric agonists and PAMs, possess antipsychotic character.14,23 The atypical antipsychotic 
agent risperidone has been shown to mediate its effects by binding to the 5-HT2A/mGlu2 receptor 
heteromer which then balances Gi/o and Gq/11 signaling.
22 Gonzalez-Maeso et al.18 have shown that 
the 5-HT2A receptor is upregulated and the mGlu2 receptor is downregulated in postmortem brain 
samples of untreated schizophrenic patients. These changes suggest that the 5-HT2A/mGlu2 
receptor heteromer may be involved in the altered cortical processes in schizophrenia, and 
represents an attractive novel therapeutic target for the treatment of schizophrenia.18 A long-term 
goal of the project is to synthesize bivalent ligands having a 5-HT2A receptor antagonist portion 
based on a risperidone scaffold connected to an mGlu2 receptor PAM via a linker.  
 
Goals of the current investigation are to study structure activity relationships of risperidone at 5-
HT2A receptors to determine the minimal structural features required for risperidone to retain 5-
HT2A receptor affinity and antagonist activity, and to identify where on the risperidone “partial 
structure” an mGlu2 receptor PAM might be attached. Additional goals include studying the 
binding modes of various PAMs at the mGlu2 receptor and identifying a PAM as well as a potential 
site to install the “minimized” risperidone structure that will contribute towards the long-term goal 
of synthesizing a bivalent molecule that can target the mGlu2/5-HT2A receptor heteromeric 
complex. 
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II. BACKGROUND 
 
 
 
 
1. Schizophrenia 
Schizophrenia is a chronic, recurring psychotic illness that remains a significant health problem 
affecting more than 21 million people worldwide are affected by schizophrenia,1,2,24 and the Global 
Burden of Disease study has ranked schizophrenia as the ninth leading cause of disability-adjusted 
life-years for those aged 15-44.8 There is emerging evidence to show that schizophrenia might be 
a part of a larger group of disorders called “schizophrenia spectrum disorder” that is prevalent in 
~6% of the general population.1 These disorders are related to each other in terms of 
pathophysiology, cognitive characteristics, symptom expression, and genetics, with schizophrenia 
being the most severe of the class.1  
 
The concept of schizophrenia as a disease is of recent origin and has been grouped with conditions 
such as mania, melancholia and generic “insanity” since ancient times.8,25 During the 19th century 
Kraeplin, as reviewed by Jablensky,25 first used the term “dementia praecox’ to describe the illness. 
Bleuler, as reviewed by Kuhn and Cahn,26 subsequently changed the name from dementia to 
schizophrenia and provided the disease with a distinct diagnostic profile. The word schizophrenia 
has Greek origins and translates as “splitting of the mind” (shizein = splitting; phren = soul, spirit, 
mind).26 
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The diagnosis of schizophrenia is solely based on the presentation of clinical symptoms that can 
be classified into positive and negative symptoms, and cognitive deficits.1,3,4 The positive 
symptoms include delusions (persecutory, referential, somatic, nihilistic, and grandiose delusions), 
hallucinations, reality distortion, paranoia, disorganized speech and grossly disorganized or 
catatonic behavior.1,3,4 The negative attributes include anhedonia, asociality, alogia, avolition, 
inappropriate social skills, and affective flattening.1,3,4 Cognitive deficits that are sometimes 
classified as a part of the negative symptoms are related to working memory, executive functions, 
and attention.1,3,4 There can also be neurophysiological disturbances such as abnormal smooth 
pursuit and saccadic eye movements and abnormal evoked potentials (P300, P50) in patients with 
schizophrenia.1 Various modifications have been made to the diagnosis of schizophrenia over the 
years and the current diagnosis of schizophrenia is based on the criteria of the Diagnostic and 
Statistical Manual for Mental Disorders, fifth edition (DSM-5)27 or of the older International 
Classification of Diseases, tenth addition (ICD-10),28 published by the American Psychiatric 
Association and the World Health Organization, respectively.  
 
Schizophrenia is a neurodevelopmental rather than a neurodegenerative disorder and an interplay 
between several environmental factors such as substance abuse, trauma, and pre- or perinatal 
stressors, developmental factors, and genetic factors (where a risk for schizophrenia is inherited) 
contribute to the development of schizophrenia.1,29 There is altered brain function and structure in 
schizophrenia, and patients with schizophrenia show enlarged cerebral ventricles, a 5% reduction 
in the size of the medial temporal cortex, decreased volume of the superior temporal gyrus, and 
  6 
hippocampal shape irregularities.1 Cerebral cortical atrophy is a hallmark feature of 
schizophrenia.1,5 Proper functionality of connections between the different spatially-distributed 
brain regions is important for higher- order brain function and changes throughout the connected 
neural networks rather than damage to a single brain area that might result in schizophrenia.8 At 
the neurotransmitter level, there could be abnormalities in dopamine (DA), serotonin (5-HT), 
glutamate (GLU), γ-aminobutyric acid (GABA), and acetylcholine (ACh) receptor pathways.4–6 
Several hypotheses have been proposed to link altered brain function and schizophrenia. 
 
2. Theories of schizophrenia 
a. The dopamine (DA) hypothesis of schizophrenia 
DA (1) (Figure 1) functions as a neurotransmitter in the brain and plays an important role in 
maintaining normal physiological function.30 DA’s effects are mediated via G-protein coupled DA 
receptors (D1-D5).
30 The physiological functions of  DA include, but are not limited to, sleep 
regulation, affect, cognitive function, attention, voluntary movement, reward, feeding, and 
hormonal regulation.30 The DA hypothesis is central to the pathophysiology of schizophrenia and 
has undergone refinement and modification over the years.31 The initial DA hypothesis was 
formulated on the basis of the observed antipsychotic effects of drugs such as chlorpromazine 
(CPZ) (2) (Figure 1) that act as DA receptor blockers (i.e.; antagonists).31 The ability of 
psychostimulants such as amphetamine (3) (Figure 1) to induce psychosis by increasing the 
synaptic concentrations of monoamine neurotransmitters,32 and the effectiveness of the indole 
alkaloid reserpine (4) (Figure 1) in treating psychosis by blocking the reuptake of DA and other 
monoamine neurotransmitters by irreversibly blocking the vesicular monoamine transporters,33 
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provided further evidence for the DA hypothesis of schizophrenia. In the 1970s it was realized that 
the effectiveness of clinical antipsychotics such as CPZ (2) and haloperidol (5) (Figure 1) was 
related to their affinity for the D2 dopamine receptor.
10,31,34 The “first” version of the DA hypothesis 
assumed a general dopaminergic hyperfunction.31 A major drawback of the initial DA hypothesis 
was that it focused on blockade of DA receptors to treat psychosis, but there was no relation 
between abnormal dopaminergic activity and expression of positive and negative symptoms, and 
little was known about where the abnormality occurred in the brain.31 The hypothesis was also 
unable to explain the inability of  antipsychotics to treat the negative symptoms and cognitive 
deficits of schizophrenia.31  
 
 
Figure 1. Structures of the neurotransmitter dopamine (DA) (1), the typical antipsychotic agents 
chlorpromazine (CPZ) (2), and haloperidol (5), the psychostimulant amphetamine (3), and the 
indole alkaloid reserpine (4). 
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In 1991, a “modified hypothesis of schizophrenia” was proposed by Davis et al.35 They 
hypothesized that there is hyperdopaminergia in the subcortical DA pathway that is responsible 
for the positive attributes of schizophrenia, and hypodopaminergia in the prefrontal cortex that 
accounts for the negative attributes of schizophrenia. They also proposed that the excessive 
dopaminergic activity in the mesolimbic region might be a result of low dopaminergic activity in 
the prefrontal cortex.35  
 
Based on the availability of newer evidence, Howes et al.31 further modified the DA hypothesis. 
They postulated that the DA hypothesis has four distinct components that are as follows: 1. 
Psychosis in schizophrenia is the result of DA dysregulation due to the interaction of “multiple 
hits” such as stress, genes, drugs and fronto-temporal dysfunction. 2. DA dysfunction is at the 
presynaptic control level rather than at the D2 receptor level. 3. The DA hypothesis does not explain 
all facets of schizophrenia; rather, it explains the “psychosis” associated with schizophrenia.31 4. 
Dysregulation of the dopaminergic system may lead to an altered appraisal of stimuli by a process 
of aberrant salience.31,36 
 
The DA model of schizophrenia has been a leading hypothesis, and the role of dopamine in the 
pathophysiology of schizophrenia is well established.37,38 However, D2 receptor antagonism alone 
did not seem to be addressing the core pathophysiology of schizophrenia, since typical 
antipsychotic agents were unable to alleviate the negative and cognitive symptoms of 
schizophrenia.37,38 A dysfunction of multiple neural networks and transmitter systems might be 
responsible for the negative symptoms and cognitive deficits in patients with schizophrenia.37,38 
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The DA hypothesis addressed a more downstream effect and did not account for the 
neurocognitive deficits and, the wide range of symptoms, thus eliciting a need for newer 
hypotheses.37,38 
 
b. The serotonin (5-HT) hypothesis of schizophrenia 
Serotonin or 5-hydroxytryptamine (5-HT; 6) (Figure 2) is a monoamine neurotransmitter that is 
essential for maintaining normal brain function.39 5-HT receptors are classified into seven main 
classes that are further divided into subtypes.39 The 5-HT1, 5-HT2, and 5-HT4-7 receptors are G-
protein coupled receptors (GPCRs) whereas the 5-HT3 receptor is a ligand-gated ion channel 
receptor.39 Lysergic acid diethylamide (LSD; 7) (Figure 2), a hallucinogenic agent, is structurally 
similar to 5-HT (6), was found to produce symptoms that resembled the psychotic symptoms of 
schizophrenia.40 The hallucinogenic effects of  LSD (7) were thought to be a result of its ability to 
antagonize 5-HT in the CNS and the initial 5-HT hypothesis of schizophrenia attributed the 
symptoms of schizophrenia to a 5-HT deficit in the CNS.40 It was soon realized that LSD (7) could 
not only antagonize but also mimic the effects of 5-HT41 and the hypothesis was revised such that 
a surplus or deficit of 5-HT could be responsible for the psychosis associated with 
schizophrenia.42,43 
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Figure 2. Structures of the monoamine neurotransmitter serotonin (5-HT; 6), the hallucinogenic 
agent lysergic acid diethylamide (LSD; 7), and the atypical antipsychotic agent clozapine (8). 
 
 
The focus of schizophrenia research shifted to the DA hypothesis of schizophrenia with the 
discovery that neuroleptics (i.e., antipsychotic agents) such as CPZ (2), with DA blocking 
properties, were effective antipsychotic agents. The 5-HT hypothesis of schizophrenia took a back 
seat and it was only with the discovery of the ability of atypical antipsychotic agents such as 
clozapine (8) (Figure 2) to block certain subtypes of the 5-HT receptors, that attention was 
refocused on the role of 5-HT in schizophrenia and resulted in a mixed 5-HT/DA hypothesis of 
schizophrenia.44 
 
Per the current 5-HT hypothesis of schizophrenia there is a stress-induced serotonergic overdrive 
coming from the dorsal raphe nucleus that can disrupt cortical neuronal function in schizophrenia. 
This, along with the hyperactivity of 5-HT in the cerebral cortex (mainly in the anterior cingulate 
cortex and the dorsolateral frontal lobe), is the upstream cause of schizophrenia.5 
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Among the 5-HT receptors, the 5-HT2 (5-HT2A) receptor has been suggested to be most important 
for the efficacy of antipsychotic agents.45 The 5-HT2A receptor is widely distributed in many 
regions of the brain such as the cerebral cortex and the nucleus accumbens, with high density in 
the frontal cortex.10,43 Activation of  5-HT2A receptors in the prefrontal cortex can lead to an 
increase in the release of glutamate that is indicated by the enhanced spontaneous excitatory 
postsynaptic potentials/currents in layer V pyramidal cells, an effect that can be blocked by α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptor 
agonists and by group II/III metabotropic glutamate receptor agonists.10,43,46,47 Hence, the 5-HT 
hypothesis by itself cannot explain the symptoms of schizophrenia and a number of other 
hypotheses have been postulated, one of which was the glutamate hypothesis of schizophrenia 
 
c. The glutamate (GLU) hypothesis of schizophrenia 
GLU (9) (Figure 3) is an amino acid that is the most abundant and primary excitatory 
neurotransmitter in the brain and accounts for ~40% of neurons and ~60% of synapses in the 
brain.48,49 Almost all cortical pyramidal neurons use GLU as the primary excitatory 
neurotransmitter.48 Glutamatergic neurotransmission is modulated via two main types of receptors: 
the ligand-gated ion channel receptors that include N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, and the G-protein 
coupled metabotropic glutamate receptors that are divided into 3 groups (I-III) and eight 
subtypes.50 The similarity between the psychosis induced by dissociative anesthetics such as 
phencyclidine (10) and ketamine (11) (Figure 3) and the psychotic syndrome associated with 
schizophrenia has been appreciated since the introduction of these agents in the early 1960s. 51,52 
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Based on the knowledge that dissociative anesthetics are non-competitive NMDA receptor 
antagonists, and the emerging pharmacology of the NMDA receptor, it was proposed that 
schizophrenia might result from a hypofunction of NMDA receptors.38,51,53 
 
 
Figure 3. Structures of glutamate (GLU) (9) and the dissociative anesthetics: phencyclidine (10) 
and ketamine (11). 
 
The glutamate hypofunction hypothesis suggested that the positive or psychotic symptoms of 
schizophrenia might be linked to excessive release of DA from neurons in the mesolimbic pathway 
due to an abnormal functioning of the GLU-GABA-GLU-DA circuit. (Figure 4) The defective and 
hypofunctioning NMDA receptors do not receive adequate stimuli form the primary GLU neuron 
resulting in a loss of GABA output to the secondary GLU neuron leading to excessive firing of the 
neuron and an ultimate excess of DA in the mesolimbic pathway.54 
  13 
 
Figure 4. NMDA receptor hypofunction hypothesis for the positive symptoms of schizophrenia 
(adapted from Schwartz et al.54). 
 
The negative and cognitive symptoms of schizophrenia can be attributed to the malfunctioning of 
another GLU neurocircuit (GLU-GABA-GLU-GABA-DA neuronal circuit) leading to insufficient 
release of DA in the mesocortical region (Figure 5).37,54 Hypofunction of the NMDA receptor on 
the GABA interneuron may lead to an increased tone of the secondary GLU neuron and an 
increased firing of the GABAergic interneuron in the ventral tegmental area resulting in an 
inadequate release of DA by the dopaminergic neurons in the mesocortical DA pathway.37,55  
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Figure 5. NMDA receptor hypofunction hypothesis for the negative and cognitive symptoms of 
schizophrenia (adapted from Schwartz et al.54). 
 
 
Direct NMDA receptor agonists or metabotropic glutamate receptor type 2/3 (mGlu2/3) agonists or 
PAMs of mGlu2 could be therapeutically useful in patients with schizophrenia, and some of these 
agents have advanced into clinical trials.54 mGlu2/3 receptors are autoreceptors located on the 
secondary GLU neuron.54 Activation of these receptors with mGlu2/3 receptor agonists or mGlu2 
receptor PAMs would lead to a decrease in firing of the overactivated GLU neuron resulting in 
modulation of DA release and an amelioration of the positive, negative and cognitive symptoms 
of schizophrenia.54  
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5-HT (5-HT1A and 5-HT2A) receptors are widely distributed in the prefrontal cortex and can 
regulate NMDA receptor activity, and a change in 5-HT signaling in the prefrontal cortex could 
alter NMDA receptor activity and also contribute to the cognitive and negative symptoms of 
schizophrenia.37,56  
 
The GLU hypofunction hypothesis of schizophrenia looks at more upstream effects that ultimately 
leads to a final common pathway culminating in the release of DA. GLU- manipulating agents 
may prove to be therapeutically useful in treating both the positive, negative and cognitive 
symptoms of schizophrenia.54 
 
d. The GABA hypothesis of schizophrenia 
GABA (12) (Figure 6) is an inhibitory neurotransmitter in the central nervous system and plays 
an important role in reducing neuronal excitability. 
 
 
Figure 6. Structure of the inhibitory neurotransmitter GABA (12). 
 
GABAergic neurons play a crucial role in maturation of neural circuitry during the postnatal 
period, and impaired maturation of the GABAergic neurons could result in psychiatric disorders 
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such as schizophrenia.29 Additionally, the GABAergic interneurons are important for maintaining 
proper cortical functioning29 as well as supporting cortical functions that include maintaining a 
balance between excitation and inhibition,57 and proper synaptic inhibition at dendrites and 
somata.58 The imbalance between excitation and inhibition in the cerebral cortex due to 
GABAergic dysfunction might lead to increased sub-cortical DA and underlie a part of the 
pathophysiology of schizophrenia.29,59 
 
e. The cholinergic hypothesis of schizophrenia 
The nicotinic and muscarinic cholinergic systems interact with one other as well as other 
neurotransmitter systems such as GABA, GLU and DA in a complex and bi-directional manner.6 
The cholinergic system is important for maintaining normal dopaminergic tone in the cortex and 
striatum.60  The glutamatergic neurons in the mesolimbic and mesocortical dopaminergic pathways 
have alpha 7 nicotinic receptors located on them.60 Activation of the alpha 7 nicotinic receptors 
(by alpha 7 receptor agonists and PAMs61) on hypofunctional glutamatergic neurons can alleviate 
the positive, negative symptoms, and the cognitive deficits of schizophrenia by normalizing 
dopaminergic tone in the cortex and striatum.60 The muscarinic agents can have antipsychotic 
effects via both direct muscarinic effects (pro-cognitive effects) and by modulating the 
dopaminergic system (effects on the positive symptoms of schizophrenia).6 M1 and M4 muscarinic 
cholinergic agonists might be therapeutically useful in schizophrenia.6,62 
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f. The adenosine hypothesis of schizophrenia 
Adenosine (13) (Figure 7) is a homeostatic bioenergetic network modulator and affects brain DA 
and GLU activities.63,64  
 
Figure 7. Structure of the bioenergetic network modulator adenosine (13). 
 
Adenosine (13) is relevant to the etiology of schizophrenia because it is not only important for 
regulation of immune responses but also for early brain development. The adenosine hypothesis 
suggests that a dysfunction of the purinergic system, resulting in reduced adenosinergic activity, 
might be responsible for the dysfunctioning of multiple neurotransmitter systems that are 
associated with schizophrenia. Adenosine (13) can be controlled and rebalanced in multiple ways 
to modulate brain function and restore the homeostatic bioenergetic network balance. Some of the 
targets include enzymes such as adenosine kinase and transporters that control the tone of 
adenosine levels.64 
 
g. The α-adrenoceptor hypothesis of schizophrenia 
α1-, α2-Adrenoceptor blockade might contribute to the antipsychotic efficacy of atypical agents 
such as clozapine (8) (Figure 2).65 α1-Adrenoceptor blockade leads to a reduction of striatal DA 
and a reduction in the positive symptoms of schizophrenia. α2-Adrenoceptor blockade can 
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ameliorate the negative and cognitive symptoms of schizophrenia by improving prefrontal 
dopaminergic functioning.66  
 
The ability of the atypical antipsychotics such as clozapine (8) and risperidone (14) (Figure 8)  to 
antagonize α2- adrenoceptors might be important for their superior clinical profiles.66,67 
 
Figure 8. Structure of the atypical antipsychotic agent risperidone (14). 
 
g. The cannabinoid hypothesis of schizophrenia 
The relationship between the use of cannabinoids and schizophrenia is complex and not completely 
understood. It has been proposed that hyperactivity of the central cannabinoid system might be 
involved in the pathogenesis of schizophrenia and that the endogenous cannabinoid system could 
represent a novel therapeutic target for the treatment of schizophrenia.68,69 The CB1 receptor 
system and the dopaminergic system interact in a complex manner and studies have suggested that 
cannabidiol (15) (Figure 9) ( a CB1 and CB2 receptor antagonist) and SR141716 (16) (Figure 9)  
(a selective CB1 receptor antagonist), have a pharmacological profile similar to that of atypical 
antipsychotic agents.68,70 The antipsychotic agent-like profile of cannabidiol might also be due to 
its actions at other targets. 
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Figure 9. Structures of cannabidiol (15) and SR141716 (16). 
 
2. Antipsychotic agents 
a. History 
Psychiatric states have been associated with specific areas of the cerebral cortex since the late 19th 
century, and the process of lobotomy was common practice for the treatment of neuropsychiatric 
disorders in the early 1900s.8 Lobotomies involve localized lesions or surgical destruction of 
certain cerebral sites, and were based on the hypothesis that their anatomical location correlated 
with functional effects, and severance of certain sections of the brain, especially the frontal lobes, 
would modify the affective expression of psychosis or neurosis.71,72 
 
The introduction of CPZ (2) (Figure 1) by Rhône-Poulenc in 1952 marked a new era of drug 
treatment in psychiatry and resulted in the demise of psychosurgery.8,9 CPZ (2) was initially 
developed as an antihistaminic agent that was used to potentiate the effect of other anesthetic 
agents; its antipsychotic effects were discovered serendipitously by Delay and Deniker, as 
reviewed by Shen13 and Tamminga.73 Patients that were administered CPZ (2) behaved in a manner 
that was similar to lobotomized patients, and CPZ (2) was regarded as a non-permanent 
pharmacological lobotomy.9  
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In 1952, extrapyramidal symptoms (EPS) were observed as a side effect associated with CPZ (2) 
therapy, and led clinicians and pharmacologists to believe that antipsychotic efficacy and EPS 
were linked.11 EPS include dystonia, akathisia, parkinsonism, tardive dystonia, and tardive 
dyskinesia.11 The introduction of haloperidol (5) (Figure 1) in 1958 further bolstered this belief.74 
The widespread use of CPZ (2) resulted in large decreases in psychiatric inpatient populations 
worldwide, and fueled a search for other antipsychotic drugs.13 By the 1970s, at least 40 new 
antipsychotic agents were introduced worldwide.13 These agents were “typical” antipsychotic 
agents (Figure 10) that exerted their antipsychotic effects by blocking DA (particularly D2) 
receptors and included drugs such as CPZ (2), haloperidol (5) (Figure 1), thioridazine (17), 
trifluoperazine (18), thiothixene (19), and loxapine (20) (Figure 10) among others.13,73,75 
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Figure 10. Examples of typical antipsychotic agents.  
 
There was a lull in antipsychotic drug development from 1975 to 1990. The introduction of 
clozapine (8) (Figure 2) in 1990 was a hallmark in antipsychotic therapy. Clozapine (8) was 
initially introduced as an antipsychotic in the mid-1960s.76 However, it was withdrawn from the 
market for two reasons: it produced life-threatening agranulocytosis as a side effect, and it did not 
produce EPS, a side-effect that was thought to be correlated with antipsychotic efficacy.13 
Clozapine (8) was reintroduced to the market in the 1990s following a successful double-blind 
study in treatment-resistant patients whose blood levels were carefully monitored. Clozapine (8) 
was different from the previously marketed antipsychotics in being able to ameliorate both the 
positive and negative attributes of schizophrenia, as well as in having a lower propensity to cause 
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EPS.12 The introduction of clozapine (8) led to the development of the concept of “atypical” 
antipsychotics, and its clinical success prompted the development of other atypical antipsychotic 
agents (Figure 11) such as risperidone (14) (Figure 8) (1994), olanzapine (21) (1996), and 
quetiapine (22) (Figure 11) (1997).13 Risperidone (14) was developed using the chemical structure 
of haloperidol (5) (Figure 1) as a starting point,74 while the chemical structures of olanzapine (21) 
and quetiapine (22) were derived from clozapine (8).13 
 
 
Figure 11. Examples of atypical antipsychotic agents. 
 
 Antipsychotic therapy has come a long way from the serendipitous discovery of the antipsychotic 
effects of CPZ (2) to a more precise receptor-targeted approach for the synthesis of newer 
antipsychotics.13 There has been a paradigm shift in the design of antipsychotic agents from drugs 
that solely target the dopaminergic system to a more multi-target approach with newer drugs 
targeting multiple neurotransmitter systems that include, but are not limited to, 5-HT, GLU, and 
cholinergic systems.13 
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b. Classification 
Antipsychotics can be classified into two main groups: first-generation or “typical” 
antipsychotics/“neuroleptics” and second-generation or “atypical” antipsychotics. There is an 
emerging class of atypical antipsychotic agents that are also commonly referred to as third-
generation antipsychotic agents.77 The terminology, and classification of antipsychotics have been 
a subject of considerable debate until the early 1970s, and terms such as “neuroleptic”, 
“tranquilizer” and “ataraxic” have been used to refer to “typical” antipsychotic agents. The terms 
tranquilizer, and ataractics were popular until the 1960s, while the term neuroleptic was a more 
lasting term. These terms have been replaced by the term antipsychotic, and it now is the most 
popular term used to describe both typical and atypical agents.78 
 
Typical antipsychotic agents include drugs such as CPZ (2), haloperidol (5) (Figure 1), thioridazine 
(17), trifluoperazine (18), thiothixene (19), and loxapine (20) (Figure 10) among others, and are 
mainly D2 receptor antagonists.
73,75 
 
Atypical antipsychotic agents are classified based on their pharmacological action and reflect their 
affinities for specific receptors.79 They can be classified into serotonin-dopamine antagonists 
(SDAs), multi-acting receptor-targeted antipsychotics (MARTAs), and combined D2/D3 receptor 
antagonists.79 The third-generation atypical antipsychotic agents include partial DA receptor 
agonists such as aripiprazole (23) (Figure 12).79 SDAs are atypical antipsychotic agents that 
possess a high affinity for 5-HT2A and D2 receptors and include agents such as risperidone (14) 
(Figure 8), iloperidone (24) (Figure 12), and ziprasidone (25) (Figure 12).79 MARTAs include 
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agents that have high affinities for 5-HT2A receptors, D2 receptors, and receptors of other 
neurotransmitter systems such as cholinergic, histaminergic, and other serotonin receptors such as 
5-HT1A and 5-HT2C, some representative examples include agents such as clozapine (8) (Figure 
2), quetiapine (22), and olanzapine (21) (Figure 11).67 Agents such as amisulpride (26) and 
remoxipride (27) (Figure 12) are combined D2/D3 receptor antagonists.
79  
 
 
Figure 12. Structures of the partial DA receptor agonist aripiprazole (23), the SDAs: iloperidone 
(24), and ziprasidone (25), and the combined D2/D3 receptor antagonists: amisulpride (26) and 
remoxipride (27). 
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c. Typical versus atypical antipsychotic agents 
Typical antipsychotic agents, effective against only the positive symptoms of schizophrenia, are 
known to cause multiple side effects.7 The side effect profiles for different chemical classes vary, 
however, the most prominent side effects that are common to conventional (i.e., typical) 
antipsychotics are EPS and hyperprolactinemia.7 Neuroleptic malignant syndrome can occur at 
higher doses.7 
 
Atypical antipsychotic agents have a broader spectrum of clinical efficacy and ameliorate the 
positive symptoms, negative symptoms, and cognitive deficits of schizophrenia.79 They are more 
sparing in their side effects and have a reduced propensity to cause EPS and hyperprolactinemia, 
the side effects that are commonly associated with the use of typical antipsychotic agents.79 Even 
though atypical antipsychotic agents have their own adverse effects such as metabolic side effects, 
they have an overall better safety profile and are associated with a lower risk of suicide, higher 
rate of responders and an improved quality of life.79 
 
Studies have suggested that atypical antipsychotic agents are equally effective in the control of 
positive attributes, and are superior in controlling the negative symptoms, and cognitive deficits 
of schizophrenia as compared to typical antipsychotic agents.79,80 However, evidence of their 
superior efficacy is inconsistent, and several double-blind, randomized, controlled trials have been 
conducted to compare the clinical efficacy of atypical antipsychotic agents over conventional 
antipsychotic agents as well as a placebo.79,80 Meta-analyses of published clinical trials by two 
groups; Geddes et al.81 and Leucht et al.82 have suggested that atypical antipsychotic agents offer 
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modest clinical efficacy over typical antipsychotic agents. Geddes et al.81 concluded that the 
atypical antipsychotic agents were moderately better than conventional antipsychotics. At lower 
doses of the conventional antipsychotic agent; haloperidol (5) (Figure 1), there was no difference 
in terms of efficacy and overall tolerability over atypical agents; however, the first-generation 
antipsychotic agents demonstrated a liability for EPS even at low doses. A meta-analysis study of 
published clinical trials using low-potency conventional antipsychotics by Leucht et al.82 was in 
agreement with the study by Geddes et al.81 and suggested that the benefits of atypical agents over 
typical agents with the exception of clozapine (8) (Figure 2) were only moderate. These studies 
were limited by the lack of available data to evaluate other dimensions such as suicide risk, and 
quality of life. Contrary to the studies by Geddes et al.81 and Leucht et al.82 the meta-analysis of 
124 trials by Davis et al.83 has suggested that some atypical antipsychotic agents such as clozapine 
(8), risperidone (14) (Figure 8), olanzapine (21) (Figure 11), and amisulpride (26) (Figure 12) were 
significantly more efficacious than conventional antipsychotics. 
 
The US clinical antipsychotic trials of intervention effectiveness (CATIE) study, in 2005, and the 
UK cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1), in 2006, 
showed no differences in effectiveness and overall quality of life between the first- and second-
generation (i.e., typical and atypical) agents.84 
 
Atypical antipsychotic agents are a heterogeneous group of agents, and differ in terms of 
effectiveness and side-effects.79 It has been suggested that rather than using a dichotomous typical-
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atypical antipsychotic agent classification, viewing these agents in a dimensional fashion might be 
best,80 and the choice of use of drug should be based on the drug as well as patient profile.84 
 
3. Newer concepts 
i. Serotonin-dopamine antagonists (SDA) 
Clozapine (8), the first atypical antipsychotic agent, lacked EPS, a side effect associated with 
conventional antipsychotic therapy, and is a potent antagonist at multiple receptors with the 5-
HT2A receptor being one among the many.
85 Activity at serotonergic pathways that impinge on 
striatal dopaminergic pathways can reduce DA-mediated activity in these pathways, leading to the 
hypothesis that EPS could be reduced by the addition of 5-HT2A receptor blockade to D2 receptor 
antagonism.85,86 The addition of ritanserin (28) (Figure 13), a selective 5-HT2A receptor antagonist 
as an adjunctive treatment to conventional antipsychotics in patients with schizophrenia resulted 
in a significant reduction of EPS, and further bolstered the hypothesis.87  
 
Figure 13. Structure of the 5-HT2A receptor antagonist ritanserin (28). 
 
Medicinal chemistry efforts to synthesize agents that combined D2 receptor and 5-HT2A receptor 
antagonism in one molecule have resulted in several drugs, with risperidone (14) (Figure 8) being 
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the first marketed SDA. As opposed to conventional antipsychotic agents that are more potent D2 
rather than 5-HT2 receptor antagonists, SDAs have a higher affinity for 5-HT2A receptors as 
compared to D2 receptors.
85 The 5-HT2A/ D2 receptor binding affinity ratio has been defined by 
Meltzer et al.45 and most atypical antipsychotic agents have a 5-HT2A/D2 receptor binding affinity 
ratio ≥ 1.12. Disinhibition of dopaminergic neurotransmission in the nigrostriatal pathway by 5-
HT2A receptor blockade resulting in the release of DA in the striatum by offsetting the D2 receptor 
blockade may be a potential mechanism by which SDAs can reduce the expression of EPS. SDAs 
shift the EPS dose-response curve to the right while the antipsychotic dose response curve remains 
unchanged, resulting in a reduced propensity to cause EPS.85 These agents not only produce lower 
incidence of EPS, but might also be effective against the negative symptoms of schizophrenia and 
have pro-cognitive effects. The antiserotonergic component of SDAs may increase dopaminergic 
activity in the frontal cortex leading to an amelioration of negative symptoms of schizophrenia.45  
 
Rather than using the term SDAs, a better term to describe these agents is 5-HT spectrum dopamine 
modulators (SSDMs), since most of these agents have a wide spectrum of activity at 5-HT 
receptors that includes 5-HT2A receptor antagonism, direct or indirect 5-HT1A receptor agonism, 
and/or 5-HT2C, 5-HT6, and 5-HT7 receptor antagonism, and could be either antagonists or partial 
agonists at D2/D3 receptors. The spectrum of action at 5-HT receptors differs among various 
members of this class of agents resulting in differences in efficacy and tolerability among the 
different SSDMs.88 
 
  29 
ii. Role of inverse agonists in antipsychotic activity 
The ability of active conformations of receptors to produce a response in the absence of an agonist 
is known as constitutive activity, and ligands that decrease constitutive activity are known as 
inverse agonists. Most ligands (>80% of classical GPCR ligands) that were initially classified as 
antagonists are inverse agonists.89,90 5-HT2A and 5-HT2C receptors modulate the release of DA in 
the brain.90 5-HT2A receptor inverse agonists such as M100907 (29) (Figure 14) increase the 
release of DA in the mesocortical and mesolimbic brain regions,90,91 whereas 5-HT2C receptor 
inverse agonists such as SB206553 (30) (Figure 14)  increase the release of DA in the nucleus 
accumbens.90,92 The activity of atypical antipsychotic agents at 5-HT2A, 5-HT2C, and 5-HT1A 
receptors increases the release of DA in the prefrontal cortex.90  Most atypical antipsychotic agents 
such as clozapine (8) (Figure 2), risperidone (14) (Figure 8), and olanzapine (21) (Figure 11) are 
5-HT2A and 5-HT2C receptor inverse agonists, and it has been hypothesized that inverse agonist 
action at these receptors might be responsible for the ability of atypical antipsychotic agents to 
ameliorate the negative attributes and cognitive deficits of schizophrenia.90,93 An effective 
therapeutic strategy to treat the positive symptoms of schizophrenia might be the use of 5-HT2A/2C 
receptor inverse agonists to indirectly modulate DA levels. Pimavanserin (31) (Figure 14), a 
selective 5-HT2A receptor inverse agonist was found to have antipsychotic activity as well as a 
better side effect profile than the other atypical and conventional agents in animal models 
predictive of antipsychotic activity.94 Although clinical trials with pimavanserin (31) monotherapy 
were disappointing, it is currently available for treating secondary psychosis associated with 
Parkinsonism.90,95 The therapeutic potential of 5-HT2 receptor inverse agonists in treating 
psychosis associated with Alzheimer’s disease is also being evaluated.96  
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Even though targeting a single receptor subtype may not be effective in treating disorders with 
multiple etiologies such as schizophrenia, understanding the role of 5-HT receptor inverse agonism 
might pave the way for development of novel agents.90 
 
 
Figure 14. 5-HT2A receptor inverse agonists: M100907 (29) and pimavanserin (31), and the 5-
HT2C receptor inverse agonist: SB206553 (30). 
 
iii. Dopamine stabilizing agents 
DA stabilizing drugs are a novel therapeutic approach to reduce the side effects associated with 
conventional antipsychotic agents.97 D2 receptor partial agonists represent one class of “DA 
stabilizers”, and can reduce hyperdopaminergia in the mesolimbic area without producing a state 
of hypodopaminergia in the nigrostriatal DA pathway, thus avoiding EPS, a troublesome side 
effect that is associated with the first-generation antipsychotic agents that are D2 receptor 
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antagonists.98 Aripiprazole (23) (Figure 12), a prototypical DA stabilizing agent that was approved 
by the US FDA in the early 2000s for the treatment of schizophrenia, is a D2 receptor partial 
agonist.77,99 It can reduce the hyperactivity of the dopaminergic system in a manner that is 
dependent not only on its intrinsic efficacy but also on systems downstream of DA receptors, and 
can also enhance dopaminergic activity in the mesocortical circuit, and improve the negative and 
cognitive symptoms of schizophrenia.97,98 Besides D2 receptor partial agonist action, another 
feature that makes aripiprazole (23) (Figure 12) unique, is its functional selectivity at the D2 
receptor: it inhibits accumulation of cAMP and affects the release of arachidonic acid to a much 
greater extent as compared to its ability to activate mitogen-activated protein kinases (MAPK).98–
101 Aripiprazole (23) regulates dopaminergic function based on the hypoactivity or hyperactivity 
of the system, and based on the cellular environment of the receptor.98,99 An advantage of using 
D2 receptor partial agonists is that they do not up-regulate the D2 receptors, a phenomenon that is 
observed with long-term treatment with DA receptor antagonists99 Aripiprazole (23) also binds to 
5-HT receptors (5-HT1A receptor partial agonist, 5-HT2A receptor antagonist), and this combined 
with D2 receptor partial agonist action may be responsible for its therapeutic efficacy in 
schizophrenia.99 Brexpiprazole (32) (Figure 15) is another D2, and 5-HT1A receptor partial agonist, 
and a potent antagonist at 5-HT2A, α2A, and α2c receptors that was approved by the US FDA in 
2015 for the treatment of schizophrenia.102  
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Figure 15. Structure of the DA stabilizing agent brexpiprazole (32). 
 
D2 receptor partial agonists such as aripiprazole (23) (Figure 12) are as efficacious as first-and 
second-generation antipsychotic agents in terms of antipsychotic action, with the added advantages 
of lower incidence of EPS, and reduced side effects such as hyperprolactinemia and weight gain.98 
 
4. Serotonin receptors 
Gaddum and Picarelli103 had initially classified the 5-HT receptors into two groups, the ‘D’- type 
that was responsible for the contraction of smooth muscles, and the ‘M’- type that mediated 
cholinergic nerve depolarization. The effects of 5-HT at the 5-HT-D receptor subtype could be 
blocked by an irreversible antagonist phenoxybenzamine (33) (Figure 16) whereas the effects of 
5-HT at the 5-HT-M receptor subtype could be blocked by morphine (34) or cocaine (35) (Figure 
16). 
 
Figure 16. Structures of phenoxybenzamine (33), morphine (34), and cocaine (35). 
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In 1979, Peroutka and Snyder104 identified two distinct brain 5-HT binding sites and named them 
5-HT1 and 5-HT2 receptors. 5-HT-D, and 5-HT-M receptors were renamed as 5-HT2 and 5-HT3 
receptors, respectively. By the early 1990s, several 5-HT receptor sub-populations had been 
identified, and cloned, and currently 5-HT receptors are classified into seven different families, 5-
HT1 through 5-HT7; except for the 5-HT3 receptor, which is a ligand-gated ion channel receptor, 
all the others are type A or rhodopsin-like GPCRs. These receptors are further divided into sub-
populations, and a total of 14 different 5-HT receptor sub-types have been described (Table 1).39 
 
Table 1. Classification of 5-HT receptors (adapted from Glennon and Dukat39). 
 
 
Populations and 
subpopulations 
(Currently 
accepted name) 
 
 
 
Second 
messenger 
system* 
 
Comments 
5-HT1 
  5-HT1A (5-HT1A) 
 
  5-HT1B (5-HT1B) 
 
  5-HT1Bβ 
 
 5-HT1D 
  5-HT1Dα  
 
AC(-) 
 
AC(-) 
 
 
 
 
 
AC(-) 
 
Cloned and pharmacological  
5-HT1A receptors. 
 
 
Rodent homolog of h5-HT1B receptors 
 
 
A mouse homolog of 5-HT1B receptors 
 
 
 
 
A cloned human 5-HT1D subpopulation 
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  (h5-HT1D) 
  5-HT1Dβ   
  (h5-HT1B) 
 
 5-HT1E 
  5-HT1Eα 
  5-HT1Eβ 
  (5-HT1F) 
 5-HT1F 
5-HT2 
 5-HT2 (5-HT2A) 
 5-HT2F (5-HT2B) 
 5-HT1C (5-HT2C) 
5-HT3 
5-HT4 
 5-HT4s 
 5-HT4L 
 5-HT4(b)-4(d) 
5-HT5 
 5-HT5A 
 5-HT5B (5-HT5A) 
5-HT6 
5-HT7 
 
 
AC(-) 
 
 
 
AC(-) 
 
 
 
AC(-) 
 
 
 
PI 
 
PI 
 
PI 
 
Ion channel 
 
AC (+) 
 
 
 
 
AC (-)105 
 
 
 
 
AC (+) 
 
AC (+) 
 
A second cloned human 5-HT1D subpopulation; 
human counterpart of rat 5-HT1B 
 
 
 
 
An alternate name that has been used for cloned 
human 5-HT1E receptors 
A cloned mouse homolog of 5-HT1F receptors 
 
A cloned human 5-HT1 receptor population 
 
 
 
Original “5-HT2” (sometimes called 5-HT2α) 
receptors 
5-HT2-like receptors originally found in rat fundus 
 
Originally described as 5-HT1C (5-HT2β) receptors 
 
An ion channel receptor 
 
 
 
Short form of cloned 5-HT4 receptors 
 
Long form of cloned 5-HT4  receptors 
 
Recently identified human 5-HT4 receptor isoforms 
 
 
 
Cloned mouse, rat, and human 5-HT5 receptors 
 
Cloned mouse, and rat 5-HT5A-like receptor 
 
Cloned rat and human 5-HT receptor 
 
Cloned rat, mouse, guinea pig, and human 5-HT 
receptors 
 
 *AC: adenylate cyclase; (-): negatively coupled; (+) positively coupled; PI: phospholipase 
coupled. 
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a. 5-HT2A Receptors 
Branchek et al106 cloned the human 5-HT2A receptor in 1990. The 5-HT2A receptor plays a role in 
maintaining normal physiological function, and is widely distributed in the CNS. The 5-HT2A 
receptor has been mapped by receptor binding, autoradiography using radioligands such as 
[3H]ketanserin (36), [3H]spiperone (37), [125I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
(DOI) (38) (Figure 17), and [3H]M100907 (29) (Figure 14), in situ hybridization, and 
immunocytochemistry. High densities of 5-HT2A receptors have been identified in forebrain 
regions that include cortical areas such as the neocortex, claustrum, entorhinal and pyriform cortex, 
and the olfactory tubercle, nucleus accumbens, caudate nucleus and hippocampus.107 The 5-HT2A 
receptor is also expressed in C-fibers and dorsal root ganglia of the spinal cord, activation of these 
receptors produces analgesia. Peripherally, 5-HT2A receptors have been identified on 
cardiovascular-related tissues, where they modulate functions such as arterial vasoconstriction and 
proliferation of arterial fibroblasts.105 
 
 
Figure 17. Examples of radioligands used to label the 5-HT2A receptor. 
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The 5-HT2A receptor is a class A GPCR that has seven transmembrane-spanning helices, an 
intracellular C-terminus, and an extracellular N-terminus. The transmembrane (TM) domains are 
connected via extracellular and intracellular loops. The intracellular loop between TM5 and TM6 
is associated with coupling to second messenger systems (Figure 18). The orthosteric binding site 
is located in the TM domain, and involves an aspartate moiety in TM3.39  
 
 
Figure 18. Schematic representation of the 5-HT2A receptor. Transmembrane (TM) spanning 
helices are numbered as TM1 to TM7 (adapted from Glennon and Dukat39). 
 
5-HT2A receptors are coupled to Gαq, and activation of the receptor leads to hydrolysis of 
membrane phosphoinositides by the activation of phospholipase C (PLC) resulting in diacyl 
glycerol (DAG) and inositol phosphates; DAG activates other downstream effectors such as 
protein kinase C, whereas inositol phosphates can result in an increase in intracellular Ca2+ levels, 
which then activates inwardly rectifying chloride channels.39,105,107,108 Activation of the rho 
signaling pathway regulates structural changes in cells.105 
  37 
 
Agonist action at 5-HT2 receptors might be involved in the action of classical hallucinogens such 
as LSD (7) (Figure 2), and DOI (38) (Figure 17).109 There is a close correlation between the human 
hallucinogenic potency of these agents and 5-HT2A receptor affinity, and 5-HT2A receptors might 
play an important role in the behavioral effects of hallucinogenic agents.39,110 The 5-HT2A receptor 
is an important target for antipsychotics, antidepressants, and anxiolytics.108 The role of 5-HT2A 
receptors in antipsychotic drug action has evoked considerable interest based on the relationship 
between 5-HT2A receptors, and hallucinogens, and the high affinity of atypical antipsychotic agents 
such as clozapine (8) (Figure 2), olanzapine (21) (Figure 11), and risperidone (14) (Figure 8) for 
5-HT2A receptors.
107,108 
 
5. Metabotropic glutamate receptors (mGluRs) 
mGlu Receptors are class C GPCRs.111 There are eight different mGluR subtypes that are divided 
into three groups, group I through group III, based on sequence homology, pharmacology, and 
coupling mechanism.111 Group I consists of mGlu1 and mGlu5 receptors, group II includes mGlu2 
and mGlu3 receptors, and Group III consists of mGlu4, mGlu6, mGlu7 and mGlu8 receptor 
subtypes.111 Group I receptors couple to Gq/11 and activate phosphoinositide hydrolysis, while 
group II and III couple to Gi/o and inhibit adenylyl cyclase.
112 The sequence identity between 
groups is ~45%, while the sequence identity among members of a group is ~70%. 113 
 
Class C GPCRs differ from class A GPCRs in having a large extracellular N-terminal domain, 
termed the venus flytrap domain that houses the orthosteric binding site.111,113 The venus flytrap 
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domain is a clam-shaped structure composed of two lobes with the orthosteric binding site located 
in between the two lobes.111,113 The extracellular domain is connected to the heptahelical 
transmembrane domain via a cysteine rich domain.111,113 The cysteine-rich domain transmits 
signals from the venus flytrap domain to the heptahelical transmembrane domain111,113 (Figure 19).  
mGlu2/5 receptor PAMs, Group II orthosteric agonists have demonstrated antipsychotic activity in 
preclinical models, and some have advanced into clinical trials.54,112 
 
 
Figure 19. Schematic representation of an mGlu receptor. Transmembrane (TM) spanning helices 
are numbered as TM1 to TM7 (adapted from Conn et al.113). 
 
a. Group II mGlu receptors: mGlu2 and mGlu3 receptors 
Group II mGlu receptors are widely expressed in the CNS with higher expression levels in brain 
regions such as the prefrontal cortex, the thalamus, the hippocampus, the amygdala, and dorsal 
and ventral striatum.23 These regions of the brain have been shown to be involved in cognition and 
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emotional states, and the distribution of the mGlu3 receptor is more dispersed than that of the 
mGlu2 receptor.
23 mGlu2 receptors are found both presynaptically and postsynaptically while 
mGlu3 receptors are mainly presynaptic.
23 The mGlu2 receptors can function  as autoreceptors that 
serve as a negative feedback mechanism and suppress the excessive release of GLU, thus 
maintaining homeostasis.23 Group II mGluRs can also modulate the release of other 
neurotransmitters such as GABA, DA, 5-HT, and norepinephrine.114 They are coupled to Gi/o 
proteins and mediate downstream effects via inhibition of adenylyl cyclase and modulation of 
voltage-gated ion channels.23 They might also activate phosphoinositide-3 kinase (pI3K) and 
MAPK pathways.23 
 
There is a large body of evidence suggesting that activation of group II mGlu receptors, specifically 
the mGlu2 receptor, might be a novel and promising approach to treat anxiety and 
schizophrenia.23,115 Preclinical data with orthosteric group II mGlu receptor agonists has been 
promising, and agents such as LY354740 (39), LY404039 (40), LY379268 (41) (Figure 20) have 
been shown to possess antipsychotic action in animal models of schizophrenia.23 LY2140023 (42) 
(Figure 20), an oral prodrug of the Group II mGlu2/3 orthosteric agonist LY404039 (40), entered 
clinical trials; however, it was found to be no more efficacious than placebo in multiple 
studies.23,116,117 
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Figure 20. Group II mGlu receptor orthosteric agonists. 
 
Studies with mGlu2- and mGlu3-receptor knock-out mice have suggested that the antipsychotic 
effects mediated by group II mGlu orthosteric agonists might be due to its action at the mGlu2 
receptors, rather than mGlu3 receptors.
118 However, due to  similarity and high homology between 
the orthosteric binding sites of the mGlu2 receptor and mGlu3 receptor, there are no agents that are 
selective for either subtype thus far.115 Orthosteric agonists have the disadvantages of non-
selectivity and development of tolerance. mGlu2 receptor PAMS are an alternative strategy.
112 
Several mGlu receptor PAMs such as BINA (43), LY487379 (44), JNJ-40411813 (45), JNJ-
40068782 (46), CBiPES (47), and AZD8529 (48) (Figure 21) have demonstrated antipsychotic 
activity in preclinical trials, with some of them such as JNJ-40411813 (45)119 and AZD8529 (48)120 
having advanced into clinical trials.23 
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Figure 21. mGlu2 receptor-selective PAMs. 
 
6. Role of the 5-HT2A-mGlu2 receptor heteromer 
Roles for the 5-HT2A receptor and the mGlu2 receptor in the pathophysiology of schizophrenia 
have been well established.23,88 Several lines of evidence point towards the formation of a 
functional 5-HT2A-mGlu2 receptor heterocomplex,
18–21 that has been implicated in the  mechanism 
of action of both antipsychotic agents22 as well as hallucinogenic agents.20,121 Gonzalez-Maeso et 
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al.18 and Moreno et al.20,121 have validated the necessity of a 5-HT2A/mGlu2 receptor 
heterocomplex for the behavioral effects of hallucinogenic agents such as LSD (7) (Figure 2) and 
DOI (38) (Figure 17). Additionally, Moreno et al.20 have also identified that three amino acid 
residues Ala677, Ala681, and Ala685, located at the intracellular end of the TM4 of the mGlu2 
receptor are important for formation of the heteromer. Fribourg et al.22 have demonstrated that the 
high affinity 5-HT2A receptor atypical antipsychotic agents clozapine (8) (Figure 2) and risperidone 
(14) (Figure 8) mediate their effects by binding to the 5-HT2A/mGlu2 receptor heteromer, which 
then balances Gi/o and Gq/11 signaling. Gonzalez-Maeso et al.
18 have demonstrated that the 5-HT2A 
receptor is upregulated and the mGlu2 receptor is downregulated in postmortem brain samples of 
untreated schizophrenic patients. These changes suggest that the 5-HT2A/mGlu2 receptor 
heteromer may be involved in the altered cortical processes in schizophrenia, and represents an 
attractive novel target for the treatment of schizophrenia.18
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III. SPECIFIC AIMS
 
 
 
 
In pursuit of new antipsychotic agents that cause reduced incidence of EPS than haloperidol (5) 
(Figure 1), Dr. Paul Janssen, as reviewed by Awouters and Lewi,74 designed more compounds, 
and based on their pharmacological properties and clinical information selected agents that were 
better than haloperidol (5) (Figure 1). The goal was to synthesize an antipsychotic agent that had 
an additional effect that could complement DA blocking activity.74 Central 5-HT2A  receptor 
blockade has been found to rectify and complement central D2 receptor antagonism, leading to 
development of molecules such as risperidone (14) (Figure 8)  that combine 5-HT2A and D2 
receptor antagonism in one molecule.15,122 Some of the earlier butyrophenone analogs such as 
pipamperone (49) (Figure 22) did possess serotonin activity (strong tryptamine antagonism),74,123 
however, this effect was overlooked since the clinical implications of serotonin in schizophrenia 
were not clear at that time.74 Pipamperone (49) had efficacy in treating the negative symptoms of 
schizophrenia, and had resocializing effects.74,124 However, the relationship between 5-HT 
antagonism and amelioration of negative symptoms of schizophrenia had not been established at 
that time.74 The pharmacological and clinical profiles of pipamperone (49) were quite distinctly 
different from that of haloperidol (5) (Figure 1).74,122,125 Risperidone (14) (Figure 8), a prototypical 
SDA, was found to have a pharmacological profile very similar to that of pipamperone (49) (Ki = 
1 nM (5-HT2A receptor), Ki = 98 nM (D2 receptor)), with serotonin receptor antagonism preceding 
D2 receptor occupancy,
14 and with risperidone (14) (Figure 8) (Ki = 0.16 nM (5-HT2A receptor), Ki 
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= 3.1 nM (D2 receptor) being more potent.
15 Risperidone (14) is effective in treating the positive 
and negative symptoms of schizophrenia, and has a lower propensity to cause EPS.14 Moderate D2 
receptor occupancy, predominantly 5-HT2A receptor occupancy, and the avoidance of D2 receptor 
over blockade, might be the mechanism for its effectiveness against the positive, and negative 
symptoms of schizophrenia, with reduced side effects.14 There has been marked progress from 
pipamperone (49) to risperidone (14), with a hundred-fold reduction in dosing.74 
 
 
Figure 22. Structure of the butyrophenone analog pipamperone (49). 
 
The pharmacological differences between haloperidol (5) (Figure 1) and pipamperone (49), and 
the chemical structures of benperidol (50) and lenperone (51) (Figure 23), led to the development  
of risperidone (14) (Figure 23).15 
 
Benperidol (50) and lenperone (51) are butyrophenone analogs that bind to D2 receptors.
15 The 
butyrophenone moiety is common to both molecules, and since they both bind to D2 receptors 
(Table 2), it was hypothesized that the benzimidazolone fragment of benperidol (50) and the 
benzoyl fragment of lenperone (51) had pharmacophoric similarity.15 Lenperone (51) can be 
considered to be an almost symmetrical molecule that has two aromatic regions at a distance of 
four carbon atoms from the central nitrogen atom, with the only difference being the cyclic form 
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of the chain in the 4-benzoylpiperidine fragment.15 Hence the open form of the benzimidiazolone 
fragment of benperidol (50) might have potential activity like the open form of the 4-
benzoylpiperidine fragment  (butyrophenone fragment) of lenperone (51).15 Declenperone (52) 
and milenperone (53) (Figure 23) were a result of combining fragments of benperidol (50) and 
lenperone (51).15 Declenperone (52) and milenperone (53) were both centrally active and potent 
DA antagonists, and weak 5-HT antagonists, (Table 2) with milenperone (53) being more potent 
than declenperone (52).15 However, milenperone (53) was no more efficacious than haloperidol 
(5) (Figure 1) in clinical trials.15  
 
Expansion of the five membered imidazolone ring to a larger ring system that retained the urea 
moiety, and four atoms between the aromatic ring and central nitrogen atom, resulted in ketanserin 
(36) (Figure 23), a molecule that possessed 100-fold higher affinity for 5-HT2A receptors as 
compared to D2 receptors.
15 Ketanserin (36) is a potent peripheral 5-HT2A receptor antagonist, and 
an α1-adrenoceptor antagonist at higher doses.15 Ketanserin (36) is therapeutically useful as an 
antihypertensive agent.15  
 
Chemical modification of the quinazolinedione ring of ketanserin (36) led to pirenperone (54) and 
setoperone (55) (Figure 23).15 Both these agents were centrally active D2 receptor, and 5-HT2A 
receptor antagonists with a higher affinity for 5-HT2A receptors (Table 2).
15 Setoperone (55) 
showed antipsychotic potential in preclinical studies,126 however, it had limited bioavailability due 
to enzymatic reduction of the keto functionality to an inactive alcohol, and hence was not pursued 
further.15 Bioisosteric replacement (to avoid metabolism) of the 4-fluorobenzoyl moiety with 6-
  46 
fluorobenzisoxazole resulted in risperidone (14) (Figure 23).15 Risperidone (14) was a potent and 
centrally active D2 and 5-HT2A receptor antagonist, with higher affinity for 5-HT2A receptors 
(Table 2), and good bioavailability.15 Risperidone (14) also antagonizes the α1-adrenoceptors (Ki 
= 2.4 nM), and histamine H1 receptors.(Ki = 2.1 nM).
15,127  Paliperidone (56) (Figure 23), an active 
metabolite of risperidone, has a pharmacological profile (Table 2) similar to that of risperidone 
(14).15,128–130 
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Figure 23. Development of risperidone.15 
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Table 2. Activity profile of risperidone and other analogs (adapted from Megens and Kennis15). 
 
Compound Binding affinity* 
Ki (nM) 
Functional activity** 
ED50 (mg/kg) 
  
D2 
 
5-HT2A 
 
Apomorphine 
 
Tryptamine 
Benperidol (50) 
 
Lenperone (51) 
 
Declenperone (52) 
 
Milenperone (53) 
 
Ketanserin (36) 
 
Pirenperone (54) 
 
Setoperone (55) 
 
Risperidone (14) 
 
Paliperidone (56) 
   0.35 
 
   4.6 
 
   9.3 
 
   3.9 
 
220 
 
 16 
 
 24 
 
  3.1 
 
 4.1 
6.6 
 
Not tested 
 
2.4 
 
9.2 
 
2.1 
 
2.1 
 
2.3 
 
0.16 
 
0.22 
     0.0093 
 
     0.085 
 
     0.44 
 
     0.025 
 
> 40 
 
     0.098 
 
     0.22 
 
     0.15 
 
     0.39 
0.29 
 
0.39 
 
2.4 
 
0.51 
 
2.4 
 
0.11 
 
0.11 
 
0.13 
 
0.22 
*Radioligand: [3H]spiperone (37) (Figure 17). 
**ED50 for antagonism of apomorphine-, and tryptamine-induced behavioral effects in the 
apomorphine- tryptamine- and norepinephrine-interaction test in rats. 
 
The pharmacological profile of risperidone (14) has been compared to that of haloperidol (5), a D2 
receptor antagonist, and ritanserin (28) a selective 5-HT2A receptor antagonist.
122 Similar to 
ritanserin (28), risperidone (14) showed activity in tests related to central and peripheral 5-HT2A 
receptor antagonism such as a reduction in central serotonergic over activity induced by agents 
such as 5-hydroxytryptophan, mescaline or tryptamine at doses of 0.014-0.049 mg/kg, and is a 
more potent 5-HT2A receptor antagonist than ritanserin (28).
122 Similar to haloperidol (5), 
risperidone (14) inhibits the central and peripheral expression of hyperdopaminergia.122 It inhibits 
behavioral reactions linked to normal dopaminergic function such as conditioned responses, and 
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ICS; additionally, it inhibits central hyperdopamaninergia produced by dopaminomimetic agents 
such as amphetamine, cocaine, and apomorphine at doses of 0.016-0.16 mg/kg.122  
 
Ritanserin (28) when given as an additional therapy with a typical antipsychotic agent can help 
decrease EPS, and cause an improvement in the negative and affective symptoms of 
schizophrenia.122,131,132 The effects of haloperidol (5) include antimanic, antihallucinatory, and 
antidelusional actions, with the possibility of EPS at higher doses.122 Hence, since risperidone is 
an SDA, it should be able to produce clinical effects of both ritanserin (28) and haloperidol (5) 
(Figure 1).122 However, the haloperidol-like antidopaminergic effects can be modified with greater 
5-HT2A receptor blockade.
122 Induction of catalepsy and inhibition of locomotor activity by 
haloperidol (5) was seen at the doses used to inhibit evoked responses, while much larger doses of 
risperidone were required to inhibit locomotor activity and induce catalepsy.122 Risperidone differs 
from haloperidol (5) and ritanserin (28) in being able to antagonize LSD in drug discrimination 
studies, an effect that is common to SDAs, and thought to be a result of simultaneous 5-HT2 and 
D2 receptor antagonism.
122 Ritanserin (28) (Figure 13) is a poor blocker of the LSD cue,133,134 
while haloperidol (5) reduces response rates without affecting the discriminative stimulus.122 
Hence, in spite of being able to antagonize 5-HT2A and D2 receptors, it has a pharmacological 
profile that is different from that of ritanserin (28) and the typical antipsychotic agent haloperidol 
(5). 
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Studies have suggested that risperidone (14) is an inverse agonist at 5-HT2A receptors.
135,136 
Risperidone has structural features that make it unique and distinguish it from structurally-related 
compounds such as ketanserin (36) (Figure 17). 
 
Risperidone is used as monotherapy for schizophrenia, as well as an adjunct therapy to lithium or 
valproate to treat acute manic episodes, and for the maintenance treatment of bipolar disorder I.16 
Even though risperidone has a much lower tendency to cause EPS than typical antipsychotic 
agents, therapy with risperidone is associated with side effects such as hyperprolactinemia, weight 
gain, and metabolic disorders such as glucose dysregulation,13,16,17 and there is a need for newer 
antipsychotic agents with fewer side effects.   
 
Goals of this project are to study the structural features of risperidone (14) (Figure 8), and 
determine the minimal structural features required for 5-HT2A receptor antagonist activity, and to 
identify an mGlu2 receptor PAM from known mGlu2 receptor PAMs, that will contribute towards 
the long-term goal of synthesizing a bivalent molecule that can target the mGlu2/5-HT2A receptor 
heteromer. 
 
The specific aims of the current project are: 
1. Deconstruction of risperidone to determine the minimal structural features 
responsible for its 5-HT2A receptor antagonist activity 
 
  51 
2. Elaboration of risperidone to investigate the role of the two halves of risperidone in 
its 5-HT2A receptor antagonist activity 
a. Investigation of the potential role of the two halves of risperidone in its activity by 
examination of structural hybrids of risperidone and ketanserin. 
b. Investigation of the potential role of the “right half “(i.e., the 6-fluoro-3-(4-
piperidinyl)-1,2-benz[d]isoxazole portion) of risperidone in its activity by making 
the right half of risperidone similar to serotonin. 
c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one portion) of risperidone. 
d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left 
half” of risperidone similar to other antipsychotic agents such as iloperidone. 
 
3. Molecular modeling studies of risperidone and its deconstructed and elaborated 
analogs at 5-HT2A receptors to study their binding mode 
 
4. mGlu2 receptor PAMs 
a. Molecular modeling studies of the allosteric site of the mGlu2 receptor to determine 
whether structurally diverse PAMs of the mGlu2 bind in a similar manner and in the 
same binding pocket. 
b. Synthesis of the mGlu2 receptor PAM JNJ-40411813. 
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5. Redefining a pharmacophore for 5-HT2A receptor antagonists. 
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IV. APPROACH, RESULTS AND DISCUSSION
 
 
 
 
A. Specific Aim 1: Deconstruction of risperidone to determine the minimal structural 
features responsible for its 5-HT2A receptor antagonist activity 
1. Approach 
To study the structure-activity relationships (SAR) of risperidone at 5-HT2A receptors and to 
possibly identify a 5-HT2A receptor antagonist pharmacophore a “deconstruction-reconstruction-
elaboration” approach was used.137 The "deconstruction-reconstruction-elaboration" approach 
involves assigning an arbitrary core to a given agent, and removing one structural feature at a 
time.137 Biological activity of the deconstructed analogs will enable us to “reconstruct” analogs 
incorporating only those structural features contributing to activity.137 The “elaboration” phase 
involves further exploration of various substituents and functional groups.137 
 
Risperidone (14) (Figure 24) can be divided into two halves consisting of the 2-methyl-6,7,8,9-
tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one portion (hereafter referred to as the “left half”) and 
the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole  portion (hereafter referred to as the “right 
half”) connected by an ethyl linker. 
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Risperidone (14) (Figure 24) was systematically deconstructed into truncated analogs 57-68 
(Figure 24) to study the structural features necessary to retain 5-HT2A receptor affinity and (where 
applicable) antagonist activity.  
 
Analogs 57-59 represent deconstructed analogs where the benz[d]isoxazole portion of risperidone 
(14) (the “right half”) was removed and the “left half” of risperidone (14) was further 
deconstructed. Analogs 60-63 will examine the “right half” of risperidone (14), whereas analogs 
64-68 will help examine other whole-molecule features. 
 
A “deconstruction-reconstruction-elaboration” approach was used by our group138 to study the 
SAR of ketanserin (36) (Figure 25), a molecule that bears structural resemblance to risperidone 
(14) (Figure 25), at 5-HT2A and 5-HT2C  receptors. The structural analogs of ketanserin (36) were 
tested for binding affinity at 5-HT2A and 5-HT2C  receptors in frontal brain cortical regions of 
Sprague-Dawley rats using 3[H]ketanserin as the radioligand.138 Figures 25 and 26 illustrate a 
comparison of the deconstruction of risperidone (14) with the deconstruction of ketanserin (36) 
 
  55 
 
Figure 24. Deconstructed analogs of risperidone (14). 
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Figure 25. A comparison of the deconstruction of risperidone (14) with the deconstruction of 
ketanserin (36). Data for ketanserin analogs are from Herndon et al.138 
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Figure 26. A comparison of the deconstruction of risperidone (14) with the deconstruction of 
ketanserin (36). Data for ketanserin analogs are from Herndon et al.138 
 
 
Analog 57 (Figure 24) lacks the 6-fluoro-1,2-benz[d]isoxazole portion (the “right half”) and will 
help establish the contribution of the “left half” of risperidone (14) towards 5-HT2A receptor 
affinity and antagonist activity of risperidone (14). In analogs 58 and 59 (Figure 24), the piperidine 
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ring has been deconstructed into a simpler tertiary amine and then an even simpler primary amine, 
and will additionally help ascertain the role of the piperidine ring, as well as the nature of the amine 
in binding. A comparison of analog 57 with 58 will additionally help understand the importance 
of a constrained ring system. Analog 59 represents the “left half” of risperidone with the linker 
and the amine portion of the “right half”. The amine has been retained because the protonated 
amine of orthosteric agonists and antagonists of the 5-HT2A receptor is involved in a crucial ionic 
interaction with an aspartate moiety (Asp 155) in TM3.139 Herndon et al.138 had deconstructed 
ketanserin in an analogous manner (analogs 69-71) and the deconstructed analogs lacked affinity 
for 5-HT2A receptors. If analogs 57-59 bind in a manner similar to analogs 69-71, they should also 
lack affinity for 5-HT2A receptors. If they bind with higher affinity it will indicate that the “left 
half” of risperidone (14) contributes to a greater extent to its binding affinity as compared to the 
“left half” of ketanserin (36). 
 
Analog 60 (Figure 24) represents the “right half” of risperidone (14) and retains a part of the linker 
in the form of a methyl group, and will help study the importance of the “right half” of risperidone 
in its 5-HT2A receptor affinity and antagonist activity. Deconstructed analog 61 (Figure 24) 
represents the desmethyl analog of 60, whereas analogs 62 and 63 (Figure 24) represent the 
desfluoro analogs of 60 and 61, respectively. Analog 61 has been shown to be a 5-HT2A receptor 
antagonist previously by our laboratory.140 In the prior study, the radioligand binding assay was 
performed in rat brain homogenates using [3H]ketanserin as the radioligand and analog 61 was 
found to bind at 5-HT2A receptors with only 16 fold lower affinity than risperidone (14). It was 
shown to be a potent 5-HT2A receptor antagonist in an in vitro assay that measures serotonin 
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induced inositol phosphate production, as well as in an in vivo assay. The in vivo assay was 
performed in rats that could discriminate 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (a 
5-HT2 receptor agonist) from vehicle. Our laboratory has recently reported that analogs 60 (Ki = 
12.27 nM) and 61 (Ki = 71.41 nM) both bind to 5-HT2A receptors and are 5-HT2A receptor 
antagonists (discussed in the results section).141 In fact, analog 60 (Ki = 12.27 nM) binds with only 
~ 2 fold lower affinity than risperidone (14; Ki = 5.29 nM).
141 Herndon et al.138 had tested the “right 
halves” of ketanserin (analogs 72 and 73) and they demonstrated a decrease in affinity for the 5-
HT2A receptors as compared to ketanserin (36).
138 Analogs 62 and 63 will help establish the 
importance of the fluoro group for 5-HT2A receptor affinity and antagonism.  
 
Deconstructed analog 64 (Figure 24) retains only the 6-methyl-3H-pyrimidin-4-one portion of the 
“left half” of risperidone (14), whereas in abbreviated analogs 65-68 (Figure 24) the 6-methyl-3H-
pyrimidin-4-one ring system has been deconstructed and will help ascertain the role of the “left 
half” of risperidone (14) in its 5-HT2A receptor antagonist activity. Analog 65 retains the amide 
portion of the 6-methylpyrimidin-4(3H)-one ring system. In analog 66 the carbonyl group present 
in analog 65 has been removed, whereas in analog 67 the amide nitrogen of 65 has been replaced 
by a methylene group. Deconstructed analog 68 represents the descarbonyl analog of 67. 
Analogous deconstruction of ketanserin (36) resulted in molecules (75-77) that bind to 5-HT2A 
receptors with high affinity.138 Our laboratory has recently reported that analogs 65 (Ki = 39.81 
nM) and 66 (Ki = 34.83 nM) bind with high affinity to 5-HT2A receptors and are 5-HT2A receptor 
antagonists (discussed in the results section).141 
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2. Results 
A. Chemistry 
The synthesis of compound 57 was initially attempted as outlined in Scheme 1 via a nucleophilic 
substitution reaction. Piperidine was alkylated with the primary alkyl halide 78 in DMF in the 
presence of K2CO3. K2CO3 was added to neutralize the HCl that is formed as a by-product of the 
reaction. However, the reaction did not progress, and analog 57 was ultimately synthesized using 
a Finkelstein reaction (Scheme 1- ii and iii). The Finkelstein reaction is a nucleophilic substitution 
reaction. A small amount of KI is added to the reaction mixture to facilitate halide exchange 
between the chloride of the alkyl chloride and the iodide of the KI. Synthesis of compound 57 was 
attempted in two solvents- DMF and MeCN. When MeCN was used as a solvent for the reaction, 
the yield was comparatively higher (yield: 20%) as compared to when DMF was used as a solvent 
(yield: 12%). Reported literature suggests that solvents such as i-PrOH and MeCN work better 
than DMF.142 Compound 57 was unknown and was characterized by NMR and elemental analysis 
for C, H and N. 
 
 Scheme 1. Synthesis of compound 57.a 
 
aReagents and conditions: (i) piperidine, K2CO3, DMF, reflux, 17 h; (ii) (a) piperidine, K2CO3, 
KI, DMF, reflux, 17 h; (b) EtOH, HCl/EtOH; (iii) (a) piperidine, K2CO3, KI, MeCN, reflux, 17 
h; (b) EtOH, HCl/ EtOH. 
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Compound 58 was synthesized in a manner analogous to compound 57, and the synthesis is 
outlined in Scheme 2. Analog 58 was synthesized by a Finkelstein reaction between 3-(2-
chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) and 
dimethylamine in the presence of  K2CO3 and KI (catalytic amount) in MeCN. Compound 58 was 
unknown and was characterized by NMR and elemental analysis for C, H and N. 
 
Scheme 2. Synthesis of compound 58.a 
 
aReagents and conditions: (i) (a) N,N-dimethylamine (2 M solution in MeOH), K2CO3, KI, MeCN, 
reflux, 30 h; (b) CHCl3, (COOH)2/Et2O. 
 
Compound 59 was synthesized using a Gabriel synthesis reaction (Scheme 3). The Gabriel 
synthesis is a nucleophilic substitution reaction that utilizes potassium phthalimide as an  
-NH2 synthon. The primary alky halide 78 was allowed to react with potassium phthalimide to 
yield intermediate 79 that was subsequently converted to compound 59 by hydrazine hydrate. 
Compound 59 was unknown and was characterized by NMR and elemental analysis for C, H and 
N. 
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Scheme 3. Synthesis of compound 59.a
 
aReagents and conditions: (i) Potassium phthalimide, DMF, 22h, reflux; (ii) (a) hydrazine hydrate, 
EtOH, reflux, 4h; (b) 1 N HCl, reflux, 5 min; (c) EtOH, HCl/EtOH. 
 
The Gabriel synthesis was used to synthesize analog 59 as opposed to the direct alkylation of 
ammonia, since alkylation of ammonia is often unselective with poor yields, and can result in a 
mixture of primary, secondary, tertiary, and quarternary amines. 
 
Compounds 60-63 were synthesized by Dr. Supriya A. Gaitonde, who was a graduate student in 
the Dukat and Glennon laboratory, and their syntheses are outlined in Schemes 4 (60, 61) and 5 
(62, 63).143 
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Scheme 4. Synthesis of compounds 60 and 61.a 
 
aReagents and conditions: (i) (a)HCOOH, Ac2O, 65 ºC, 1 h; (b) room temperature, 16 h; (ii) SOCl2, 
DMF, room temperature, 6 h; (b) 1,3-difluorobenzene, AlCl3, reflux, 45 h; (iii) NH2OH•HCl, 
NaOH/H2O, EtOH, reflux, 96 h; (iv) (a) NaH, DMF, room temperature, 48 h; (v) (a) conc. HCl, 
EtOH, reflux 3 h; (b) room temperature, 48 h; (vi) (a) HCOOH, HCHO, reflux, 10 h; (b) HCl/Et2O. 
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Scheme 5. Synthesis of compounds 62 and 63.a 
 
aReagents and conditions: (i) (a) 4-Chloro-N-methylpiperidine, THF, Mg, bromoethane, reflux, 
1h; (b) room temperature, 2-fluorobenzonitrile, reflux, 3 h; (c) room temperature, 36 h; (d) NH4Cl, 
50 ºC, 2 h; (e) HCl/Et2O; (ii) (a) KOH (85%), hydroxylamine hydrochloride, ethoxyethanol, reflux, 
6 h; (b) HCl/Et2O (iii) (a) NaOH, toluene, phenyl chloroformate, reflux, 24 h; (b) petroleum ether; 
(iv) (a) KOH (85%), EtOH, reflux, 48 h; (b) HCl/Et2O. 
 
The synthesis of analog 64 is outlined in Scheme 6.  
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Scheme 6. Synthesis of compound 64.a 
 
aReagents and conditions. (i) (a) EtONa, EtOH, room temperature, 0.5 h; (b) 2-bromoethyl ether, 
reflux, 18 h; (ii) thiourea, EtONa, EtOH, reflux, 4 h. (iii) NiCl2, NaBH4, MeOH, room temperature, 
0.5 h; (iv) conc. HCl, 150 ºC, 3 h; (v) (a) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole, K2CO3, KI, 
DMF, 134 °C, 18 h; (b) CHCl3, (COOH)2/Et2O. 
 
Intermediate 89 was synthesized from ethyl acetoacetate (88). Intermediate 89 has been reported 
in the literature,144 however, the procedure was modified. The literature procedure generates 
sodium ethoxide in situ from sodium metal and EtOH. For the purpose of this reaction, 
commercially available sodium ethoxide, available in the laboratory, was used instead. Ethyl 
acetoacetate (88) was allowed to stir with sodium ethoxide for 0.5 h to generate a carbanion, and 
was followed by the addition of 2-bromoethyl ether to ultimately yield intermediate 89. 
Intermediate 89 was cyclized with thiourea to yield intermediate 90. Intermediate 90 is a known 
compound;145 however, here, it was synthesized using a literature procedure for a similar 
compound146 so as to avoid the in situ generation of sodim ethoxide. Reductive desulfurization of 
intermediate 90 yielded the substituted pyrimidone 91. Intermediate 91 has been reported in the 
literature,145 however, the procedure necessitates the use of reagents such as lead acetate, hydrogen 
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peroxide as well as hydrogen sulfide that are potentially toxic. Hence, a different procedure that 
has been reported for the synthesis of quinazolin-4(3H)-ones and 2,3-dihydro-4(1H)-
quinazolinones,147 that are structurally similar to intermediate 91, was used and resulted in good 
yields. The reaction uses relatively milder conditions, has higher selectivity, and is relatively 
cleaner.147 The reaction involves the slow addition of sodium borohydride to a solution of 
intermediate 90 and nickel chloride that results in the in situ generation of nickel boride.147 Nickel 
boride is responsible for the reductive desulfurization reaction.147 It has been hypothesized by 
Khurana and  Kukreja,147 that the reaction mechanism might involve hydrogenolysis of the CH-
SH bond that has been obtained from the reduction of the C=S bond, and that there is no formation 
of colloidal sulfur. The nickel boride needs to be formed in situ since preformed nickel boride 
loses its activity.147 However,  the reaction could potentially result in a mixture of intermediate 91 
and its reduced form 93 (Figure 27) (a second product was noted on TLC but was not isolated), 
and this was circumvented by optimizing the conditions and using a specific molar ratio of 
substrate: nickel chloride: sodium borohydride. The use of a 1:3:9 molar ratio of substrate: nickel 
chloride: sodium borohydride147 yielded only intermediate 91, and the time was optimized to 0.5 
h. However, the work-up presented a problem due to low solubility of product 91, in multiple 
solvents such as dichloromethane, chloroform, and ethyl acetate, and a modified work-up 
procedure was explored. Intermediate 92 was synthesized according to a literature procedure145 by 
heating intermediate 91 in a sealed tube with conc. HCl. The hydrochloride salt of intermediate 92 
is known,145 however, it was extremely hygroscopic and, hence, the free base was synthesized.  
Analog 64 was synthesized using a Finkelstein reaction. The yields of the reaction were poor (5%) 
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but most of the unreacted starting material was recovered and could be re-used. Compound 64 was 
unknown and was characterized by NMR and elemental analysis for C, H and N. 
 
 
Figure 27. Reduced form of intermediate 91. 
 
Compounds 65 and 66 were synthesized by Dr. Supriya A. Gaitonde, and it might be noted that 
we, both, were working on similar projects, to a common goal, and the synthesis is illustrated in 
Scheme 7.143 
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Scheme 7.  Synthesis of compounds 65 and 66.a
aReagents and conditions. (i) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h; 
(ii) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole, K2CO3, KI, MeCN, 88 ºC, 16 h; (iii) (a) 
BH3.THF, reflux, 2 h; (b) 6N HCl, reflux, 1 h. 
 
The synthesis of analogs 67 and 68 is described in Scheme 8. The synthesis of analog 67 and 68 
was initially attempted via common intermediate 98. Intermediate 97 was synthesized using a 
Grignard reaction. The Grignard reagent was synthesized in situ by reacting freshly distilled 
cyclohexylbromide with magnesium, and was subsequently reacted with cyclobutanone. 
Intermediate 97 is known and was synthesized using a literature procedure.148,149 Intermediate 98 
is also known and was synthesized by a literature procedure.150 Phenyliodine diacetate might be 
playing a role by forming a complex with intermediate 97, leading to C-C bond cleavage and the 
generation of a cation, followed by nucleophilic addition of H2O.
150 The purpose of the 1,1,1,3,3,3-
hexafluoro-2-propanol is to stabilize the cationic intermediate.150 Intermediate 99 was synthesized 
by tosylating intermediate 98. Synthesis of analog 67 was attempted via a nucleophilic substitution 
reaction, however the reaction led to multiple side-products and analog 67 could not be isolated. 
The synthesis of analog 67 was abandoned. 
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The carbonyl group of intermediate 98 was reduced using a Wolff-Kishner reduction to yield 
intermediate 100. Intermediate 100 was also synthesized via the reduction of 4-cyclohexylbutanoic 
acid (101) using LiAlH4. Intermediate 100 was known
151 and was synthesized via a procedure for 
a similar compound.152 Tosylation of 100 resulted in known intermediate 102,151 and, 
subsequently, analog 68 was synthesized via a nucleophilic substitution reaction between 102 and 
6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61). Compound 68 was unknown and was 
characterized by NMR and elemental analysis for C, H and N. 
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Scheme 8. Synthesis of compounds 67 and 68.a 
 
aReagents and conditions: (i) (a) Magnesium turnings, iodine, Et2O, 40 °C, 2h; (b) cyclobutanone, 
room temperature, 4 h; (ii) phenyliodine diacetate, 1,1,1,3,3,3-hexafluoro-2-propanol, H2O, room 
temperature, 15 min; (iii) tosyl chloride, Et3N, CH2Cl2, room temperature, 48 h; (iv) 6-fluoro-3-(4-
piperidinyl)benz[d]isoxazole, K2CO3, MeCN, 80 ºC, 18 h; (v) (a) Hydrazine hydrate, KOH, 
diethylene glycol, 135 °C, 2 h; (b) 200 ºC, 6 h; (vi) LiAlH4, THF, room temperature, 6 h; (vii) tosyl 
chloride, Et3N, CH2Cl2, room temperature, 48 h; (viii) (a) 6-fluoro-3-(4-
piperidinyl)benz[d]isoxazole , K2CO3, MeCN, 80 ºC, 96 h; (b) EtOH, HCl/EtOH. 
 
B. Radioligand binding studies 
Radioligand binding studies of the compounds were performed in HEK 293 cells expressing 5-
HT2A receptors. [
3H]Ketanserin ([3H]36) (Figure 17) was used as the radioligand, and non-specific 
  71 
binding was determined in the presence of methysergide. Competition curves were generated and 
analyzed by nonlinear regression to determine the binding affinities (Ki values) of the compounds.  
 
The binding affinities of risperidone (14) and the compounds 57, 60, 61, 62, 63, 65, and 66 for 5-
HT2A receptors were found to be 5.29 nM (log Ki = -8.27 ± 0.06), 2732 nM ( n = 1, performed in 
duplicate), 12.27 nM (log Ki = -7.91 ± 0.1), 71.41 nM (log Ki = -7.14 ± 0.09), 307.7 nM (n = 1; 
performed in duplicate), 198.9  nM (n = 1; performed in duplicate), 39.81 (log Ki = -7.40± 0.11), 
34.83 nM (log Ki = -7.45 ± 0.12), respectively. The displacement curves for compounds 57, 62 
and 63 are shown in Figure 28. 
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Figure 28. Ketanserin competition binding curves of deconstructed analogs 57, 62, and 63 in HEK 
293 cell membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate). 
 
C. Functional activity studies 
Functional activity studies of risperidone (14), and the deconstructed analogs 60, 61, 65, and 66 
were conducted in Dr. Diomedes Logothetis’s laboratory and have already been published.141 
 
Risperidone (14), and compounds 60, 61, 65, and 66, were initially tested in a two-electrode 
voltage-clamp (TEVC) electrophysiological assay that utilized a Xenopus laevis oocyte 
heterologous expression system that expresses 5-HT2A receptors and the G protein-gated inwardly 
  73 
rectifying K+ channel (GIRK4*) that serves as a sensitive reporter for GPCR activity.141 However, 
the ability of the compounds to directly inhibit the GIRK4* channel at higher concentrations (10 
µM) for analogs 60, 61, and 65 limited their full characterization.141 Analog 66 inhibited the 
GIRK4* channel at concentrations as low as 5 µM, and its actions could not be characterized.141 
The assay indicated that analogs 60, 61 and 65 are 5-HT2A receptor antagonists, however, to fully 
characterize them, a complementary epifluorescence assay in HEK 293 cells expressing 5-HT2A 
receptors that utilizes the Fura-2 dye to detect changes in intracellular Ca2+ concentrations was 
used.141 The IC50 values in order of decreasing potency were as follows: risperidone (14) (IC50 = 
5.59 ± 1.41 µM), analog 60 (IC50 = 7.40 ± 1.45 µM), analog 65 (IC50  = 16.65 ± 1.39 µM), analog 
61 (IC50 = 20.12 ± 2.24 µM), and analog 66 (IC50 43.88 ± 1.47 µM).
141  
 
Additionally, analog 61 was able to crosstalk at the 5-HT2A/mGlu2 heteromer (Figure 29), whereas 
analogs 60, 65, and 66 were unable to exert this effect. 
 
 
Figure 29. The crosstalk exhibited by analog 61 in the 5-HT2A/mGlu2 heteromeric receptor 
system (figure provided by Jason Younkin). 
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3. Discussion 
Deconstruction studies of risperidone (14) suggest that the entire structure of risperidone (14) is 
not needed for 5-HT2A receptor affinity or antagonist activity. Analog 60, that bears only half the 
structural features of risperidone (14), binds with only ~2-fold lower affinity than risperidone (14) 
and is nearly equipotent as a 5-HT2A receptor antagonist as compared to risperidone (14). 
Additionally, the other structurally abbreviated analogs (61, 62, 63, 65, and 66) of risperidone (14), 
bind with nanomolar affinity and retain 5-HT2A receptor antagonist activity. 
 
Analog 61, the desmethyl analog of 60, binds with ~6-fold lower affinity at 5-HT2A receptors than 
analog 60, suggesting that the methyl group makes additional interactions at the receptor. 
 
Analogs 62 and 63 represent desfluoro analogs of 60 and 61, respectively. Preliminary data suggest 
that analogs 62 and 63 bind with ~24- and ~3-fold lower affinity than analogs 60 and 61, indicating 
additional interactions by the fluoro group at the receptor. Analog 63 binds with similar affinity as 
analog 62, suggesting that the methyl group might not be making favorable interactions at the 
receptor, and that analogs 60 and 61 might be binding differently as compared to analogs 62 and 
63. However, additional replications are required to confirm the present results. 
 
Analog 66 is the descarbonyl analog of 65. Both bind with comparable affinities at 5-HT2A 
receptors, suggesting that the carbonyl group may not be an important structural requirement for 
binding affinity. However, the descarbonyl analog is ~2.5-fold less potent as a 5-HT2A receptor 
antagonist as compared to analog 65, suggesting that the carbonyl group might be contributing. 
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Even though this difference is very small it is statistically significant. (Unpaired t test; P- value = 
0.0027; α = 0.05). 
 
The “right half” of risperidone (14) seems be important for high binding affinity, since the “right 
half” of risperidone (14) i.e. analog 61 binds with ~13-fold lower affinity than risperidone (14), 
whereas, the “left half” of risperidone (14) i.e. analog 57 binds with ~500-fold lower affinity than 
risperidone (14). These and other studies previously conducted in our laboratory on analog 61,140 
suggest that the “right-half” portion of risperidone (14) is more important than the “left-half” 
portion of risperidone (14). However, the “left-half” portion of risperidone (14) seems to contribute 
to binding. 
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B. Specific Aim 2: Elaboration of risperidone to investigate the role of the two halves of 
risperidone in its 5-HT2A receptor antagonist activity 
1. Approach 
Elaboration is a part of the “deconstruction-reconstruction-elaboration” approach that is 
commonly used to study SAR.137 It involves modifying certain structural features one at a time. In 
this study, elaboration was used to investigate the roles of the “right” (i.e., the 6-fluoro-3-(4-
piperidinyl)-1,2-benz[d]isoxazole portion) and “left” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one portion) halves of risperidone in their contribution to its 5-HT2A 
receptor affinity and/or antagonist activity. 
 
a. Investigation of the potential role of the two halves of risperidone in its activity by 
examination of structural hybrids of risperidone and ketanserin 
Ketanserin (36) (Figure 30) is a prototypical, and the first identified, 5-HT2A receptor antagonist 
that has high affinity for 5-HT2A receptors (Ki = 19 nM). The structure of ketanserin (36) (Figure 
30) can be divided into two halves in a manner analogous to that of risperidone (14) (Figure 30; 
see also, Figure 25), consisting of the 4-(4-fluorobenzoyl)piperidine ring system (right half) and 
the 2,4-(1H,3H)-quinazolinedione ring (“left half”) connected by an ethyl linker. 
 
The structures of ketanserin (36) and risperidone (14) possess some structural similarities as well 
as some structural differences. In fact, the “right halves” of ketanserin (36), [4-(4-
fluorobenzoyl)piperidine], and risperidone (14), [6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole, 
are considered as being bioisosteres.153 Previous studies by our laboratory have shown that the 
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right halves of ketanserin (36), analogs 72 and 73 (Ki = 125 nM and 430 nM, respectively) bind to 
5-HT2A receptors with ~35- and ~123-fold  lower affinity than ketanserin (36) (Ki = 3.5 nM) 
(Figure 25).138 Deconstructed analogs 60 and 61 (Ki = 12.27 and 71.41 nM) bind with only 2- and 
13-fold lower affinity than risperidone (14) (Ki = 5.29 nM) while retaining 5-HT2A receptor 
antagonist action,141 suggesting that the right half of risperidone (14) might contribute to binding 
affinity to a greater degree as compared to the right half of ketanserin (36).  
 
As a part of this study, two structural hybrids of risperidone (14) and ketanserin (36), Ris/Ket (103) 
and Ket/Ris (104) (Figure 30), were synthesized to study the contribution of the “left” and “right” 
halves of risperidone (14), and to determine if risperidone (14) and ketanserin (36) bind in a similar 
manner. Analog 104 was synthesized by Dr. Supriya A. Gaitonde of our laboratory, but its 
synthetic details are provided here.143 
 
Figure 30. Compounds 103 and 104 represent structural hybrids of risperidone (14) and ketanserin 
(36). Compound 103 has been termed Ris/Ket, and 104 has been termed Ket/Ris. 
Ris/Ket (103) Ket/Ris (104) 
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 Hypothesis 
If the right half of risperidone (14) is important for binding affinity and functional activity, Ket/Ris 
(104) will have a higher binding affinity and/or activity than Ris/Ket (103), and vice versa.  
 
If ketanserin (36) and risperidone (14) bind in a common manner, hybrid ligands bearing features 
of both should bind with high affinity. 
 
In hybrid molecule 103, the “right half” of risperidone (14) was replaced with the “right half” of 
ketanserin (36), whereas in hybrid molecule 104, the “left half” of risperidone (14) was replaced 
by the “left half” of ketanserin (36). If Ris/Ket (103) retains high 5-HT2A receptor affinity, it might 
indicate that the “right half” of risperidone (14) is not important or that the “left half” is important 
for binding affinity. Conversely, if Ket/Ris (104) retains high affinity for 5-HT2A receptors, it 
might indicate that either the “left half” of risperidone (14) is not crucial or that the “right half” of 
risperidone (14) is important for 5-HT2A receptor antagonism and binding affinity. If both the 
hybrids bind with equally high affinity it might suggest that risperidone (14) and ketanserin (36) 
bind in a similar manner.  
 
b. Investigation of the potential role of the “right half” (i.e., the 6-fluoro-3-(4-piperidinyl)-
1,2-benz[d]isoxazole portion) of risperidone in its binding by making the “right half”  of 
risperidone similar to serotonin 
The “right half” of risperidone (14) was substituted with moieties found in agonists [i.e.; the 
tryptamine portion of 5-HT (6)] such as compounds 105-108 (Figure 31) to give compounds 109-
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112 (Figure 31), respectively. Compounds 105, and 107 are known to bind to 5-HT2A receptors 
and are partial agonists.154 Binding affinities were measured in COS-1 cells expressing 5-HT2A 
receptors using [3H]ketanserin as the radioligand.154 Analogs 105, and 107 bind with affinities of 
960 nM and 509 nM, respectively.154 Functional activities of analogs 105 (EC50 = 2647 nM, Emax 
= 0.43) and 107 (EC50 = 1736 nM, Emax = 0.12) were determined in HEK 293 cells that stably 
express 5-HT2A receptors in an assay that measures accumulation of [
3H] inositol phosphates.154 
Compound 106 is 5-HT2A receptor agonist in an in vitro calcium mobilization assay in HEK 293 
cells that over-express 5-HT2A receptors. (EC50 = 4.56; Emax = 101).
155  
 
Hypothesis  
If the right half of risperidone (14), and the tryptamine portion of 5-HT (6) bind in a similar 
manner then analogs bearing the tryptamine portion of 5-HT should bind. 
 
If analogs 109-112 retain high binding affinity, it will indicate that the indole ring binds in a 
manner similar to the benz[d]isoxazole ring of risperidone (14). If compounds 109-112 retain 
antagonist activity, it will be in accordance with the Ariens hypothesis of conversion of agonists 
to antagonists by addition of bulky substituents on amines. Lack of antagonist activity would 
indicate that the “left half” of risperidone (14) might not be contributing or that the “right half” of 
risperidone (14) is important for 5-HT2A receptor antagonist activity. Additionally, 109 and 110 
are secondary amines, whereas 111 and 112 retain the tertiary amine nature of risperidone (14), 
and will help ascertain the importance of the nature of the amine. Also, analogs 109 and 111 lack 
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the fluoro group and comparing them to analogs 110 and 112 will help investigate the role of the 
fluoro group. 
 
 
Figure 31. Elaboration of risperidone (14) by substituting the “right half” of risperidone with 
tryptamines. 
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c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one portion) of risperidone 
Several different, but relatively similar, pharmacophores for 5-HT2A receptor antagonists exist, 
and they all imply that multiple binding modes might exist for these antagonists.156–159 The 
pharmacophore consists of a basic amine and two hydrophobic/aromatic portions.156–159 The 
distances of the hydrophobic moieties from each other and from the basic amine vary among the 
different pharmacophores156–159 (discussed in detail in specific aim 5). These pharmacophores 
suggest that aromatization of the left-hand portion of risperidone (14) should result in enhanced 
binding affinity. Hence, we prepared analog 113 (Fgure 32), wherein the “left half” of risperidone 
(14) (Fgure 32) was aromatized.  
 
 
Figure 32. Aromatization of the “left half” of risperidone (14). 
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d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left half” of 
risperidone similar to other antipsychotic agents such as iloperidone 
Iloperidone (24) (Figure 33) is an atypical antipsychotic agent that has high affinity for 5-HT2A 
receptors (Ki = 5.6 nM).
160,161 Risperidone (14) and iloperidone (24) both have the same “right 
half” consisting of the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole moiety. We synthesized 
analogs 114 and 115 (Figure 33), wherein the “left half” of risperidone was made similar to the 
left half of iloperidone (24). Also, our laboratory has previously shown that deconstructed analogs 
76 and 77 (Figure 33) of ketanserin (36) that have the same “left half” as that of analogs 114 and 
115 respectively, retained 5-HT2A receptor antagonist activity and bind with only ~2 fold lower 
affinity than ketanserin (36).138 Since the 4-(4-fluorobenzoyl)piperidine moiety present in analogs 
76 and 77 and the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole  moiety present in analogs 114 
and 115 are bioisosteric,153 we might expect analogs 114 and 115 to bind with at least equally high 
affinity. 
   
In analogs 116 and 117 (Figure 33) we extended the chain connecting the phenyl ring and the 
piperidinyl nitrogen by one carbon atom to investigate the influence of chain length on 5-HT2A 
receptor binding affinity and activity.  
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If analogs 114-117 retain high affinity for 5-HT2A receptors and 5-HT2A receptor antagonism, it 
might indicate that either the entire “left half” of risperidone (14) is not crucial for activity and 
affinity or that the “right half” of risperidone (14) is important for 5-HT2A receptor activity and 
affinity.  
 
Figure 33. Elaboration of risperidone (14) by making the “left half” of risperidone similar to 
iloperidone (25). 
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2. Results 
A Chemistry 
a. Investigation of the potential role of the two halves of risperidone in its activity by 
examination of structural hybrids of risperidone and ketanserin 
Hybrid molecule 103 was synthesized using a Finkelstein alkylation reaction between the primary 
alkyl chloride 78 and 4-(4-fluorobenzoyl)piperidine. The synthesis is outlined in Scheme 9. The 
reaction was carried out in the presence of KI as a catalyst and 2 equivalents of K2CO3 (since the 
hydrochloride salt of 4-(4-fluorobenzoyl)piperidine was used) in MeCN as the solvent. Analog 
103 was unknown and was characterized by NMR and elemental analysis for C, H, and N atoms. 
 
Scheme 9. Synthesis of compound 103.a 
 
aReagents and conditions. (i) (a) 4-(4-fluorobenzoyl)piperidine hydrochloride, K2CO3, KI, MeCN, 
reflux 24 h; (b) CHCl3, (COOH)2/Et2O. 
 
Hybrid molecule 104 was synthesized by Dr. Supriya A. Gaitonde and its synthesis is outlined in 
Scheme 10.143 
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Scheme 10. Synthesis of compound 104.a 
 
aReagents and conditions. (i) K2CO3, acetone, reflux, 2 h; (ii) (a) 6-fluoro-3-(4-piperidinyl)-1,2-
benz[d]isoxazole, toluene, sealed tube, 100 °C, 44 h (b) 12 N HCl. 
  
b. Investigation of the potential role of the “right half “(i.e., the 6-fluoro-3-(4-piperidinyl)-
1,2-benz[d]isoxazole portion) of risperidone in its activity by making the “right half”  of 
risperidone similar to serotonin 
Compound 106 was successfully synthesized after attempting several synthetic routes. The 
synthesis of compound 106 is illustrated in Scheme 11. The first synthetic route attempted to 
synthesize 6-fluorotryptamine (106) was the Speeter-Anthony synthesis of tryptamines.162 The 
method involves reacting an indole with oxalyl chloride to yield the corresponding 3-indoleglyoxyl 
chloride, that is subsequently converted to the corresponding glyoxylamide. Reduction of the 
gyloxylamide should yield the corresponding tryptamine.162 Glyoxyl chloride intermediate 121 is 
known, and a literature procedure was followed for its synthesis.163 Intermediate 121 was 
synthesized from 6-fluoroindole (120) by treating it with with oxalyl chloride, and was 
subsequently reacted with ammonium hydroxide to afford the glyoxylamide 122. However, the 
product could not be isolated. Hence the synthetic route was changed. Intermediate 122 is 
unknown and a literature procedure that has been reported for the synthesis of 3-
indolylglyoxylamide was used instead.164 The alternative synthetic route utilized a modified Henry 
reaction, and involved reacting 6-fluoroindole (120) with 1-dimethylamino-2-nitroethylene in the 
119 118 104 
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presence of trifluoroacetic acid to yield intermediate 123. The reduction of intermediate 123 should 
yield compound 106. Intermediate 123 is known165,166 and was synthesized using a procedure for 
the same compound.165 The reduction of intermediate 123 was initially attempted using NaBH4 
and boron trifluoride etherate as the reducing agent (using a procedure for a similar compound167), 
however, product 106 was difficult to isolate.  
 
Hence, a similar model reaction was tried using indole (124), to synthesize tryptamine (105), and 
is outlined in Scheme 12. Indole (124) was treated with 1-dimethylamino-2-nitroethylene in the 
presence of trifluoroacetic acid to yield intermediate 125, that was subsequently reduced using two 
different reducing agents- one with NaBH4, boron trifluoride etherate complex (yield: 40%) using 
a procedure for a similar compound,167 and another method utilizing LiAlH4 (yield: 80%) using a 
procedure for the same compound.168  
 
Compound 105168 is known and was characterized by melting point. Both these methods yielded 
tryptamine (105), however the yields with LiAlH4 as a reducing agent were much better.  
 
Based on the model reaction for the synthesis of tryptamine (105), LiAlH4 was chosen as the 
reagent of the choice for the reduction of intermediate 123 to 6-fluorotryptamine (106). For the 
synthesis of tryptamine (105), 20 equivalents of LiAlH4 were used. However, the number of 
equivalents of LiAlH4 that could be used for the synthesis of compound 106 was limited by the 
fact that it could potentially defluorinate the compound. Several different reaction conditions were 
evaluated (Scheme 11 v-viii). A literature procedure for the same compound was used for the 
  87 
reduction, wherein 6 equivalents of LiAlH4 were used, and the reaction was carried out in THF at 
room temperature for 36 h (Scheme 11 v).166 However, the reaction yielded multiple products and 
106 could not be isolated. We next utilized conditions reported in a patent,165 wherein 5 equivalents 
of LiAlH4 were used and the reaction was carried out in THF at 60 ºC for 1 h. (Scheme 11 vi). The 
reaction was relatively cleaner and purification using Kugelrohr distillation was attempted, a 
hydrochloride salt was made. However, the yield was low and the salt was hygroscopic. The 
reaction was next carried out using the same conditions (Scheme 11 vii), however the work-up 
procedure was modified. A short column using CHCl3, MeOH and NH4OH (90:10:1) as eluents, 
was used to separate 106 from the side products and an oxalate salt was made. The yield was low 
and hence the reaction conditions were further optimized. We altered the solvent used for the 
reaction and used a mixture of THF and Et2O, as opposed to only using THF, keeping all the other 
reaction conditions constant (Scheme 11 viii). The reaction was much cleaner, and the oxalate salt 
was made. The oxalate salt was purified by reflux in MeCN for 0.5 h to remove impurities, and 
was subsequently recrystallized from acetone/H2O to yield compound 106. The oxalate salt of 
compound 106 was unknown, and was characterized by NMR and elemental analysis for C, H, 
and N atoms. 
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Scheme 11. Synthesis of compound 106.a
 
aReagents and conditions. (i) Oxalyl chloride, Et2O, room temperature, 3.5 h; (ii) NH4OH, THF, 
room temperature, 48 h; (iii) 1-dimethylamino-2-nitroethylene, trifluoroacetic acid, room 
temperature, 1 h; (iv) (a) NaBH4, BF3.Et2O, THF, reflux 2 h; (b) 1N HCl, 85 ºC, 2h; (c) Et2O, 
HCl/Et2O; (v) LiAlH4 (6 equivalents), THF, room temperature, 36 h; (vi) (a) LiAlH4 (5 
equivalents), THF, 60 ºC, 1 h; (b) Et2O, HCl/Et2O; (vii) (a) LiAlH4 (5 equivalents), THF, 60 ºC , 
1 h; (b) Et2O, (COOH)2/Et2O (viii) (a) LiAlH4 (5 equivalents), THF, Et2O, 60 ºC, 1 h; (b) Et2O, 
(COOH)2/Et2O. 
 
Scheme 12. Synthesis of compound 105.a
 
aReagents and conditions. (i) 1-dimethylamino-2-nitroethylene, trifluoroacetic acid, room 
temperature, 1 h; (ii) (a) NaBH4, BF3•Et2O, THF, reflux 2 h; (b) 1N HCl, 85 ºC, 2h; (c) Et2O, 
HCl/Et2O; (iii) (a) LiAlH4 (20 equivalents), THF, Et2O, reflux; (1) 3 h, reflux; (2) 12 h, room 
temperature; (b) Et2O, HCl/Et2O. 
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The synthesis of compound 108 is illustrated in Scheme 13. The initial synthetic route attempted 
was the Speeter-Anthony synthesis of tryptamines.162 6-Fluoroindole (120) was converted to the 
gyloxyl chloride intermediate 121 as previously described,163 and was followed by conversion to 
the corresponding glyoxylamide 126. Reduction of intermediate 126 was attempted using LiAlH4. 
Intermediate 126 is unknown, and a procedure for a similar compound was followed.163 However, 
the reaction for the reduction was not clean and multiple products were formed that were difficult 
to isolate.  
 
A model reaction was attempted to synthesize N-methyltryptamine (107), and the synthesis is 
outlined in Scheme 14. Indole (124) was allowed to react in a similar manner to yield the 
corresponding glyoxylamide 129 via the gyloxyl chloride intermediate 128. Intermediate 128 has 
been reported in the literature and was synthesized using the same procedure.169 Intemediate 129 
is known170 and was synthesized using a general procedure. The reaction for the reduction of the 
glyoxylamide intermediate 129 to the tryptamine was cleaner,163 and we observed that rather than 
getting the tryptamine (107) we obtained a side product that was characterized by melting point 
and found to be 130,171 and hence utilized a different synthetic route. The reaction of 105 with 
ethyl chloroformate yielded intermediate 131 that was subsequently converted to the tryptamine 
107 by LiAlH4. Intermediates 131,
172 and compound 107,172,173 have been reported in the literature 
and were synthesized using the procedures reported by Ignatenko et al.172  Analog 107 is known 
and was characterized by melting point and NMR. Tryptamine 108 was synthesized in an 
analogous manner from tryptamine 106 (synthesized as previously described), and the synthesis is 
illustrated in Scheme 13 (v-viii). Compound 108 was unknown and was synthesized from 106 
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using the procedures for the synthesis of 107 that have been reported in the literature by Ignatenko 
et al.172 Compound 108 was characterized by NMR and elemental analysis for C, H, and N atoms. 
 
Scheme 13. Synthesis of compound 108.a 
 
aReagents and conditions. (i) Oxalyl chloride, Et2O, room temperature, 3.5 h; (ii) methylamine in 
water (40%), THF, room temperature, 48 h; (iii) LiAlH4 (5 equivalents), THF, reflux, 8 h; (iv) 
LiAlH4 (1.2 equivalents), THF, reflux, 20 h (v) 1-dimethylamino-2-nitroethylene, trifluoroacetic 
acid, room temperature, 2 h; (vi) LiAlH4 (5 equivalents), THF, Et2O, 60 ˚C, 1 h; (vii) ethyl 
chloroformate, Et3N, CH2Cl2, room temperature, 3 h. (viii) (a) LiAlH4 (3 equivalents), THF, reflux, 
1.5 h; (b) Et2O, HCl/Et2O.  
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Scheme 14. Synthesis of compound 107.a
 
aReagents and conditions. (i) Oxalyl chloride, Et2O;(a) 0 ºC, 3 h; (b) room temperature, 1 h; (ii) 
methylamine in water (40%), THF, room temperature, 24 h; (iii) LiAlH4 (5 equivalents), THF, 
reflux, 8 h; (iv) ethyl chloroformate, Et3N, CH2Cl2, room temperature, 3 h; (v) (a) LiAlH4 (3 
equivalents), THF, reflux, 1.5 h. 
 
Compound 109 was synthesized after modifying several reaction conditions (Schemes 15 a-d), and 
the synthesis is outlined in Scheme 15 c xiii. The synthesis of 109 was initially attempted using a 
Finkelstein alkylation reaction, wherein an attempt was made to alkylate 105 with the primary 
alkyl chloride 78, in the presence of KI as a catalyst and K2CO3 as the base in DMF as the solvent. 
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The reaction mixture was heated at 80 ºC for 48 h. DMF was used as the solvent as opposed to 
MeCN, since 105 had limited solubilty in MeCN at room temperature. The reaction was not clean 
and it was impossible to isolate the product. We next used MeCN as the solvent. The tryptamine 
was solubilized by heating. Keeping the other conditions constant we gradually increased the 
temperature from room temperature (5 h- no reaction) to 60 ºC (18 h- no change), to finally 85 ºC 
for 48 h. A mixture of products was obtained that could not be characterized. We next carried out 
the reaction in a sealed tube at 80 ºC for 5 days using MeCN as the solvent. The reaction was 
cleaner with one spot being more prominent than the others on TLC, however, the desired product 
could not be separated. Keeping the other conditions constant we varied the solvent (toluene), to 
study whether the solvent was playing any role, and subsequently changed the base to Et3N instead 
of K2CO3 to evaluate if the base was negatively affecting the reaction. However, both attempts 
were fruitless. Further, to reduce the reaction time, the solvent MeCN was reduced to 1/3rd while 
keeping all the other reaction conditions constant (KI, K2CO3). The reaction gave multiple spots, 
however, there was one prominent spot that could be separated from the others by column 
chromatography. Characterization by NMR and mass spectrometry suggested that the product 
could be 132 (Figure 34), which indicates that the primary alkyl chloride 78 initially reacts with 
105 to yield product 109 that undergoes further N-alkylation to potentially yield 132. This was 
quite unexpected because we would not have expected an amine having a bulky substituent to react 
a second time. However, it is not unlikely since the secondary amine 109 would be more basic 
than the primary amine 105. The formation of 132 could be prevented in multiple ways (i) by 
increasing the dilution, so as to keep the reactants apart; (ii) by eliminating KI; (iii) by increasing 
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the equivalents of tryptamine (105) (not very feasible since the starting material had to be 
synthesized); and/or (iv) protecting the amine of the tryptamine. 
 
We first tried to dilute the reaction mixture (Scheme 15 b) and modified the amount of solvent 
keeping all other conditions constant, However, we still observed the formation of the side product 
132. We simultaneously also evaluated reaction conditions wherein we increased the equivalents 
of tryptamine (105) from 1 equivalent to 2 equivalents, and utilized K2CO3 as the base, KI as the 
catalyst, in MeCN (dilution: 1X) (Scheme 15 c). However, we still observed the side product 132. 
We next increased the dilution factor to 2X, and utilized 2 equivalents of 105, keeping all other 
conditions constant, and at the same time also tried to evaluate a different synthetic route (Scheme 
15 d). The alternate synthetic route involved protecting the amine terminal using an N-benzyl 
group and was achieved by a reductive amination reaction. The reaction of the protected 
tryptamine 133 yielded unknown intermediate 134 that was characterized by NMR, however, it 
was extremely hygroscopic and the HCl salt seemed to degrade.  
 
We seemed to have reduced the amount of side product that was being formed when the conditions 
as outlined in scheme 15 c were used. Hence, to further optimize the reaction conditions we 
eliminated KI. These conditions seemed to yield relatively lower amounts of the side product 132, 
and we were able to isolate and purify 109 by column chromatography and recrystallization 
techniques. Compound 109 was unknown and was characterized by NMR and elemental analysis 
for C, H and N atoms. 
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Figure 34. A side product of the Finkelstein alkylation reaction. 
 
Scheme 15 a. Synthesis of compound 109.a 
 
 
aReagents and conditions. (i) Tryptamine (105), K2CO3, KI, DMF, 80 °C, 48 h; (ii) Tryptamine 
(105), K2CO3, KI, MeCN; (a) room temperature, 5h; (b) 60 °C, 18 h; (c) 85 °C, 48 h; (iii) 
Tryptamine (105), K2CO3, KI, MeCN (dilution- 1X), sealed tube, 80 °C, 5 days; (v) Tryptamine 
(105), K2CO3, KI, toluene, sealed tube, 80 °C, 5 days; (vi) Tryptamine (105), Et3N, KI, MeCN 
(dilution- 1X), sealed tube, 80 °C, 5 days; (iv) Tryptamine (105), K2CO3, KI, MeCN (dilution- 
X/3), sealed tube, 80 °C, 5 days. 
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Scheme 15 b. Synthesis of compound 109.a 
 
aReagents and conditions. (vii) Tryptamine (105), K2CO3, KI, MeCN (dilution - 2X), reflux, 18 h; 
(viii) Tryptamine (105), K2CO3, KI, MeCN (dilution - 10X), reflux, 18 h;(ix) Tryptamine (105), 
K2CO3, KI, MeCN (dilution - 20X), reflux, 18 h; (x) Tryptamine (105), K2CO3, KI, MeCN 
(dilution - 1.8X), reflux, 18 h. 
 
Scheme 15 c. Synthesis of compound 109.a 
 
aReagents and conditions. (xi) Tryptamine (105) (2 equivalents), K2CO3, KI, MeCN (dilution - 
1X), reflux, 18 h; (xii) Tryptamine (105) (2 equivalents), K2CO3, KI, MeCN (dilution - 2X), reflux, 
18 h; (xiii) (a) Tryptamine (105) (2 equivalents), K2CO3, MeCN (dilution - 2X), reflux, 17 h; (b) 
CHCl3, (COOH)2/Et2O. 
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Scheme 15 d. Synthesis of compound 109.a 
 
aReagents and conditions. (i) (a) Benzaldehyde, MgSO4, EtOH, 60 °C, 1 h; (b) NaBH4, room 
temperature, 1.5 h; (ii) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one (78), KI, K2CO3, MeCN, reflux, 48 h. (b) CH2Cl2, HCl/EtOH. 
 
The synthesis of compound 110 is outlined in Scheme 16. The conditions that we had optimized 
for the synthesis of 109 were used to synthesize compound 110.  The tryptamine 106, was N-
alkylated by compound 78 to yield compound 110. We observed a mixture of compound 135 
(Figure 35) and compound 110. Column chromatography and recrystallization techniques were 
used to separate them. Compound 110 was unknown and was characterized by NMR and elemental 
analysis for C, H and N atoms. 
 
 
Figure 35. A side product of the Finkelstein alkylation reaction. 
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Scheme 16. Synthesis of compound 110.a 
 
aReagents and conditions. (i) 1-Dimethylamino-2-nitroethylene, trifluoroacetic acid, room 
temperature, 2 h; (ii) LiAlH4 (5 equivalents), THF, Et2O, 60 ºC, 1 h; (iii) (a) 3-(2-Chloroethyl)-2-
methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78), K2CO3, MeCN, reflux, 17 h; (b) 
CHCl3, (COOH)2/Et2O. 
 
The synthesis of compounds 111 and 112 are outlined in Scheme 17 and 18, respectively. 
Compounds 107 and 108 were synthesized as previously described in Schemes 14 and 13, 
respectively. Finkelstein alkylation reactions between compounds 107, 108 with compound 78 in 
MeCN yielded compounds 111 and 112, respectively. Compounds 111 and 112 were unknown 
and were characterized by NMR and elemental analysis for C, H and N atoms. 
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Scheme 17. Synthesis of compound 111.a 
 
Reagents and conditions. (i) Ethyl chloroformate, Et3N, CH2Cl2, room temperature, 3 h; (ii) (a) 
LiAlH4 (3 equivalents), THF, reflux, 1.5 h; (iii) (a) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-4-one (78), K2CO3, KI, MeCN. Reflux, 48 h; (b) CH2Cl2, 
(COOH)2/Et2O. 
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Scheme 18. Synthesis of compound 112.a 
 
aReagents and conditions: (i) 1-Dimethylamino-2-nitroethylene, trifluoroacetic acid, room 
temperature, 2 h; (ii) LiAlH4 (5 equivalents), THF, Et2O, 60 ˚C, 1 h; (iii) ethyl chloroformate, 
Et3N, CH2Cl2, room temperature, 3 h; (iv) (a) LiAlH4 (3 equivalents), THF, reflux, 1.5 h; (b) Et2O, 
HCl/Et2O; (v) (a) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-
one (78), K2CO3, KI, MeCN, reflux, 48 h; (b) CH2Cl2, (COOH)2/Et2O. 
 
c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one portion) of risperidone 
Scheme 19 outlines the synthesis of compound 113. A Finkelstein alkylation reaction between 6-
fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) and 136 in MeCN, yielded compound 113. The free 
base of compound 113 is known.174 The oxalate salt of compound 113 was unknown and was 
characterized by NMR and elemental analysis for C, H and N atoms. 
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Scheme 19 Synthesis of compound 113.a 
 
aReagents and conditions. (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, K2CO3, 
MeCN, reflux, 20 h; (b) CH2Cl2, COOH2/Et2O. 
 
 
d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left half” of 
risperidone  similar to other antipsychotic agents such as iloperidone 
 
Scheme 20 illustrates the synthesis of compounds 114 and 115. A Finkelstein alkylation reaction 
between 137, 138 with 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) in MeCN, yielded 
compounds 114 and 115 respectively. Compounds 114 and 115 were unknown and were 
characterized by NMR and elemental analysis for C, H and N atoms. 
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Scheme 20. Synthesis of compound 114 and 115.a 
 
aReagents and conditions. (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole  (61), KI, K2CO3, 
MeCN, reflux, 20 h; (b) 1 M HCl; (ii) (a) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, 
K2CO3, MeCN, reflux, 36 h; (b) EtOAc, HCl/EtOAc.  
 
The synthesis of compound 116 is illustrated in Scheme 21. Compounds 140175 and 141176 are 
known and were synthesized by procedures for the same compounds. 5-Chlorovaleroyl chloride 
(140) was synthesized by the reaction of 5-chlorovaleric acid (139) with thionyl chloride. A 
Friedel-Crafts acylation reaction between 140 and benzene yielded intermediate 141. Several side 
products were obtained (potentially the Freidel-Crafts alkylation product), and 141 was separated 
from the side-products by recrystallization and column chromatography. A Finkelstein alkylation 
reaction between 141 and 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) in MeCN yielded 
compound 116. Compound 116 was unknown and was characterized by NMR and elemental 
analysis for C, H and N atoms. 
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Scheme 21. Synthesis of compound 116.a 
 
aReagents and conditions: (i) SOCl2, reflux, 3 h; (ii) AlCl3, benzene; (a) 0 ºC, 1 h; (b) room 
temperature, 1 h; (iii) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), K2CO3, KI, sealed tube, 80 
ºC, 48 h; (b) EtOH, HCl/EtOH. 
 
The Finkelstein alkylation of 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) with 142 yielded 
compound 117, and the synthesis is outlined in Scheme 22. Compound 117 was unknown and was 
characterized by NMR and elemental analysis for C, H and N atoms. 
 
Scheme 22. Synthesis of compound 117.a 
 
Reagents and conditions: (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, K2CO3, 
MeCN, sealed tube, 80 ºC, 96 h; (b) MeOH, HCl/EtOH. 
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B. Radioligand binding studies 
Radioligand binding studies of the compounds were performed in HEK 293 cells expressing 5-
HT2A receptors. [
3H]Ketanserin (36) was used as the radioligand, and non-specific binding was 
determined in the presence of methysergide. Competition curves were generated and analyzed by 
nonlinear regression to determine the binding affinities of the compounds (Ki values). 
 
Binding affinities of risperidone (14), ketanserin (36) and their structural hybrids Ris/Ket (103) 
and Ket/Ris (104) were determined. The displacement curves for risperidone (14), ketanserin (36), 
103 and 104 are shown in Figure 36. 
 
Ketanserin (36) and risperidone (14) bound with affinities of 18.55 nM (log Ki = -7.7 ± 0.1), and 
5.29 nM (log Ki = -8.27 ± 0.06). Both the structural hybrids Ris/Ket (103) (Ki = 12.74 nM; log Ki 
= -7.8 ± 0.15) and Ket/Ris (104) (Ki = 0.96 nM; log Ki = -9.0 ± 0.12) bound with high affinity to 
5-HT2A receptors. 
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Figure 36. [3H] Ketanserin competition binding curves for risperidone (14), ketanserin (36), and 
their hybrids 103 (Ris/Ket) and 104 (Ket/Ris) in HEK 293 cell membrane preparations expressing 
5-HT2A receptors (for analogs 103 and 104: n = 2, performed in duplicate; figures provided by Dr. 
Jose Moreno). 
 
Preliminary competition curves for elaborated analogs 111 and 112 are shown in Figure 37. 
Analogs 111 and 112 exhibited high affinity for 5-HT2A receptors and bound with affinities of 285 
nM (n = 1; performed in duplicate), and 4.82 nM (n = 1, performed in duplicate), respectively. 
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Figure 37. [3H] Ketanserin competition binding curves for elaborated analogs 111 and 112 in HEK 
293 cell membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate). 
 
C. Functional activity studies 
Risperidone (14), ketanserin (36) and their structural hybrids were tested in a TEVC 
electrophysiological assay that utilizes the Xenopus laevis heterologous expression system as 
previously described.  
 
The Gαq mediated activity of 1 µM 5-HT was antagonized by 10 µM of risperidone (14), ketanserin 
(36), and the structural hybrid Ris/Ket (103), and reduced the activity to ~20, 15 and 21 % 
respectively. (Figure 38) Analog 104 did not reduce the activity of 5-HT. When ketanserin (36) (a 
5-HT2A receptor antagonist) and 104 were tested in the absence of 5-HT, both showed activities of 
~45 and 20% as compared to 5-HT suggesting potential partial agonist activity (Figure 39). This 
positive efficacy might be attributed to its direct effects on the GIRK4* channel or other effects 
and needs to be investigated further.  
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Figure 38. Functional activity of risperidone (14), paliperidone (pali, 56), ketanserin (36), and 
hybrids 103 and 104 in the presence of 5-HT. 
 
 
 
Figure 39. Functional activity of ketanserin (36) and hybrid 104 in the absence of 5-HT. 
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3. Discussion 
The structural hybrids of risperidone (14) and ketanserin (36) i.e. Ris/Ket (103) and Ket/Ris (104) 
both retain high affinity for 5-HT2A receptors. Ris/Ket (103) (Ki = 12.7 nM) binds with ~ 2-fold 
lower affinity than risperidone (Ki = 5.3 nM), and ~1.5-fold higher affinity than ketanserin (36) 
This suggests that the “right half” of risperidone (14) might be contributing more to binding 
affinity as compared to the “right half” of ketanserin (36). Ket/Ris (104) (Ki = 0.96 nM) binds with 
~5.5- and ~19- fold higher affinity than risperidone (14) (Ki = 5.29 nM), and ketanserin (36) (Ki = 
18.6 nM), respectively, suggesting that the “left half” of ketanserin (36) might be contributing to 
the binding affinity at 5-HT2A receptor to a greater extent as compared to the “left half” of 
risperidone (14). Hence, consistent with our results from deconstruction of risperidone (14) 
studies, the “right half” of risperidone (14) seems to be contributing to its binding affinity to a 
greater extent as compared to its “left half”. 
 
The hybrid molecules seem to have different functional activities at the 5-HT2A receptor. In the 
presence of 5-HT, risperidone (14), ketanserin (36) and Ris/Ket (103) were antagonists, whereas 
Ket/Ris (104) appeared to have partial agonist activity. In the absence of 5-HT, both ketanserin (a 
known neutral 5-HT2A receptor antagonist) as well as analog 104 exhibited partial agonist activity. 
This could be due to their direct effects at the GIRK4* channel or due to other effects. However, 
to determine if analog 104 is a partial agonist, further investigation is needed. 
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Analogs 111 and 112 both retain high affinity for 5-HT2A receptors. Analog 112 binds with 
nanomolar affinity that is comparable to the binding affinity of risperidone. Analog 111 binds with 
~57-fold lower affinity than analog 112 and risperidone (14). Analog 111 represents the desfluoro 
analog of 112 and indicates that the fluoro group might be making additional interactions with the 
5-HT2A receptors that enhances the binding affinity of analog 112 as compared to analog 111. 
Since analog 112 and risperidone (14) bind with comparable affinity, it might indicate that the 
benz[d]isoxazole ring of risperidone (14), and the indole ring of analog 112 might be interacting 
in a similar manner at 5-HT2A receptors.  
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C. Specific Aim 3. Molecular modeling studies of risperidone and its deconstructed and 
elaborated analogs at the 5-HT2A receptor to study their binding modes 
1. Approach 
Molecular modeling studies at 5-HT2A receptors were conducted to compare the binding modes of 
risperidone (14) (Figure 8) and its deconstructed and elaborated analogs, and to study receptor-
ligand interactions at a molecular level. Studying receptor-ligand interactions will help put into 
perspective the importance of different structural features. We also wanted to compare the binding 
modes of risperidone (14) to the prototypical 5-HT2A receptor antagonist ketanserin (36) (Figure 
17) to gain insight into the similarities and differences in their interactions at the 5-HT2A receptor.  
 
The 5-HT2A receptor has not been crystallized; hence, 3-dimensional homology models of 5-HT2A 
receptors were generated for the purpose of the study, and risperidone (14), ketanserin (36) and 
deconstructed and elaborated analogs of risperidone (14) were docked in the homology models. 
The homology models were already available in our laboratory, and were used for these studies;143 
their construction is briefly described below.  
 
a. Template, alignment and generation of homology models of 5-HT2A receptors 
 The 5-HT2 subfamily of receptors share ~70% homology with each other.
39 The crystal structure 
of the human (h)5-HT2B receptor (PDB ID: 4IB4; resolution: 2.7 Å) in complex with the agonist 
ergotamine that was solved by Wacker et al.177 in 2013 was used as a template to construct 
homology models of h5-HT2A receptors.
143 The software CLUSTALX 2.1178 was used to generate 
the multiple sequence alignment between 5-HT2A and 5-HT2B receptors.
143 Homology models 
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were constructed using MODELLER 9.1179 and were further processed to add hydrogen atoms and 
build disulfide bonds using SYBYL-X 2.1.143  
 
b. Validation of homology models, docking studies, and HINT analysis 
The models were validated by docking ketanserin (36) and comparing the results to those that have 
been reported in published homology models of 5-HT2A receptors as well as by site-directed 
mutagenesis data.143  
 
Homology models reported in the literature, and site-directed mutagenesis studies, have implicated 
a number of residues in TM3, TM5, TM6, and TM7 to be important for binding of orthosteric 
agents to 5-HT2A receptors, and include Trp151,
180 D155,139,180,181 S159 (TM3),182 S239 (TM5),183 
S242 (TM5),183 W336,180 F339,184 F340 (TM6),184–186 and Y370 (TM7).184  
 
Ketanserin (36), risperidone (14), and deconstructed, and elaborated analogs of risperidone were 
docked using GOLD Suite 5.2, GOLD Suite 5.3, or GOLD Suite 5.4187 depending on the version 
available at the time the docking studies were performed. Risperidone (14), an orthosteric 5-HT2A 
receptor antagonist/inverse agonist, binds at the same site as 5-HT (6).127 The amino acid residue 
Asp155 was used to define the binding site (radius: 10 Å) as this residue has been shown to be 
important and necessary for the binding both of orthosteric agonists such as 5-HT, as well as 
orthosteric antagonists such as ketanserin (36), by site-directed mutagenesis.139,181 Asp155, 
anchors the terminal amine moiety of 5-HT via an ionic interaction.181 The docked solutions were 
clustered (using a script provided by Dr. Philip D. Mosier). Solutions in the same cluster have a 
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similar docking pose, and the intra-cluster RMSD is less than 2 Å. Models were chosen based on 
ChemPLP scores (the higher the score, the better the interactions), cluster size, and the ability of 
the protonated amines of the compounds to form an ionic interaction with Asp155. The selected 
models were energy minimized in SYBYL-X 2.1 and the interactions were quantified by 
Hydropathic INTeraction (HINT) analysis.188 The HINT score is the sum of interactions between 
two molecules and accounts both for favorable and unfavorable interactions. A positive HINT 
score indicates overall favorable interactions.188 In our study, the HINT score indicates the sum of 
the interactions between the 5-HT2A receptor and the docked ligand. The HINT scores for the 
receptor-ligand complexes can be converted into free energy values and ~515 HINT score units 
correspond to 1 kcal/mol.189,190 
 
2. Results and discussion 
Risperidone (14) showed two docking/binding modes at 5-HT2A receptors (Figures 40 and 41). In 
one binding mode, the fluorine atom was oriented towards TM5 and is shown in Figure 40 
(docking mode 1). In the other mode, the fluorine atom was oriented towards TM7 and is shown 
in Figure 41 (docking mode 2). The second docking mode is consistent with what has been 
previously reported in the literature for risperidone.191  
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Figure 40. Docking mode 1 of risperidone (14) (cyan) at the 5-HT2A receptor with the fluorine 
atom oriented toward TM5. The red dashed lines indicate ionic interactions and the blue dashed 
lines indicate hydrogen bonds. 
 
 
 
Figure 41. Docking mode 2 of risperidone (14) (cyan) at the 5-HT2A receptor with the fluorine 
atom oriented toward TM7. The red dashed lines indicate ionic interactions and the blue dashed 
lines indicate hydrogen bonds. 
 
Risperidone (14) formed strong hydrophobic and polar interactions at the receptor. In docking 
mode 1, the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety (“right half”) of risperidone (14) 
predominantly formed polar interactions whereas the 6,7,8,9-tetrahydro-4H-pyrido[1,2-
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a]pyrimidin-4-one ring system (“left half”) of risperidone (14) appeared to predominantly form 
hydrophobic interactions. On the other hand, in mode 2, while the “right half” formed 
predominantly polar interactions, the “left half” seemed to form polar as well as hydrophobic 
interactions. In both modes, the indispensable ionic interaction between the protonated amine of 
the piperidine ring and Asp155 (TM3) was present. In mode 1, the nitrogen and oxygen atoms of 
the benz[d]isoxazale ring formed a bifurcated hydrogen bond with Ser159. In mode 2, the oxygen 
atom of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system formed a hydrogen 
bond with Ser159, whereas the fluorine atom and the oxygen atom of the benz[d]isoxazole ring 
formed hydrogen bonds with Trp367 and Thr134, respectively. Additionally, hydrophobic 
interactions with Trp151, Leu228, Leu229, Trp336, Phe339, Phe340, Trp367 and Tyr370 were 
observed for both binding modes.  
 
Both binding modes of risperidone at 5-HT2A receptors seem possible; however, mode 1 (HINT 
score = 1204) has a higher total HINT score as compared to mode 2 (HINT score = 1001), 
indicating more overall favorable interactions at the receptor (Table 3). However, the differences 
in the total HINT scores do not appear to be substantial. The binding and functional activity data 
available so far suggest that the fluorine atom is important for enhancing binding affinity, and that 
the carbonyl group of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system might 
be important for functional activity (albeit to a very small extent). In mode 2 the carbonyl oxygen 
and fluorine atom both formed hydrogen bonds with Ser159 and Trp367 making this mode more 
likely. However, both binding modes might exist, or be in equilibrium. 
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Table 3. Summary of HINT scores of the two binding modes of risperidone (14).  
Binding mode Polar Hydrophobic Total HINT score* 
Mode 1 1523 1225 1204 
Mode 2 1475 1280 1001 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
a. Molecular modeling studies of the deconstructed analogs at 5-HT2A receptors 
Figure 42 shows docking modes of truncated analogs 57, 58 and 59 relative to risperidone (14). 
They docked at the 5-HT2A receptor in a manner similar to docking mode 2 of risperidone (14). 
Analogs 57-59 predominantly show only one binding mode. 
 
For analogs 57-59, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system is flipped 
by ~180 ° about the horizontal axis. (Figure 42).  
 
 
Figure 42. Docking modes of deconstructed analogs 57 (light pink), 58 (salmon), and 59 (violet) 
at the 5-HT2A receptor relative to risperidone (14) (cyan).  
 
Figure 43 illustrates the interactions that analogs 57-59 make with the 5-HT2A receptor. The 
protonated amines of analogs 57, 58 and 59 made the crucial ionic interaction with Asp155. The 
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protonated amine of 59 also formed a hydrogen bond with Tyr370. Analogs 57, 58 and 59 showed 
hydrophobic interactions with the residues: Leu229, Phe234, Val235, Trp336, Phe339, and 
Phe340. Analog 57 made an additional hydrophobic interaction with Val366.  
 
 
Figure 43. Docking modes of deconstructed analogs 57 (light pink), 58 (salmon), and 59 (violet) 
at the 5-HT2A receptor. The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds. 
 
HINT scores for analogs 57, 58 and 59 are shown in Table 4. 
Table 4. Summary of HINT scores for risperidone (14) and analogs 57, 58 and 59.  
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14); Mode 1 1523 1225 1204 
Risperidone (14); Mode 2 1475 1280 1001 
57 1103 1037 670 
58 1194 988 309 
59 2793 734 1851 
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*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
The total HINT scores for analogs 57 and 58 are lower than that for risperidone (14) (Table 4), and 
suggest that risperidone (14) makes overall more favorable interactions with 5-HT2A receptors as 
compared to analogs 57 and 58. The binding affinity of analog 57 (Ki = ~2732 nM) is ~500-fold 
lower than the binding affinity of risperidone (Ki = 5.29 nM), and the “right half” of risperidone 
(14) seems to be more important for retaining binding affinity since analogs 60 (Ki = 12.27 nM 
and 61 (Ki = 71.41 nM) bind with only ~2 and ~14 fold lower affinity than risperidone (14) (Ki = 
5.29 nM) The total HINT score for analog 59 is higher than that for risperidone (14) suggesting 
that it makes overall more favorable interactions at the 5-HT2A receptor as compared to risperidone 
(14). However, preliminary binding data suggests that analog 59 might have a very low binding 
affinity for 5-HT2A receptors [(Ki > 10,000 nM]. The binding affinity might reflect the hydrophobic 
interactions (Table 4) since analog 59 has a lower score for total favorable hydrophobic 
interactions as compared to risperidone and analog 57. 
 
Molecular modeling studies for analogs 60-63, 65, and 66 have been reported previously.143 
 
Analogs 64 and 68 (Figure 44 and 45) have two binding modes that closely resemble docking 
modes 1 and 2 of risperidone (14). Figures 44 and 45 illustrate the interactions that the 
deconstructed analogs 64, 68, and risperidone (14) make with the 5-HT2A receptor in docking 
modes 1 and 2, respectively. 
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In binding mode 1 (Figure 44), analogs 64 and 68 docked in a manner similar to risperidone (14) 
and formed the interactions that were previously described for binding mode 1 of risperidone (14). 
In addition to those interactions, the pyrimidone oxygen of deconstructed analog 64 formed a 
hydrogen bond with Ser131. 
 
 
Figure 44. Docking modes of risperidone (14) (cyan), and analogs 64 (magenta) and 68 (green) at 
the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic interactions and the 
blue dashed lines indicate hydrogen bonds. 
 
In binding mode 2 (Figure 45), the molecules 64 and 68 docked in a manner similar to binding 
mode 2 of risperidone (14), and formed interactions that were consistent with what was previously 
described for binding mode 2 of risperidone (14). The pyrimidone oxygen of deconstructed analog 
64 formed a hydrogen bond with Ser159 whereas analog 68 lacks the carbonyl group that is present 
in risperidone (14), and hence lacks the hydrogen bond with Ser159. 
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Figure 45. Docking modes of risperidone (14) (cyan), and analogs 64 (magenta) and 68 (green) 
at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic interactions and the 
blue dashed lines indicate hydrogen bonds. 
 
As seen previously with risperidone (14), both binding modes seem possible. HINT scores for both 
analogs are summarized in Table 5. Total HINT scores for analogs 64 and 68 in binding mode 1 
were higher than that for binding mode 2 suggesting that it makes more overall favorable 
interactions in binding mode 1 with the receptor. However, the differences in HINT scores do not 
appear to be substantial. 
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Table 5. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs 64 
and 68. 
 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14); Mode 1  1523 1225 1204 
Risperidone (14); Mode 2  1475 1280 1001 
64; Mode 1 1936 810 847 
64; Mode 2 1538 811 616 
68; Mode 1 1464 1036 1166 
68; Mode 2 1156 1111 1057 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
b. Molecular modeling studies of elaborated analogs of risperidone 
Figures 46-49 show risperidone (14), ketanserin (36) and their structural hybrids (103 and 104) 
docked in homology models of the 5-HT2A receptor.  
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Figure 46. Docking modes of risperidone (14) (cyan), ketanserin (magenta), analogs 103 (green) 
and 104 (salmon) at the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic 
interactions and the blue dashed lines indicate hydrogen bonds. 
 
Figure 46 shows Ris/Ket (103) and Ket/Ris (104), as well as ketanserin (36), docked in a manner 
that is consistent with binding mode 1 of risperidone (14). The protonated amines of all analogs 
formed the crucial ionic interaction with Asp155. Ketanserin (36) interacts with the 5-HT2A 
receptor in a manner similar to that described previously for binding mode 1 of risperidone (14). 
The oxygen atom of the carbonyl group of the 4-fluorobenzoyl piperidine ring (“right half” of 
ketanserin) is engaged in a hydrogen bond with Ser159. Ris/Ket (103) has the “left half” of 
risperidone (14) and the “right half” of ketanserin (36). The “left half” of Ris/Ket (103) aligned 
well with the “left half” of risperidone (14) whereas the “right half” of Ris/Ket (103) aligned well 
the “right half” of ketanserin (36). The “left half” of Ris/Ket (103) interacts with the receptor in a 
manner similar to the binding mode 1 of risperidone (14), whereas the “right half” interacts in a 
manner that has been described for the “right half” of ketanserin (36). Ket/Ris (104) has the “left 
half” of ketanserin (36) and the “right half” of risperidone (14). Despite having the “left half” of 
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ketanserin (36) i.e. the quinazolinedione ring, the molecule docked in a manner such that the 
quinazolinedione ring was flipped by ~180 ° about the horizontal axis [when compared to the 
docking solution for ketanserin (36)] (Figure 47 A), and seemed to align better with the “left half” 
of risperidone (14) (Figure 47 B). The “right half” of Ket/Ris (104) overlapped well with the “right 
half” of risperidone (14) and showed the same interactions at the 5-HT2A receptor as were 
previously described for docking mode 1 of risperidone (14). 
 
 
Figure 47. A comparison between (A) binding modes of Ket/Ris (104) (salmon) and ketanserin 
(36) (magenta); (B) binding modes of Ket/Ris (104) (salmon) and risperidone (14) (cyan). 
 
Figure 48 shows a comparison of the Ris/Ket (103) and the Ket/Ris (104) hybrid with risperidone 
(14) and ketanserin (36) at the 5-HT2A receptor when oriented in docking mode 2. The “left half” 
of Ris/Ket (103) docked in a manner similar to risperidone (14) (Figure 48 B), whereas the “right 
half” was flipped by ~180 º about the horizontal axis as compared to the “right half” of ketanserin 
(36) (Figure 48 A). The “left half” of Ket/Ris (104) was flipped by ~180 º about the horizontal 
axis as compared to the “left half” of ketanserin (36) (Figure 48 C), and aligned better with the 
“left half” of risperidone (14) as opposed to the “left half” of ketanserin (36) (Figure 48 D) whereas 
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the “right half” of Ket/Ris (104) docked in a manner similar to the “right half” of risperidone (14) 
(Figure 48 D). 
  
 
Figure 48. A comparison between (A) binding modes of Ris/Ket (103) (green) and ketanserin (36) 
(magenta); (B) binding modes of Ris/Ket (103) (green) and risperidone (14) (cyan); (C) binding 
modes of Ket/Ris (104) (salmon) and ketanserin (36) (magenta); (D) binding modes of Ket/Ris 
(104) (salmon) and risperidone (14) (cyan). 
 
Figure 49 shows Ris/Ket (103), Ket/Ris (104) and ketanserin (36) docked in a manner that was 
consistent with binding mode 2 of risperidone (14). Risperidone (14) interacts with the 5-HT2A 
receptor in a manner previously described for binding mode 2 of risperidone (14). The protonated 
amines of ketanserin (36) and the two structural hybrids 103 and 104 formed an ionic salt-bridge 
interaction with Asp155. The carbonyl oxygen atom of Ris/Ket (103) formed a hydrogen bond 
with Ser131. The O2 and O1 oxygen atoms of the quinazolinedione rings of the Ket/Ris hybrid 
(104) and ketanserin (36), respectively, and the oxygen atom of the 6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one ring of risperidone (14) formed a hydrogen bond with Ser159. The 
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fluorine atoms of risperidone (14), ketanserin (36) and the Ket/Ris hybrid (104) formed a hydrogen 
bond with Trp367. The oxygen atoms of the benz[d]isoxazole rings of risperidone (14), and the 
Ket/Ris hybrid (104) formed a hydrogen bond with Thr134. Additionally, hydrophobic interactions 
with Trp151, Leu228, Leu229, Trp336, Phe339, Phe340, Trp367, and Tyr370 were observed for 
hybrid molecules 103 and 104, risperidone (14) and ketanserin (36). 
 
 
Figure 49. Docking modes of risperidone (14) (cyan), ketanserin (magenta), analogs 103 (green) 
and 104 (salmon) at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic 
interactions and the blue dashed lines indicate hydrogen bonds. 
 
Total HINT scores for risperidone (14), ketanserin (36), and their structural hybrids are 
summarized in Table 6. Both binding modes seem possible for risperidone (14) and the Ris/Ket 
(103), and Ket/Ris (104) hybrid. However, our molecular modeling studies suggest that binding 
mode 1 appears to be more likely for ketanserin (36) (total HINT score for binding mode 1 is 2-
fold higher than total HINT score for binding mode 2), and hence, risperidone (14) and ketanserin 
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(36) might not be binding in a similar manner at the 5-HT2A receptor. This could potentially explain 
the differences in binding affinities of the hybrids. Also the Ket/Ris (104) hybrid binds in a manner 
similar to risperidone (14), and this is supported by binding data since Ket/Ris (104) (Ki = 0.96 
nM) had a binding affinity similar to that of risperidone (14) (Ki = 5.29 nM). 
 
Ris/Ket (103) (Ki = 12.74 nM) binds with ~ 2-fold lower affinity than risperidone (Ki = 5.29 nM) 
and ~1.5-fold higher affinity than ketanserin (36). This suggests that the “right half” of risperidone 
(14) makes stronger interactions as compared to the “right half” of ketanserin (36). Ket/Ris (104) 
(Ki = 0.96 nM) binds with ~5.5- and ~19-fold higher affinity than risperidone (14) (Ki = 5.29 nM), 
and ketanserin (36) (Ki = 18.55 nM), respectively, suggesting that the “left half” of ketanserin (36) 
makes stronger interactions at the 5-HT2A receptor as compared to the “left half” of risperidone 
(14). The high binding affinity of the Ket/Ris hybrid might be attributed to the quinazolinedione 
ring of the Ket/Ris hybrid (104) aligning/superimposing better with the 6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one ring of risperidone (14) as opposed to the quinazolinedione ring of 
ketanserin (36). 
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Table 6. Summary of HINT scores for binding modes 1 and 2 of risperidone (14), ketanserin 
(36), and analogs 103 and 104. 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14); Mode 1  1523 1225 1204 
Risperidone (14); Mode 2  1475 1280 1001 
Ketanserin (36); Mode 1 1658 900 1112 
Ketanserin (36); Mode 2 1649 872 556 
Ris/Ket (103); Mode 1 1387 1054 1044 
Ris/Ket (103); Mode 2 1429 1357 992 
Ket/Ris (104); Mode 1 1547 870 1121 
Ket/Ris (104); Mode 2 1699 872 848 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
Figure 50 shows analogs 109 and 110 docked at the 5-HT2A receptor. It can be compared to 
docking mode 1 of risperidone (14), however, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-
4-one ring system ring system was displaced, and the fluorine atom of analog 110 is oriented 
differently as compared to the fluorine atom of risperidone (14) (Figure 50). 
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Figure 50. A comparison of the docking modes of analogs 109 (salmon) and 110 (green) with 
risperidone (14) (cyan) (docking mode 1). 
 
Figure 51 shows the receptor-ligand interactions that analogs 109 and 110 make with the 5-HT2A 
receptor in docking mode 1. A bidentate ionic interaction between the protonated amines of 
analogs 109 and 110 and Asp155 as well as a hydrogen bond between the oxygen atom of the 
6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system and Tyr370 was observed. 
Hydrophobic interactions with the amino acids Thr134, Ile152, Val156, Leu228, Phe234, Val235, 
Phe339, Phe340, Leu362, Trp336, Trp367, and Tyr370 were observed for analogs 109 and 110. 
Analog 109 had a total HINT score of 1065, whereas analog 110 had a HINT score of 881 (Table 
7), suggesting that analog 109 makes overall more favorable interactions in docking mode 1 at the 
5-HT2A receptor. However, the difference in total HINT scores does not appear to be substantial. 
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Figure 51. Docking modes of analogs 109 (salmon) and 110 (green) at the 5-HT2A receptor 
(docking mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds. 
 
Figure 52 shows analogs 109 and 110 docked at the 5-HT2A receptor. It can be compared to 
docking mode 2 of risperidone (14), however, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-
4-one ring system ring system was flipped by ~180 º along the horizontal axis, and the fluorine 
atom of analog 110 was oriented differently as compared to the fluorine atom of risperidone (14) 
(Figure 52). 
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Figure 52. A comparison of the docking modes of analogs 109 (salmon) and 110 (green) with 
risperidone (14) (cyan) (docking mode 2). 
 
Figure 53 depicts the receptor-ligand interactions that analogs 109 and 110 make with the 5-HT2A 
receptor in docking mode 2. The nitrogen atoms of the indole rings of analogs 109 and 110 formed 
a hydrogen bond with Asn363. An ionic interaction between the protonated amines and Asp155 
as well as a hydrogen bond between the N1 nitrogen atom of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one ring system and Ser159 was observed. Hydrophobic interactions with the amino 
acids Thr134, Trp151, Ile206, Leu228, Leu229, Ile236, Phe234, Phe339, Phe340, and Tyr370 were 
observed for analogs 109 and 110. The fluorine atom of analog 110 was involved in a hydrophobic 
interaction with Leu362. Analog 109 had a total HINT score of 1083, whereas analog 110 had a 
HINT score of 1297 (Table 7), suggesting that analog 110 makes overall more favorable 
interactions at the 5-HT2A receptor in docking mode 2. However, the difference in total HINT 
scores does not appear to be substantial. 
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Figure 53. Docking modes of analogs 109 (salmon) and 110 (green) at the 5-HT2A receptor 
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds. 
 
Based on the total HINT scores both binding modes might exist for analog 109, whereas binding 
mode 2 seems to be more likely for analog 110.  
 
Table 7. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs 
109 and 110. 
 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14) Mode 1  1523 1225 1204 
Risperidone (14) Mode 1  1475 1280 1001 
109; Mode 1 2038 952 1065 
109; Mode 2 2175 1026 1083 
110; Mode 1 2010 890 881 
110; Mode 2 2160 1091 1297 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
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Analogs 111 and 112 showed two docking modes at the 5-HT2A receptor (Figures 54, 55 and 56).  
 
Figure 54 shows analogs 111 and 112 docked at the 5-HT2A receptor. The binding mode was 
consistent with binding mode 1 of risperidone (14), however, the 2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of analogs 111 and 112 was oriented 
differently. Both analogs formed the essential ionic interaction with Asp155. The nitrogen atoms 
of the indole rings of both analogs formed a hydrogen bond with Ser159. Hydrophobic interactions 
with amino acid residues Trp151, Val156, Leu228, Leu229, Ile236, Trp336, Phe339, Phe340, and 
Tyr370 were observed for both analogs. 
 
 
Figure 54. Docking modes of risperidone (14) (cyan), and analogs 111 (violet) and 112 (magenta) 
at the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic interactions and the 
blue dashed lines indicate hydrogen bonds.  
 
In the second binding pose, analogs 111 and 112 were positioned in a manner similar to binding 
mode 2 of risperidone (14) at 5-HT2A receptors (Figure 55). However, the 6,7,8,9-tetrahydro-4H-
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pyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of analogs 111 and 112 was flipped by 
~180º about the horizontal axis when compared to the “left half” of risperidone (14).  
 
 
Figure 55. A comparison of docking modes of analogs 111 (violet) and 112 (magenta) with the 
docking mode 2 of risperidone (14) (cyan) at 5-HT2A receptors. 
 
The receptor-ligand interactions that analogs 111 and 112 make with the 5-HT2A receptor in 
docking mode 2 are illustrated in Figure 56. The “left halves” of analogs 111 and 112 
superimposed well, and were predominantly involved in hydrophobic interactions. The “right 
halves” of analogs 111 and 112 are comprised of an indole ring system and were oriented 
differently with respect to each other as well as with respect to the “right half” (benz[d]isoxazole 
ring) of risperidone (14). The protonated amines of both analogs formed a bidentate ionic 
interaction with the amino acid residue Asp155, and a hydrogen bond with Tyr370. The fluorine 
atom of analog 112 formed a hydrogen bond with Thr134. Additional hydrophobic interactions 
with amino acid residues Ile163, Trp151, Val156, Thr160, Leu228, Leu229, leu362, Trp336, 
Phe340, Val366 and Tyr370 were observed.  
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Figure 56. Docking modes of analogs 111 (violet) and 112 (magenta) at the 5-HT2A receptor 
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds.  
 
Modeling studies suggest that both binding modes are equally possible. Total HINT scores for 
analogs 111 and 112 are summarized in Table 8. Binding mode 2 seemed to have an overall higher 
HINT score as compared to the HINT score for binding mode 1 for analogs 111 and 112, and 
suggested more favorable interactions at 5-HT2A receptors in binding mode 2. However, the 
differences in the total HINT scores do not appear to be substantial. Analog 111 represents the 
desfluoro analog of compound 112. Preliminary biological data indicate that analog 111 (Ki ~ 285 
nM) binds with ~57-fold lower affinity than analog 112 (Ki  ~ 5 nM) , suggesting that the fluoro 
group of analog 112 is playing a role in enhancing its binding affinity. In binding mode 1 for 
analog 112, the fluorine atom did not seem to be making any significant contributions whereas in 
binding mode 2 the fluorine atom of analog 112 formed a hydrogen bond with Thr134. Hence, 
analogs 111 and 112 might be binding at the receptor in a manner that is consistent with binding 
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mode 2. The binding affinity of analog 112 is similar to the binding affinity of risperidone (14) 
suggesting that they might bind in a similar manner. However, the nitrogen atom of the indole ring 
of 112 is a hydrogen bond donor whereas the nitrogen and oxygen atoms of the benz[d]isoxazole 
ring of risperidone (14) are hydrogen bond acceptors and the nature of the hydrogen bonds they 
make with the receptor are different. This also suggests that the bifurcated hydrogen bond may not 
be crucial for binding affinity, and that risperidone (14) might be binding in a manner that is 
consistent with binding mode 2, even though both modes might exist. 
 
Table 8. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs 
111 and 112. 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14), Mode 1  1523 1225 1204 
Risperidone (14), Mode 2  1475 1280 1001 
111 ; Mode 1 1316 1161 629 
111; Mode 2 1495 1163 648 
112; Mode 1 1263 1217 666 
112; Mode 2 1411 1238 782 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
Analog 113 showed two docking modes at 5-HT2A receptors (Figures 57 and 58). 
 
Figure 57 depicts analog 113 docked at the 5-HT2A receptor in a manner similar to docking mode 
1 of risperidone (14). Analog 113 interacted with the 5-HT2A receptor in a manner that has been 
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previously described for risperidone (14). The 2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one ring 
system (“left half”) of analog 113 is oriented differently as compared to the 2-methyl-6,7,8,9-
tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of risperidone (14), and 
makes an additional hydrophobic interaction with Leu362. 
 
 
Figure 57. Docking modes of risperidone (14) (cyan) and analog 113 (pink) at the 5-HT2A receptor 
(docking mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds.  
 
Figure 58 shows analog 113 docked at the 5-HT2A receptor in a manner similar to docking mode 
2 of risperidone (14). Analog 113 interacts with the 5-HT2A receptor in a manner that has been 
previously described for docking mode 2 of risperidone (14). 
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Figure 58. Docking modes of risperidone (14) (cyan) and analog 113 (pink) at the 5-HT2A receptor 
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds.  
 
Table 9 summarizes the HINT scores for docking modes 1 and 2 of analog 113. Both modes seem 
possible, and there does not appear to be a substantial difference in the total HINT scores of 
risperidone (14) and analog 113. 
 
Table 9. Summary of HINT scores for binding modes 1 and 2 of risperidone (14), and analog 113. 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14); Mode 1  1523 1225 1204 
Risperidone (14); Mode 2  1475 1280 1001 
113; Mode 1 1654 1131 904 
113; Mode 2 1575 1008 1102 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
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Analogs 114, 115, 116 and 117 showed two docking modes at the 5-HT2A receptor (Figures 59, 
60, 61 and 62). 
 
Figure 59 shows analogs 114-117 docked at the receptor in a pose that is analogous to docking 
mode 1 of risperidone (14). The benz[d]isoxazole rings (“right half”) of all four analogs (114, 115, 
116 and 117) were oriented in a manner similar to risperidone (14), the nitrogen and oxygen atoms 
of the benz[d]isoxazole rings form a bifurcated hydrogen bond with Ser159. The “left halves” of 
the molecules were oriented differently with respect to each other as well as risperidone (14). 
Hydrophobic interactions with amino acid residues Trp151, Val156, Thr134, Leu228, Leu229, 
Trp336, Phe339, Phe340 and Tyr370 were observed for all analogs. The phenyl rings of analogs 
115 and analogs 117 formed additional hydrophobic interactions with Leu362 and Asn363. Analog 
116 and 118 formed additional hydrophobic interactions with Leu362 and Trp141, respectively. 
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Figure 59. Docking modes of risperidone (14), and analogs 114 (violet), 115 (light orange), 116 
(purple), and 117 (pale yellow) at the 5-HT2A receptor (docking mode 1). The red dashed lines 
indicate ionic interactions and the blue dashed lines indicate hydrogen bonds.  
 
Figure 60 shows analogs 114 and 116 docked at the 5-HT2A receptor. The orientation can be 
compared to docking mode 2 of risperidone (14) at the 5-HT2A receptor. 
 
 
Figure 60. A comparison of the docking modes of risperidone (14), and analogs 114 (violet) and 
116 (purple), at the 5-HT2A receptor. 
 
The receptor-ligand interactions that analogs 114 and 116 make with the 5-HT2A receptor are 
depicted in Figure 61. The protonated amines of analogs 114 and 116 formed an ionic interaction 
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with the amino acid residue Asp155, and a hydrogen bond with Tyr370. The carbonyl oxygen 
atoms of both the molecules formed a hydrogen bond with Ser242, the carbonyl oxygen atom of 
analog 114 formed an additional hydrogen bond with Thr160. Additional hydrophobic interactions 
with Thr134, Ile206, Leu228, Leu229, Val235, Trp336, Phe339, Phe340, Asn343, and Val366 
were observed for both analogs. 
 
 
Figure 61. Docking modes of analogs 114 (violet) and 116 (purple) at the 5-HT2A receptor 
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines 
indicate hydrogen bonds.  
 
Figure 62 shows analogs 115 and 117 docked at the 5-HT2A receptor in an orientation similar to 
the docking mode 2 of risperidone (14). The benz[d]isoxazole rings (“right half”) of both analogs 
aligned with the benz[d]isoxazole ring of risperidone (14), and the oxygen and fluorine atoms of 
benz[d]isoxazole rings of the analogs formed hydrogen bonds with Thr134 and Trp151, 
respectively. Additionally, hydrophobic interactions with Ile135, Trp151, Ile152, Leu228, Leu229, 
Phe234, Leu362, Trp336, Phe339, Phe340, Val 366, Trp367 and Tyr370 were observed. 
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Figure 62. Docking modes of risperidone (14) (cyan), and analogs 115 (salmon) and 117 (pale 
yellow) at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic interactions 
and the blue dashed lines indicate hydrogen bonds.  
 
The HINT scores for analogs 114, 115, 116, and 117 are summarized in Table 10.  
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Table 10. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs 
114, 115, 116 and 117. 
Binding mode Polar Hydrophobic Total HINT score* 
Risperidone (14); Mode 1  1523 1225 1204 
Risperidone (14); Mode 2  1475 1280 1001 
114; Mode 1 1510 838 992 
114; Mode 2 1701 763 927 
115; Mode 1 1344 931 1004 
115; Mode 2 1285 897 1199 
116; Mode 1 1669 784 769 
116; Mode 2 1609 931 853 
117; Mode 1 1548 984 1274 
117; Mode 2 1287 807 996 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
Modeling studies suggest that both binding modes are possible for analogs 114, 115, 116 and 117. 
The total HINT scores for the analogs do not appear to be substantially different.  
 
3. Summary 
Modeling studies suggest that risperidone (14) might bind in two different modes that might be 
equally feasible. However, biological data suggests that a fluorine atom enhances binding affinity, 
and that the carbonyl oxygen group might contribute towards enhancing 5-HT2A receptor 
antagonist activity, albeit to a very small extent. This suggests that binding mode 2 of risperidone 
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(14) might be the preferred orientation, since both the fluoro group and the carbonyl group make 
interactions with the receptor in binding mode 2. Additionally, modeling studies suggest that 
ketanserin might be utilizing binding mode 1 suggesting that risperidone (14) and ketanserin (36) 
might have different orientations at the 5-HT2A receptor. 
 
The different scenarios for preferred binding modes of risperidone (14) and its analogs are 
summarized in Table 11.  
 
Table 11. A summary of the preferred binding modes of risperidone (14) and its deconstructed 
and elaborated analogs. 
Binding modes Analogs 
Mode 1 = Mode 2 Risperidone (14), 64, 68, 103, 104, 111, 112, 113, 114, 115, 
116, 117 
Mode 1 > Mode 2 Ketanserin (36) 
Mode 1 < Mode 2 110 
No mode 1, only mode 2 57, 58, 59 
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D. Specific Aim 4. mGlu2 receptor PAMs 
a. Molecular modeling studies of the allosteric site of the mGlu2 receptor to determine 
whether structurally diverse PAMs of the mGlu2 receptor bind in a similar manner and in 
the same binding pocket 
1. Approach 
The mGlu2 receptor allosteric site is in the TMD.
192 Molecular modeling studies of the TMD of 
the mGlu2 receptor were conducted to study the allosteric binding site, and also to determine how 
structurally diverse mGlu2 receptor PAMs bind relative to one another and whether they bind in 
the same binding pocket. 
 
At the time the modeling studies were conducted there was limited mutagenesis data available, 
and the PAM binding pocket was not well defined. Schaffhauser et al.192 have identified that 
Ser688 (TM4), Gly689 (TM4), and Asn735 (TM5) are important for positive allosteric modulation 
of the mGlu2 receptor. They identified that either Ser688 or Gly689 in combination with Asn735 
or a combination of all three residues together forms the binding pocket of the PAM LY487379 
(44) (Figure 21).192 Hemstapat et al.193 subsequently reported mutagenesis data for LY487379 (44) 
(Figure 21) binding that was consistent with  previous studies by Schaffhauser et al.192 They 
additionally reported that binding of the structurally diverse PAM BINA (43) (Figure 21) is also 
affected by Ser 688 (TM4), Gly 689 (TM4) and Asn735 (TM5) mutants, and potentially binds in 
the same binding pocket as LY487379 (44). LY487379 (44) and BINA(43) are selective for the 
mGlu2 receptor over the mGlu3 receptor.
192,193 Hempstapat et al.193 have demonstrated that the 
negative allosteric modulator (NAM) MNI-135 is not affected by mutations of Ser688, Gly689 
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and Asn735, and does not show any selectivity for the mGlu2 receptor over the mGlu3 receptor, 
suggesting that the mGlu2 receptor might have multiple allosteric binding sites. Conversely, 
Lundstrӧm et al.194 have reported that Asn 735 mutants do affect the activity of NAMs, albeit to a 
lower extent than that of PAMs. However, they were not able to find any direct interactions 
between NAMs and Asn735 and they have hypothesized that Asn735 might be important for 
receptor stabilization. Additionally, Lundstrӧm et al.194 demonstrated that NAMs: RO4988546 and 
RO5488608 can completely displace the [3H] PAM- [3H]-2,2,2-TEMPS, suggesting that NAMs 
and PAMs of the mGlu2 receptor might occupy overlapping sites.  
 
A cavity search was performed using the MOLCAD function in SYBYL-X 2.1. Five cavities were 
detected. (Figure 63 A). Ser688, Gly689 and Asn735 were not a part of the same cavity. Asn735 
was located close to a larger and more well defined pocket (Figure 63 B). Based on the cavity 
search, and site-directed mutagenesis studies, we defined the PAM binding pocket as being within 
a 10 Å radius of the amino acid residue Asn735 (TM5) for our docking studies. Figure 64 illustrates 
the PAM JNJ-40411813 (45) docked in our homology model of the TMD of the mGlu2 receptor. 
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Figure 63. (A) Potential binding pockets in the TMD of the mGlu2 receptor; (B) binding pockets 
located close to residues Ser688, Gly689 and Asn735. 
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Figure 64. JNJ-40411813 (45) docked in our mGlu2 receptor homology model. 
 
Four known mGlu2 receptor PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-
40068782 (46) (Figure 21) were selected for our docking studies. 
 
The mGlu2 receptor is composed of 872 amino acids and is about 96 kDa. [Universal Protein 
Resource (UniProt) database; accession code: Q11416]. The extracellular domain of the mGlu2 
receptor has been crystallized and houses the orthosteric binding site.195 Since the crystal structure 
of the TMD of the mGlu2 receptor has not yet been solved, three-dimensional homology models 
of the TMD of the mGlu2 receptor were constructed. 
 
2. Results and discussion 
a. Template, alignment and generation of homology models 
The metabotropic glutamate receptor type 5 (mGlu5) shares high sequence identity (~50%) with 
the mGlu2 receptor. The crystal structure of the TMD of mGlu5 receptor co-crystallized with the 
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NAM mavoglurant has been solved (PDB ID:4OO9; resolution: 2.6 Å),196 and served as a template 
for building homology models of the mGlu2 receptor. One major disadvantage of using this 
template is that it is the crystal structure of the inactive form of the receptor. The X-ray crystal 
structure of the mGlu5 receptor suggests that Lys665 in TM3 forms a salt-bridge interaction (ionic-
lock) with Glu770 in TM6, and also interacts with Ser 613 in intracellular loop 1 (ICL1).196 Arg668 
in TM3 forms a H-bond with Ser614 in ICL1, and constitutes a secondary lock tethering TM3 to 
TM6 via a secondary lock (Figure 65).196 Lys665, Glu770 and Ser613 are highly conserved across 
most class C GPCRs, and this ionic-lock can be considered a hallmark feature of the inactive state 
of the receptor.196 However, the mechanism of activation still lacks understanding and a likely 
active state is still unknown.  
 
 
Figure 65. Ionic lock mechanism for maintenance of the inactive state of the mGlu5 receptor.
196 
 
The mGlu2 receptor TMD sequence was obtained in the form of a FASTA file from the Universal 
Protein Resource (UniProt) database (UniProt accession code: Q14416), whereas the FASTA file 
for the sequence of the template was obtained from the Protein Databank (PDB ID: 4OO9). The 
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mGlu2 receptor TMD amino acid sequence was aligned with the amino acid sequence of the TMD 
of the mGlu5 receptor using CLUSTAL X 2.1.
178 Since the sequence identity between the mGlu2 
receptor and the mGlu5 receptor is high (~50%) the sequences aligned well. (Figure 66) 
 
 
Figure 66. Sequence alignment of the mGlu5 receptor (template) with the mGlu2 receptor (to be 
modeled). 
(*) fully conserved residues between the sequences; (:) highly conserved residues between the 
sequences; (.)  weakly conserved residues between the sequences. 
 
Homology models (100) were generated using MODELLER v9.12.179 Hydrogen atoms were 
added to the homology models and disulfide bonds were built using SYBYL-X 2.1. Figure 67 
illustrates a homology model of the TMD of the mGlu2 receptor that was generated as a part of 
this study. 
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Figure 67. A representative homology model of the TMD of the mGlu2 receptor that was generated 
as a part of this study. 
 
 
b. Validation and Docking studies 
Ramachandran plots were generated using MolProbity.197 The plots (Figure 68) indicated that 
97.5% (231/237) of the residues were in favored regions, 99.6% (236/237) of the residues were 
in allowed regions, and there was one outlier (Gln790).  
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Figure 68. Ramachandran plot for a homology model of the mGlu2 receptor [Gln211 corresponds 
to Gln790 (amino acids were renumbered after generation of the Ramachandran plot)]. 
 
Molecules were sketched using SYBYL-X 2.1, energy-minimized, and docked into the 100 
homology models of the mGlu2 receptor using GOLD Suite 5.2,
187 The docking solutions were 
scored using the ChemPLP function. Docked solutions were divided into clusters using a script 
provided by Dr. Philip Mosier (Intracluster RMSD ≤ 2.0 Å). Top solutions (based on ChemPLP 
scores and cluster size) were analyzed using SYBYL-X 2.1, and best models were selected. Best 
models and solutions were merged and energy-minimized. HINT188 analysis was performed to 
choose the best models.   
 
Four well characterized PAMs- BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-
40068782 (46) (Figure 21) were docked in our homology models, and all four ligands were found 
to have a common docking pose and docked in the same binding pocket (Figure 69). Based on our 
modeling studies we have proposed that the PAM binding pocket is comprised of the following 
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amino acid residues: Arg635 (ECL2). Leu639, Gly640, Phe643 (TM3), Ser731, Met728, Leu732, 
Asn735, Val736, Ser737 (TM5), Thr769, Ile772, Trp773 (TM6), Met794, Ser797, Val798 (TM7).  
 
 After the completion of our molecular modeling studies conducted to gain insight into the binding 
mode of PAMs, a study characterizing the binding pocket of PAMs with mutagenesis data and 
homology modeling of the TMD of the mGlu2 receptor by Farinha et al.
198 and more recently by 
Lundstrӧm et al.199 was reported. Site-directed mutagenesis data reported in the literature have 
shown the following residues to be important for the activity of multiple PAMs : Arg635, Leu639, 
Phe643 (TM3), Ser688, Gly689 (TM4), Leu732 (TM5) and Trp773, Phe776 (TM6), 
Ser797(TM7),192,198,199 Trp773, and Asn735 mutants impact the activity and potency of most 
PAMs to a greater extent as compared to mutants of other amino acid residues.198  
 
The binding pocket for PAMs that we characterized is similar to what has now been reported in 
the literature.198,199 Of these, the amino acid residues Arg635, Leu639, Phe643, Leu732, Asn735, 
Trp773, and Ser797 were found important in prior site-directed mutagenesis studies 
  
Ser688 and Gly689 were not located close to the binding pocket of PAMS. It has been suggested 
that Ser688 and Gly689 might be involved in indirect signaling effects or in receptor 
dimerization.198 
 
The receptor-ligand interactions for PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and 
JNJ-40068782 (46) with the mGlu2 receptor are shown in Figure 69. 
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The oxygen atoms of the indanone ring of BINA (43), the sulfonyl group of LY487379 (44), and 
the oxygen atoms of the pyridone rings of JNJ-40411813 (45) and JNJ-40068782 (46) formed a 
hydrogen bond with Ser797. The carboxylate group of BINA (43) formed an ionic salt-bridge 
interaction with Arg635. Additionally, the molecules formed hydrophobic interactions with 
Leu639, Phe643, Leu732, Val736, Ile739, Ile772, Trp773 and Val798. BINA (43) makes an 
additional hydrophobic interaction with Met794. Site-directed mutagenesis data suggests that 
Asn735 is important for binding of PAMs; however, we did not observe any hydrogen bonds with 
Asn735 in this docking pose, and as previously suggested for NAMS, Asn735 might be involved 
in receptor stabilization.194 
 
 
Figure 69. Receptor-ligand interactions of BINA (43) (cyan), LY487379 (44) (salmon), JNJ-
40411813 (45) (yellow), and JNJ-40068782 (46) (magenta) with the mGlu2 receptor (binding 
mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines indicate 
hydrogen bonds.  
  
BINA (43) and LY487379 (44) also dock in a different orientation where we observed hydrogen 
bonds with Asn735, and are shown in Figures 70 and 71, respectively.  
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The receptor-ligand interactions for BINA (43) with the mGlu2 receptor (docking mode 2) are 
shown in Figure 70. The oxygen atom of the indanone ring of BINA (43) forms a hydrogen bond 
with Asn735. Hydrophobic interactions with the amino acid residues Leu639, Leu732, Val736, 
Phe643, Met728, Trp773, Phe776, Ile 779, Val796, Val798, Thr793, and Leu800 were observed. 
 
 
Figure 70. Receptor-ligand interactions for BINA (43) with the mGlu2 receptor (docking mode 2). 
The blue dashed indicate hydrogen bonds. 
 
The receptor-ligand interactions of LY487379 (44) with the mGlu2 receptor (docking mode 2) are 
shown in Figure 71. The sulfonyl oxygen atom of LY487379 (44) formed a hydrogen bond with 
Asn735, while the pyridinyl nitrogen atom formed a hydrogen bond with Ser801. Hydrophobic 
interactions with several amino acid residues such as His723, Leu639, Leu732, Val736, Val798, 
Phe643, Phe776, Trp773, Tyr647, Ile739, and Ile772 were observed. 
 
  153 
 
Figure 71. Receptor-ligand interactions for LY487379 (44) with the mGlu2 receptor (docking 
mode 2). The blue dashed lines indicate hydrogen bonds. 
 
HINT scores for PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-40068782 (46) 
are summarized in Table 12. BINA (43) had a higher total HINT score in mode 1 as compared to 
mode 2, and mode 1 might be the preferred orientation whereas the total HINT score for mode 2 
of LY487379 (44) was higher as compared to mode 1, and LY487379 (44) might bind in a manner 
that utilizes mode 2.  
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Table 12. Summary of HINT scores for mGlu2 PAMs: BINA (43), LY487379 (44), JNJ-40411813 
(45), and JNJ-40068782 (46). 
Binding mode Polar Hydrophobic Total HINT score* 
BINA (43); Mode 1 2232 1941 1124 
BINA (43); Mode 2  531 2083 554 
LY487379 (44); Mode 1 881 1482 205 
LY487379 (44); Mode 2 1645 883 996 
JNJ-40411813 (45) 2227 1077 517 
JNJ-40068782 (46) 545 889 113 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
Modeling studies suggest that BINA (43), JNJ-40411813 (45), and JNJ-40068782 (46) might be 
binding similarly whereas LY487379 (44) might bind in a different orientation. Additionally, the 
HINT scores for all four PAMs seem to be substantially different suggesting that they may have 
different binding affinities and/or potencies. 
 
b. Synthesis of the mGlu2 receptor PAM JNJ-40411813 (45) 
1. Approach 
A long-term goal of this project is to synthesize a bivalent ligand where a 5-HT2A receptor 
antagonist will be tethered to an mGlu2 PAM via a linker. An mGlu2 PAM was chosen over an 
mGlu2 receptor orthosteric agonist for two main reasons. The allosteric modulatory site is in the 
TMD as opposed to the orthosteric agonist binding site that is in the extracellular domain of mGlu2 
receptors. This is important because the 5-HT2A receptor antagonist binding site is in the TMD, 
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and it might be easier to connect a PAM that binds to the TMD of the mGlu2 receptor as compared 
to connecting an orthosteric agonist that binds in the extracellular domain via a linker. Another 
reason was that mGlu2 receptor PAMS are selective for mGlu2 receptors over mGlu3 receptors, 
whereas orthosteric mGlu2 agonists are not selective for mGlu2 over mGlu3 receptors.
193 
 
JNJ-40411813 (45) was chosen for several reasons: (i) the SAR of JNJ-40411813 (45) at the 
mGlu2 receptor has been studied previously;119 (ii) JNJ-40411813 (45) has shown antipsychotic 
potential in preclinical studies;119 and (iii) the nitrogen atom of the pyridone ring can serve as a 
potential positon to attach a linker. 
 
Based on SAR studies we know that the nitrogen atom of JNJ-40411813 (45) can tolerate longer 
chain lengths, and our molecular modeling studies suggest that the binding pocket has room to 
accommodate a longer chain length, making JNJ-40411813 (45) an ideal candidate.  
 
The synthesis of JNJ-40411813 (45) has  been reported by Cid et al,119 and is outlined in Scheme 
23. A drawback of this scheme was that the nitrogen substituent was added in the first step. Our 
aim was to synthesize multiple compounds, with varying linkers at the nitrogen atom of the 
pyridine ring, and hence, we decided to utilize a different synthetic route where the linker would 
be added in the penultimate/final step. This would enable us to synthesize multiple molecules 
relatively quickly.  
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Scheme 23. Synthesis of JNJ-40411813 (45)a (as reported by Cid et al.119).
 
aReagents and Conditions. (i) n-Butyl bromide, K2CO3, MeCN, reflux, 16 h; (ii) Hydrogen, 
Pd/C, EtOH, 2 h, 20 ºC, 760.05 Torr; (iii) phosphorous oxybromide, DMF, 100 °C, 1 h; (iv) 4-
phenylpiperidine, palladium diacetate, sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC, 
16 h; (v) N-chlorosuccinimide, CH2Cl2, 20 °C, 0.17 h. 
 
2. Results and discussion 
Scheme 24 outlines a synthetic route that we initially proposed for the synthesis of JNJ-40411813 
(45). 4-Bromo-2-chloropyridine (148) was allowed to react with 4-phenylpiperidine to yield 
intermediate 149. The product was characterized by mass spectrometry to ensure that the bromo 
group, and not the chloro group had been substituted. The substitution of the chloro group of 
intermediate 149 with a hydroxy group was attempted. Intermediate 150 is unknown and 
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procedures for similar reactions were used. The reaction was carried out using reagents such as 
potassium hydroxide,200 sodium hydroxide,201 and acetic acid202 (scheme 24 ii-iv). However, the 
yields were low, and we could isolate most of the starting material. The reactions failed to go to 
completion, hence, we modified the synthetic route.  
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Scheme 24. Unsuccessful synthesis of JNJ-40411813 (45).a 
 
aReagents and Conditions. (i) 4-Phenylpiperidine, K2CO3, DMF, 90 ºC, 6 h; (ii) 50% KOH, 
DMF, (a) 24 h, reflux, 36 h; (iii) NaOH (2M), H2O, reflux, 30 h; (iv) AcOH, H2O, reflux, 15 h; 
(v) KOH (50%), t-BuOH, reflux, 36 h. 
 
The modified synthetic route is outlined in Scheme 25. Intermediate 149 was synthesized as 
previously described, and we subsequently attempted to substitute the chloro group with a 
benzyloxy group to yield intermediate 151, however the reaction did not progress. We next 
modified the synthetic route further. We substituted the chloro group of 148 with a benzyloxy 
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group to yield intermediate 152. Intermediate 152 was known and was synthesized using a 
procedure for the same compound.203 The nucleophilic substitution of 152 with 4-phenylpiperidne 
using K2CO3 in DMF as a solvent resulted in very low yields of 151. Hence, we used a Buchwald-
Hartwig reaction to synthesize intermediate 151. Intermediate 151 was not known and was 
synthesized by a procedure for a similar compound.119 Intermediate 150 was synthesized by the 
debenzylation of intermediate 151 using hydrogen and Pd/C as the catalyst. Intermediate 150 was 
not known and was synthesized using a procedure for a similar compound.204 The N-alkylation of 
intermediate 150 was attempted using various methods (Scheme 25 viii-x), however, they all 
resulted in the formation of the O-alkylated product (153) (Figure 72). We further modified the 
synthetic scheme. 
 
 
Figure 72. O-Alkylated product. 
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Scheme 25. Proposed synthesis of JNJ-40411813 (45).a 
 
Reagents and conditions (i) 4-Phenylpiperidine, K2CO3, DMF, 90 ºC, 6 h; (ii) benzyl alcohol, NaH, 
THF; (a) room temperature, 48 h; (b) reflux, 24 h; (iii) (a) benzyl alcohol, NaH, THF, room 
temperature 15 min; (b) 148,  reflux, 3 h; (iv) 4-phenylpiperidine, K2CO3, KI, DMF, 90 ºC, 21 h; 
(v) 4-phenylpiperidine, K2CO3, DMF, 110 ºC, 48 h; (vi) 4-phenylpiperidine, palladium diacetate, 
sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC, 27 h; (vii) H2, Pd/C, 30-40 psi, MeOH, 
EtOAc, room temperature, 2h; (viii) n-butyl bromide KI, K2CO3, MeCN, reflux, 20 h; (ix) (a) NaH, 
DMF, room temperature, 30 minutes; (b) n-butyl bromide, 78 ºC, 4 days (x) (a) NaH, DMF, room 
temperature, 1 h; (b) n-butyl bromide, 103 ºC, 3 days. 
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The modified synthetic route is outlined in Scheme 26. Intermediate 150 was synthesized as 
previously described. Intermediate 150 was chlorinated to yield intermediate 154. Intermediate 
154 was unknown and was synthesized using a procedure for a similar compound.119 The N-
alkylation of intermediate 154 was attempted using a procedure for N-alkylation of 2-pyridones in 
water,205 however the reaction was not clean, and product could not be isolated.  
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Scheme 26. Proposed synthesis of JNJ-40411813 (45).a
 
aReagents and conditions. (i) Benzyl alcohol, NaH, THF, reflux, 3 h; (ii) 4-phenylpiperidine, 
palladium diacetate, sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC, 27 h; (iii) H2, Pd/C, 
30-40 psi, MeOH, EtOAc, room temperature, 2h.; (iv) N-chlorosuccinimide, CH2Cl2, room 
temperature, 10 min; (v) n-butyl bromide, tween 20, K2CO3, 70 ºC, 22 h. 
 
We came within one step of our desired synthetic goal (Scheme 26). But we were ultimately unable 
to synthesize JNJ-40411813 (45) using a modified procedure where the linker would be added in 
the penultimate/ultimate step. Either an entirely new synthetic route will need to be devised, or the 
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scheme that was originally reported in the literature might be used to add the linker in the very 
first step since N-alkylation of the compound at a later stage did not yield the desired product.  
 
In any event, such studies are beyond the scope of the present work, and further pursuit of a novel 
method of preparation of JNJ-40411813 (45) was abandoned. 
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E. Specific Aim 5. Redefining a pharmacophore for 5-HT2A receptor antagonists 
1. Approach 
5-HT2A Receptor antagonists belong to diverse chemical classes and a number of pharmacophore 
models have been proposed to explain the receptor-ligand interactions. 156–159,206,207 Reported 
pharmacophore models for 5-HT2A receptor antagonists include two aromatic/hydrophobic regions 
and a protonated basic amine (Figure 73), and suggest that these agents might have multiple 
binding modes.156–159 When a central ring is flanked by two other ring systems, the fold angle 
between the rings seems to play a role as well.208  
 
 
Figure 73. A representative pharmacophore for 5-HT2A receptor antagonists (data from 
references 156-159). 
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Risperidone (14) (Figure 8) has been studied in two pharmacophoric studies.  A study by Sekhar 
et al.209 has identified pharmacophoric features essential for atypical antipsychotic action (SDAs) 
(Figure 74). However, the investigation did not specifically address 5-HT2A receptor binding, only 
SDA action in general. Hence, it is not particularly relevant to the studies at hand. Another study 
by Awadallah210 identified multiple pharmacophoric features for 5-HT2A receptor antagonist 
activity (Figure 75).  
 
 
Figure 74. A pharmacophore for 5-HT2A receptor antagonist action (adapted from Sekhar et al.
209). 
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Figure 75. A representative pharmacophore for SDAs F1: H-bond acceptor center; F2: aromatic 
or hydrophobic center; F3 and F5: Pi orbital accommodation; F4: aromatic center with a H-bond 
donor group; F6: hydrophobic center; F7: H-bond acceptor center (adapted from Awadallah210).  
 
The SAR of risperidone (14) at 5-HT2A receptors has not been studied extensively. Deconstruction 
studies were conducted in our laboratory to determine the minimal structural requirements for 
risperidone (14) to retain 5-HT2A receptor affinity and antagonism (described previously). We have 
shown that analog 61 (Ki = 71.41 nM) (Figure 24) that has only half the structural features of 
risperidone (14) (Ki = 5.29 nM) binds with ~ 14 fold lower affinity than risperidone (14) and retains 
5-HT2A receptor antagonism.
141 Furthermore, the N-methyl analog of 61 (analog 60, Ki = 12.27 
nM) binds with even higher affinity and retains antagonist activity. This suggests that the entire 
structure of risperidone (14) is not necessary for 5-HT2A receptor affinity and antagonism. Analog 
61 has only one aromatic region and a basic protonated amine, as opposed to the previously 
reported 5-HT2A receptor antagonist pharmacophores
156–159 that consist of two aromatic regions 
and a basic protonated amine (Figure 73), and lacks many of the features shown in Figures 74 and 
F1 
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75. To define a revised pharmacophore, analog 155 was proposed (Figure 76) for synthesis and 
evaluation. In analog 155 the nitrogen atom of the piperidine ring is located at a shorter distance 
from the aromatic center (benzene-ring centroid; Table 13; see also Appendix A) as compared to 
the distance for the same in analog 61 (6.81 Å) (in its lowest energy conformation), and will help 
evaluate the effect of this distance on 5-HT2A receptor affinity and antagonism. For 5-HT (6), the 
distance of the aromatic center from the terminal nitrogen atom is 6.51 Å, and lies in-between the 
distances of the aromatic center from the nitrogen atoms for analogs 61 and 155. Analog 63 (Figure 
76) will help evaluate the contribution to binding of the fluoro group. 
 
 
Figure 76. Analogs proposed to define a 5-HT2A receptor antagonist pharmacophore as 
compared to the structure of 5-HT (6). 
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Table 13. Distances of the aromatic centroid from the N atom and the energy of the lowest 
energy conformer (CNF_#) for the different isomers of analog 155 (see Appendix A). 
Isomer Distance (Å) Energy (kcal/mol) 
S equatorial* 155 (CNF_15) 5.75 15.56 
R axial** 155 (CNF_1) 5.75 15.22 
R equatorial* 155 (CNF_1) 6.45 15.56 
S axial** 155 (CNF_1) 5.85 15.94 
*Equatorial indicates that the benz[d]isoxazole ring is an equatorial substituent. **Axial indicates 
that the benz[d]isoxazole ring is an axial substituent. Distances of the aromatic (benzene-ring) 
centroid from the N atom for 5-HT and analog 61 are 6.51 Å and 6.81 Å, respectively. 
 
2. Results 
A. Synthesis 
The synthesis of analog 155 is outlined in Scheme 27. The amine of nipecotic acid (156) was 
protected using a formyl group. Formic acid and acetic anhydride were used to generate formic 
acetic anhydride in situ, which then acted as a formylating agent to yield intermediate 157. 
Intermediate 157 was unknown, and was synthesized using a procedure for a similar compound.143 
The reaction of 157 with thionyl chloride yielded intermediate 158 that was subsequently 
converted to 159 via a Friedel Crafts acylation reaction with 1,3-difluorobenzene. Intermediates 
158 and 159 were unknown and were synthesized using procedures for similar compounds.153 The 
Friedel Crafts acylation reaction was sensitive to moisture and it was necessary to use freshly 
sublimed aluminum chloride for the reaction. The reaction of intermediate 159 with 
hydroxylamine yielded the E and Z isomers of the oxime 160. The oxime intermediate 160 is not 
known and was synthesized by a procedure for a similar compound.143 The cyclization of oxime 
160 via intramolecular displacement of the 2-fluoro group to intermediate 161 was catalyzed by 
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sodium hydride. It has been reported in the literature that only the Z isomer of the oxime 
participates in the cyclization reaction for similar compounds.153 Intermediate 161 was deprotected 
using conc. HCl to yield analog 155. Intermediate 161 and analog 155 are unknown and were 
synthesized using procedures for similar compounds.153 Analog 155 was characterized by NMR 
and C, H, N analysis. 
 
Scheme 27. Synthesis of analog 155.a 
 
aReagents and conditions: (i) (a) HCOOH, Ac2O, 65 ºC, 1 h; (b) room temperature, 16 h; (ii) SOCl2, 
room temperature, 6 h; (iii) 1,3-difluorobenzene, AlCl3, reflux, 22 h; (iv) NH2OH•HCl, 
NaOH/H2O, EtOH, reflux, 96 h; (v) NaH, DMF, THF 75 C, 4h; (vi) HCl (3 N), EtOH, reflux 3 h. 
  170 
 
B. Radioligand binding and functional activity studies 
Radioligand binding studies were performed in HEK 293 cells expressing 5-HT2A receptors. 
[3H]Ketanserin ([3H]36) was used as the radioligand, and non-specific binding was determined in 
the presence of methysergide. Competition curves were generated and analyzed by non-linear 
regression analysis to determine the binding affinities (Ki values) of the compounds.  
 
As previously reported analog 61 has a binding affinity of 71.41 nM (log Ki = -7.14 ± 0.09), and 
is a 5-HT2A receptor antagonist,
141 whereas analog 63 binds to 5-HT2A receptors with an affinity 
of ~200 nM (n = 1, performed in duplicate). Analog 155 has a binding affinity of ~256 nM (n = 1, 
performed in duplicate) (Figure. 77). However, the racemic mixture of analog 155 was used, and 
if any of the stereoisomers are inactive, the binding affinity of the other sterioisomers might be 
higher. 
 
. 
Figure 77. [3H]Ketanserin binding competition curve by compound 155 in HEK 293 cell 
membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate). 
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C. Molecular modeling studies 
Analogs 61, 63, and 155 were docked in homology models of 5-HT2A receptors to study the 
receptor-ligand interactions. The analogs were docked into 100 homology models of the receptor 
and analyzed as previously described. Analogs 61 and 63 were docked by Dr. Supriya A. 
Gaitonde.143  
   
Figure 78 shows analogs 61, 63 and the R equatorial (CNF_1) and S equatorial (CNF_15) (see 
Appendix A) isomers of analog 155 docked at the 5-HT2A receptor. They all seem to dock in a 
similar manner, however, their benz[d]isoxazole rings are oriented slightly differently and do not 
overlap, leading to differences in their interactions with the receptor.  
 
 
Figure 78. Docking modes of analog 61 (salmon), 63 (green), R equatorial-155 (CNF_1; violet) 
and S equatorial-155 (CNF_15; pink) at the 5-HT2A receptor.  
 
Figure 79 illustrates the interactions that molecules 61 and 63 made with the 5-HT2A receptor. The 
nitrogen and oxygen atoms of the benz[d]isoxazole rings formed two bifurcated hydrogen bonds 
with Ser159 and Ser242. Both analogs formed a crucial bidentate ionic interaction with Asp155. 
R equatorial-155 S equatorial-155 
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Additionally, the fluorine atom of analog 61 seemed to be making a potential hydrogen bond with 
Ser239. The analogs made hydrophobic interactions with Phe234, Trp336, Phe339, Phe340, 
Val156, and Val366. 
 
 
Figure 79. Docking modes of analogs 61 (salmon) and 63 (green) at the 5-HT2A receptor. The 
red dashed lines indicate ionic interactions and the blue dashed lines indicate hydrogen bonds. 
 
Figure 80 shows the R equatorial (CNF_1) and S equatorial (CNF_15) isomers of analog 155 
docked at the 5-HT2A receptor. Analog 155 interacts with the receptor in a manner that is different 
from analogs 61 and 63. The benz[d]isoxazole rings of the molecules did not show a bifurcated 
hydrogen bond. The oxygen atoms of the benz[d]isoxazole rings of both isomers formed hydrogen 
bonds with Thr160 and Ser242, and the fluoro groups formed a hydrogen bond with Ser239. The 
protonated amine of the R equatorial isomer formed a bidentate ionic interaction with Asp155, 
whereas the protonated amine of the S equatorial isomer formed an ionic interaction with the 
carbonyl oxygen of Asp155, and a hydrogen bond with Tyr370. Additionally, hydrophobic 
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interactions with Phe234, Trp336, Phe339, Phe340, Val156, and Val366 were observed for both 
isomers. HINT scores (Table 14) for the R equatorial and S equatorial isomers of analog 155 are 
comparable and suggest that they might bind at 5-HT2A receptors with similar affinities. 
 
 
Figure 80. Docking modes of R equatorial-155 (CNF_1; violet) and S equatorial-155 (CNF_15; 
pink) at the 5-HT2A receptor. The red dashed lines indicate ionic interactions and the blue dashed 
lines indicate hydrogen bonds. 
 
HINT scores for analogs 61, 63 and the R equatorial (CNF_1) and S equatorial (CNF_15) isomers 
of 155 are shown in Table 14. The HINT scores for all molecules seemed to be comparable. The 
interactions of the fluorine atoms with Ser239 are quantified in Table 14. 
 
 
 
 
 
R equatorial-155 
S equatorial-155 
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Table 14. Summary of HINT scores for analogs 61, 63 and 155. 
Binding mode Polar Hydrophobic Total HINT 
score* 
Ser239 
61 1593 430 1366 33 
63 1862 342 1463 1 
R equatorial 155 
(CNF_1) 
1788 442 1391 17 
S equatorial-155 
(CNF_15) 
1946 447 1467 14 
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total. 
 
3. Discussion 
Based on the preliminary data available so far for analog 155, the distance of the nitrogen atom 
from the aromatic center might be playing a role in enhancing the binding affinity of analog 61, 
since analog 155 binds with ~3.5-fold lower affinity (if the isomers bind with equal affinity) than 
analog 61. The fluorine atom might also be playing a role in enhancing the binding affinity of 
analog 61 for 5-HT2A receptors, since analog 63 binds with ~3-fold lower affinity than analog 61. 
However, functional activity data on analogs 63 and 155 are required to draw any further 
conclusions. Also, remains to be determined: is it the benz[d]isoxazole, the presence of the fluoro 
group, the aromatic-to-amine distance, or lack of -OH that converts 5-HT to antagonists. 
 
Based on the data available for analog 61, we propose a new pharmacophore for 5-HT2A receptor 
antagonists (Figure 81).  
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Figure 81. A new pharmacophore for 5-HT2A receptor antagonists based on the structural features 
of analog 61. 
 
The proposed pharmacophore consists of only one aromatic region, as opposed to two aromatic 
regions that has been previosly reported, a basic protonated amine, and hydrogn bond acceptors. 
Interesting is that the centroid-N distance (6.8 Å) is exactly midway between the A-N distance 
shown in Figure 72 (i.e., 6.8 Å). In addition, preliminary binding data show that although the fluoro 
group of analog 61 is not required, it adds to affinity.
 
  
61 
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V. CONCLUSIONS
 
 
 
 
The 5-HT2A/mGlu2 receptor heteromeric complex has been identified as a novel therapeutic target 
for the treatment of schizophrenia.18 A long-term goal of this project is to synthesize a bivalent 
ligand that will have a 5-HT2A receptor antagonist moiety tethered to an mGlu2 PAM. The atypical 
antipsychotic agent risperidone (14) (Figure 82) is a known 5-HT2A receptor antagonist. However, 
the SAR of risperidone (14) at 5-HT2A receptors has not been extensively studied. The current 
investigation was conducted to determine the minimal structural requirements for risperidone (14) 
to retain 5-HT2A receptor affinity and antagonist action, and to determine where on the 
“minimized” structure of risperidone (14) an mGlu2 PAM can be introduced. A “deconstruction-
reconstruction-elaboration” approach was used to study the SAR of risperidone (14) at 5-HT2A 
receptors. The current investigation was also aimed at identifying where on an mGlu2 PAM a 
“partial” risperidone structure might be introduced. 
 
The entire structure of risperidone (14) does not appear to be necessary for 5-HT2A receptor affinity 
and antagonism since analog 60 (Figure 82) (Ki = 12.74 nM) that has only half the structural 
features of risperidone (14) binds with only 2-fold lower affinity than risperidone (14) Ki = 5.29 
nM) and is nearly equipotent as an antagonist. Analog 61 (Figure 82) (Ki = 71.41 nM) represents 
the “right half” of risperidone (14), and binds with ~13-fold lower affinity than risperidone (14). 
Analog 57 (Figure 82) (Ki ~ 2700 nM) represents the “left half” of risperidone (14), and binds with 
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~500-fold lower affinity than risperidone (14) suggesting that the “right half” of risperidone (14) 
might be more important for binding affinity at 5-HT2A receptors, however, the “left half” 
contributes, and might be reinforcing binding affinity. Introduction of amine substituents showed 
that the affinity of analog 61 can be enhanced. For example, compound 104 (Figure 82) (i.e., 
Ket/Ris, Ki = 0.96 nM) displayed 75-fold higher affinity than analog 61, and >5-fold higher affinity 
than risperidone (14) for 5-HT2A receptors. Deconstruction studies have also suggested that the 
fluorine atom of the benz[d]isoxazole ring might be playing a role in enhancing binding affinity 
since analogs 62 (Ki ~300 nM) and 63 (Figure 82) (Ki ~200 nM) that are desfluoro analog of 
compounds 60 and 61, respectively, bound with ~24- and ~3-fold lower affinities, respectively. 
Analog 61, the desmethyl analog of 60, binds with ~6-fold lower affinity at 5-HT2A receptors than 
analog 60, suggesting that the methyl group makes additional interactions at the receptor. Analog 
63 (Figure 82) binds with similar affinity as analog 62, suggesting that the methyl group might not 
be making additional favorable interactions in this case at the receptor, and that analogs 60 and 61 
might have different binding modes as compared to analogs 62 and 63. 
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Figure 82. Compounds discussed in the conclusion section. 
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Analogs 65 and 66 (Figure 82) bind with reduced binding affinity, and are less potent antagonists 
as compared to risperidone (14). However, the carbonyl group might contribute. 
 
Hybrid molecules Ris/Ket (103) and Ket/Ris (104) (Figure 82) were also examined to study the 
relative binding modes of risperidone (14) and ketanserin (36) (Figure 82). The Ket/Ris (104) 
hybrid that has the quinazolinedione ring of ketanserin (36) and the benz[d]isoxazole ring of 
risperidone (14) bound to 5-HT2A receptors with high affinity (Ki = 0.96 nM), and had a 5-, 13-, 
and 19-fold higher affinity than risperidone (14), the Ris/Ket (103) hybrid, and ketanserin (36). 
This suggests that the quinazolinedione ring of the Ket/Ris (104) hybrid might be enhancing the 
binding affinity of the “right half” of risperidone to a greater extent than the 6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-4-one ring system of risperidone (14). The Ris/Ket (Ki = 12.74 nM) 
hybrid has the “left half” of risperidone (14), and binds with ~2-fold lower affinity than risperidone 
(14) suggesting that the “right half” of risperidone (14) might be contributing to its binding affinity 
to a greater extent as compared to the “left half”. 
  
Functional activity data obtained from the TEVC assay suggests that the hybrids might have 
different functional activities at 5-HT2A receptors. Ris/Ket (103) blocked the effects of 5-HT in a 
manner similar to that of risperidone (14), and appears to be a 5-HT2A receptor antagonist whereas 
Ket/Ris (104) did not block the effects of 5-HT. When examined in the absence of 5-HT, Ket/Ris 
(104) demonstrated partial agonist activity. However, the observed efficacy of the Ket/Ris (104) 
hybrid might have been due to its direct effects at the GIRK4* channel that might be masking its 
potential antagonist activity, and this needs to be evaluated further. The “left” and “right” half of 
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the Ket/Ris (104) hybrid is composed of 5-HT2A receptor antagonists ketanserin (36), and 
risperidone (14), respectively. The “right half” of risperidone (14) is represented by analog 61 that 
has been shown to be a 5-HT2A receptor antagonist as a part of this investigation as well as in 
previous studies conducted in our laboratory.140 The 6-fluoro-(3-piperidinyl)benz[d]isoxazole 
moiety is common to atypical antipsychotic agents such as risperidone (14), paliperidone (56) 
(Figure 23), and iloperidone (24) (Figure 12), as well as in agents that produce antipsychotic effects 
such as ADN-1184 (162) (Figure 83), a MARTA that is a high affinity 5-HT2A receptor antagonist 
(Ki = 2 nM),
211 and compound 163 (Figure 83), a 5-HT2A/dopamine D3 receptor antagonist that 
has high affinity for 5-HT2A receptors (Ki = 2 nM).
212 Binding affinities (Ki values) for ADN-1184 
(162)211 and 163212 were determined in HEK 293 cell membrane preparations that utilized [3H] 
ketanserin as the radioligand.  
 
All of them have diverse “left halves”, however, they all retain 5-HT2A receptor affinity and 
antagonism. Based on literature precedent, Ket/Ris (104) should be a 5-HT2A receptor antagonist 
since it has a 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety that is common to multiple 5-HT2A 
receptor antagonists. However, we can only speculate until further functional activity studies are 
conducted.  
 
 
Figure 83. Representative agents that show antipsychotic activity. 
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Analog 60 (Ki = 12.27 nM) and the Ket/Ris (104) (Ki = 0.96 nM) hybrid bind with ~6- and ~74-
fold higher affinities than analog 61, respectively. Also, as previously discussed above, analog 61 
is common to several high affinity 5-HT2A receptor antagonists that have diverse “left halves”. 
This suggests that adding substituents to the piperidinyl nitrogen atom can enhance binding 
affinity, and represents a position where a linker might be attached without potentially 
compromising the molecules 5-HT2A receptor binding affinity. Additionally, studies have shown 
that analog 61 can also crosstalk at the 5-HT2A receptor/mGlu2 receptor heteromer. This crosstalk 
has been demonstrated for antipsychotic agents such as clozapine (8) and risperidone (14).22 
Hence, analog 61 represents the “minimized risperidone” structure that could potentially be used 
to synthesize the bivalent ligand. 
 
Elaborated analog 112 (Figure 82) (Ki ~4.8 nM) has a 6-fluoro-N-methyltryptamine moiety instead 
of the 6-fluorobenz[d]isoxazole ring of risperidone (14), and binds with an affinity that is 
comparable to the binding affinity of risperidone (14) (Ki = 5.29 nM) at 5-HT2A receptors. This 
suggests that the benz[d]isoxazole ring of risperidone (14) might not be crucial for its binding 
affinity since it can be replaced by an indole ring. In fact, there are reports in the literature to 
suggest that indole rings of tryptamines and benz[d]isoxazole rings are isosteric, and that they 
might bind in a similar manner.213 Analog 111 (Figure 82) represents the desfluoro analog of 
compound 112, and binds with ~57-fold lower affinity than analog 112, again suggesting that the 
fluoro group might be important for binding affinity. 
 
  182 
Molecular modeling studies with deconstructed and elaborated analogs of risperidone (14) suggest 
that the fluorine atom might be involved in a hydrogen bonding interaction with 5-HT2A receptors. 
The amino acid residue that participates in the hydrogen bond with the fluorine atom varies for 
different molecules. Additionally, risperidone (14) and its analogs might utilize more than one 
binding mode.  
 
Molecular modeling studies of the mGlu2 receptor suggested that the chemically diverse PAMS: 
BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-40068782 (46) (Figure 69) dock in the 
same binding pocket.  
 
Molecular modeling studies conducted as a part of this study as well as SAR studies reported in 
the literature119 suggest that the pyridone nitrogen atom of the PAM JNJ-40411813 (45) can 
tolerate longer chain lengths, and represents a potential position to attach a linker.  
 
Deconstruction of risperidone (14) studies suggested that only half the structural features (analog 
61) of risperidone (14) are required to retain binding affinity and 5-HT2A receptor antagonism. 
This is in contrast to previously reported pharmacophores156–159 for 5-HT2A receptor antagonists in 
the literature that consist of two aromatic regions. Binding data on analogs 61 and 155 (Figure 76) 
suggests that the distance of the aromatic center from the protonated amine might influence 
binding affinity, with a distance of ~6.8 Å being optimal. Binding data on analog 63 suggest that 
the fluorine atom might be important for 5-HT2A receptor affinity. Based on the data available so 
far, we have proposed a new pharmacophore for 5-HT2A receptor antagonists that is comprised of 
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only one aromatic center, a basic protonated amine and hydrogen bond acceptors. Perhaps this 
pharmacophore was never previously identified because nearly all of the earlier agents possessed 
two or more aromatic rings. 
 
Overall we (i) identified a risperidone-like pharmacophore for 5-HT2A receptor antagonist action, 
(ii) demonstrated that a fluoro group contributes to 5-HT2A receptor affinity, (iii) investigated 
binding modes of risperidone (14) and risperidone analogs revealing that more than one mode of 
binding might be possible, (iv) identified where on the pharmacophore (i.e, the piperidine amine) 
substituents might be attached without loss (and, indeed, with enhancement) of 5-HT2A receptor 
affinity, (v) examined the modes of binding of various mGlu2 PAMs at models of the mGlu2 
receptor, (vi) identified, together with known SAR information, a PAM and a potential linker site 
for eventual construction of bivalent ligands, and (vii) explored potential synthetic routes that 
might be of value in the synthesis of bivalent ligands. 
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VI. EXPERIMENTAL
 
 
 
 
A. Synthesis 
Compounds were characterized using proton nuclear magnetic resonance (1H NMR), infrared (IR) 
spectroscopy (where applicable), mass spectrometry (MS) (where applicable). and by elemental 
analysis (if unkown) for C, H and N performed by Atlantic Microlab Inc. (Norcross, GA). 
Compounds were considered pure if the elemental analysis values obtained were within 0.4% of 
theoretical values. Melting points were measured on Thomas Hoover or MEL TEMP (if melting 
points were above 200 ºC) melting point apparatuses and are uncorrected. 1H NMR spectra were 
obtained using a Bruker ARX 400 MHz spectrometer using trimethylsilane (TMS) as an internal 
standard. The 1H NMR spectra were reported by indicating the peak positions (parts per million, 
δ), splitting pattern of peaks (s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, td: 
triplet of doublets, m: multiplet), coupling constant (J, Hz) and integration values. IR spectra were 
obtained using Thermo Nicolet iS10 FT-IR. MS was obtained using a Waters Acquity TQD 
(tandem quadrapole) spectrometer that utilizes electrospray ionization. Reactions were monitored 
using a combination of thin-layer chromatography (TLC) on silica gel GHLF plates (250 µm, 2.5 
x 10 cm; Analtech Inc. Newark, DE) and/ or IR spectroscopy where applicable. Flash 
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc. Lincoln, 
NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica 
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Flash Column, Teledyne Isco Inc., Lincoln, NE). Hydrochloride or oxalate salts (if the 
hydrochloride salt was hygroscopic) of compounds were prepared. 
 
2-Methyl-3-(2-(piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
Hydrochloride (57) 
Method A: 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.10 g, 
0.44 mmol) was added to a stirred suspension of piperidine (0.09 g, 0.44 mmol), anhydrous K2CO3 
(0.06 g, 0.44 mmol)  and KI (few crystals) in DMF (9 mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux for 17 h. The reaction mixture was allowed to cool to room 
temperature, diluted with H2O (~15 mL), and extracted with CHCl3 (3 x 10 mL). The combined 
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated 
under reduced pressure to yield 0.04 g of a pale yellow-colored solid. The solid was dissolved in 
EtOH and cooled to 0 ºC (ice-bath). A saturated solution of gaseous HCl /EtOH was added and 
the reaction mixture was allowed to stir at room temperature overnight. The precipitate was 
collected by filtration to yield a yellow-colored solid (0.03 g) which upon recrystallization from 
MeOH afforded 0.02 g (12%) of compound 57 as a pale yellow solid: mp 262-264 ºC. 
 
Method B:  
 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.10 g, 
0.44 mmol) was added to a stirred suspension of piperidine (0.09 g, 0.44 mmol), anhydrous K2CO3 
(0.06 g, 0.44 mmol)  and KI (few crystals) in MeCN (9 mL) under an N2 atmosphere. The stirred 
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reaction mixture was heated at reflux for 17 h. The hot reaction mixture was filtered and the filtrate 
was evaporated under reduced pressure to give 0.06 g of a pale yellow-colored solid. The solid 
was dissolved in H2O, basified with NaOH (3 M to ~pH 12), and extracted with CHCl3 (3 x 5 mL). 
The combined organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) 
and evaporated under reduced pressure to yield 0.05 g of a pale yellow-colored solid. The solid 
was dissolved in EtOH and cooled to 0 ºC (ice-bath). A saturated solution of gaseous HCl /EtOH 
was added and the reaction mixture was allowed to stir at room temperature overnight. The 
precipitate was collected by filtration to yield a yellow-colored solid (0.04 g) which upon 
recrystallization from MeOH afforded 0.03 g (20%) of compound 57 as a pale yellow solid: mp 
266-270 ºC. 
 1H NMR (DMSO-d6)  1.36-1.39 (m, 2H, CH2), 1.69-1.82 (m, 8H, 4 CH2), 1.87-1.92 (m, 2H, 
CH2), 2.42 (s, 3H, CH3), 2.91-2.95 (m, 6H, CH2, CH3), 3.47-3.51 (d, 2H, CH2, J = 11.5 Hz), 3.79-
3.82 (t, 2H, CH2, J = 6.1 Hz), 10.59 (br s, 1H, NH
+). Anal. Calcd for 
(C16H25N3O•2HCl•0.5H2O•0.5CH3OH) C, 53.08; H, 8.10; N, 11.26. Found: C, 52.96; H, 7.94; N, 
11.45. MS calculated [M + H]+ : 276.2070, MS found [M + H]+ : 276.2084. 
 
3-(2-(Dimethylamino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
Oxalate (58) 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.50 g, 
2.20 mmol) was added to a stirred suspension of N,N-dimethylamine (2 M solution in MeOH) (1.1 
mL, 2.2 mmol), anhydrous K2CO3 (0.30 g, 2.20 mmol)  and KI (few crystals) in MeCN (45 mL) 
under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 30 h. The hot reaction 
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mixture was filtered and the filtrate was evaporated under reduced pressure to give 0.30 g of a 
yellow liquid. The liquid was dissolved in H2O, basified with NaOH (3 M to ~pH 12), and 
extracted with CHCl3 (5 x 5 mL). The combined organic portion was washed with H2O (3 x 5 mL), 
brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.21 g of crude free 
base as a yellow-colored liquid. The liquid was purified using kugelrohr distillation (220 ºC, 0.75 
millibar) to yield 0.11 g of a colorless oil which was dissolved in CHCl3, cooled to 0 C (ice-bath) 
and treated with a saturated solution of (COOH)2 /Et2O and then the reaction mixture was allowed 
to stir at room temperature overnight. The precipitate was collected by filtration to yield a white 
solid (0.07 g) which upon recrystallization from EtOH afforded 0.05 g (12%) of compound 58 as 
a white solid: mp 154-156 ºC. 1H NMR (DMSO-d6)  1.76-1.80 (m, 2H, CH2), 1.84-1.89 (m, 2H, 
CH2), 2.24 (s, 3H, CH3), 2.50-2.52 (m, 10 H, 2CH2, 2CH3), 3.05-3.09 (t, 2H, CH2, J = 8.0 Hz), 
3.78-3.81 (t, 2H, CH2, J = 6.2 Hz). Anal. Calcd for (C13H21N3O•1.5 (COOH)2) C, 51.89; H, 6.53; 
N, 11.34. Found: C, 51.96; H, 6.66; N, 11.37. 
 
3-(2-Aminoethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
Hydrochloride (59) 
Compound 59 was synthesized using a literature procedure for a Gabriel synthesis reaction for a 
different compound.214 Hydrazine hydrate (0.20 mL, 4.10 mmol) was added to a stirred suspension 
of 79 (0.52 g, 1.55 mmol) in absolute EtOH (16 mL) under an N2 atmosphere. The stirred reaction 
mixture was heated at reflux for 4 h, cooled to room temperature and heated at reflux for 5 min 
with HCl (1 N, 15.5 mL) until a clear solution was formed. The solid that crystallized on cooling 
was removed by filtration and washed with H2O (5 mL). The filtrate was basified with NaOH (3 
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M to ~pH 12), and extracted with CHCl3 (3 x 5 mL). The combined organic portion was washed 
with H2O (3 x 5mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield 
0.21 g (66%) as a yellow-colored oil. The oil was dissolved in EtOH and cooled to 0 C (ice-bath). 
A saturated solution of gaseous HCl/EtOH was added and the reaction mixture was allowed to stir 
at room temperature overnight, the precipitate was collected by filtration to yield a yellow-colored 
solid which upon recrystallization from MeOH afforded 0.06 g (20%) of compound 59 as a pale 
yellow solid: mp 268-270 ºC. 1H NMR (DMSO-d6)  1.79-1.82 (m, 2H, CH2), 1.90-1.93 (m, 2H, 
CH2), 2.4 (s, 3H, CH3), 2.79 (m, 2H, CH2), 2.89-2.90 (m, 2H, CH2), 3.03-3.04 (m, 2H, CH2), 3.29 
(m, 2H, CH2), 8.07 (br s, 2H, NH2
+). Anal. Calcd for (C11H17N3O•2HCl) C, 47.15; H, 6.83; N, 
14.99. Found: C, 46.93; H, 6.75; N, 14.76. 
 
Compounds 60-63 were synthesized by Dr. Supriya A. Gaitonde as previously reported.143 
 
5-(2-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-6-methylpyrimidin-4(3H)-one 
Oxalate (64) 
Compound 92 (0.24 g, 1.36 mmol) was added to a stirred suspension of 6-fluoro-3-(4-
piperidinyl)benz[d]isoxazole (61) (0.33 g, 1.50 mmol), anhydrous K2CO3 (0.19 g, 1.36 mmol) and 
KI (few crystals) in DMF (4 mL). The stirred reaction mixture was heated in a sealed tube at 134 
ºC for 18 h, and allowed to cool to room temperature. The reaction mixture was diluted with H2O 
(~10 mL), and extracted with CHCl3 (3 x 10 mL). The combined organic portion was washed with 
H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.38 
g of an orange-colored oil which was purified by column chromatography (silica gel; 
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CHCl3/MeOH; 100:0 to 85:15) to afford 0.08 g of a crude, brown sticky solid.  The solid was 
dissolved in CHCl3 (10 mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O 
was added and the reaction mixture was allowed to stir at room temperature overnight. The 
precipitate was collected by filtration to yield a pale brown-colored solid (0.06 g) which upon 
recrystallization from EtOH afforded 0.03 g (5%) of compound 64 as a white solid: mp 228-230 
ºC. 1H NMR (DMSO-d6)  1.96-2.04 (m, 2H, CH2), 2.17-2.24 (m, 2H, CH2), 2.28 (s, 3H, CH3), 
2.68-2.80 (m, 5H, CH2), 2.44-2.47 (m, 2H, CH2), 3.43-3.48 (m, 2H, CH2), 7.30-7.35 (td, 1H, ArH, 
J = 2.1, 9.1 Hz), 7.71-7.74 (dd, 1H, ArH, J = 2.1, 9.1 Hz), 8.01-8.07 (m, 2H, ArH) (The -NH of 
the pyrimdone was not visible). Anal. Calcd for (C19H21N4O2F•0.5(COOH)2•0.9H2O) C, 57.52; H, 
5.74; N, 13.41. Found C, 57.77; H, 5.47; N, 13.15. MS calculated [M+H]+ : 357.1726 MS found 
[M+H]+ : 357.1754. 
 
Compounds 65 and 66 were synthesized by Dr. Supriya A. Gaitonde as previously reported.143 
 
3-[1-(4-Cyclohexylbutyl)piperidin-4-yl]-6-fluorobenz[d]isoxazole Hydrochloride (68) 
Compound 102 (0.28 g, 0.92 mmol) was added to a stirred suspension of 6-fluoro-3-(4-
piperidinyl)benz[d]isoxazole (61) (0.26 g, 1.18 mmol), anhydrous K2CO3 (0.25 g, 1.83 mmol) in 
MeCN (5 mL). The stirred reaction mixture was heated in a sealed tube at 80 °C for 96 h, filtered, 
and the filtrate was evaporated under reduced pressure to give 0.42 g of a sticky solid. The solid 
was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9.5:0.5) to afford 0.15 g of a 
sticky, white solid. The solid was dissolved in EtOH (2 mL), and cooled to 0 C (ice-bath). A 
saturated solution of gaseous HCl/EtOH was added and the reaction mixture was allowed to stir at 
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room temperature overnight. The solvent was evaporated under reduced pressure to yield 0.09 g 
of a white solid which upon recrystallization from i-PrOH/H2O afforded 0.08 g (23%) of 
compound 68 as a white solid: mp 242-244 oC. 1H NMR (DMSO-d6)  0.86-0.91 (m, 2H, CH2), 
1.11-1.36 (m, 8H, CH2), 1.61-1.74 (m, 7H, CH2,CH), 2.23-2.33 (m, 4H, CH2, J = 13.3 Hz) 3.08-
3.11 (m, 4H, CH2 ) 3.41-3.51 (m, 1H, CH), 3.60-3.63 (d, 2H, CH2, J = 11.5 Hz) 7.33-7.38 (td, 1H, 
ArH, J = 2.2, 9.2 Hz), 7.72-7.75 (dd, 1H, ArH, J = 2.0, 9.0 Hz), 8.15-8.22 (m, 1H, ArH), 10.16 (br 
s, 1H, NH+). Anal. Calcd for (C22H31N2OF•1 HCl•0.4H2O) C, 65.70; H, 8.22; N, 6.97. Found C, 
65.93; H, 8.21; N, 6.86. 
 
2-(2-(2-Methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-3-yl)ethyl)isoindoline-
1,3-dione (79) 
Compound 79 was synthesized using a literature procedure for a Gabriel synthesis reaction for a 
different compound.214 Potassium phthalimide (0.72 g, 3.87 mmol) was added to a stirred 
suspension of 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
(78) (0.80 g, 3.52 mmol) in anhydrous DMF (7.8 mL) under an N2 atmosphere. The stirred reaction 
mixture was heated at reflux for 22 h, cooled to room temperature and quenched by the careful 
addition of ice-cold H2O (15.5 mL). The precipitate was collected by filtration to yield a pale 
yellow solid (0.60 g) which upon recrystallization from EtOH afforded 0.54 g (45%) of compound 
79 as a yellow-colored solid: mp 164-166 °C. 1H NMR (DMSO-d6)  1.75-1.77 (m, 2H, CH2), 
1.82-1.85 (m, 2H, CH2),2.13 (s, 3H, CH3), 2.75-2.76 (m, 4H, CH2), 3.69-3.73 (t, 4H, CH2, J = 
5.7Hz), 7.84-7.85 (d, 4H, ArH, J = 2.6 Hz). Compound 79 was used in the preparation of 
compound 59.  
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Ethyl 2-acetyl-4-ethoxybutanoate (89) 
Compound 89 was synthesized using a modified literature procedure for the same compound.144 
Sodium ethoxide (1.36 g, 19.99 mmol) was dissolved in EtOH (20 mL) and ethyl acetoacetate (88) 
(2.55 g, 19.59 mmol) was added at 0 °C (ice-bath) and stirred at room temperature for 0.5 h. 2-
Bromoethyl ether (3.00 g, 19.61 mmol) was added dropwise when the reaction mixture started 
refluxing, and the reaction mixture was heated at reflux for 18 h. The reaction mixture was allowed 
to cool to room temperature, filtered and concentrated under reduced pressure. The residue was 
diluted with Et2O and filtered. The filtrate was concentrated under reduced pressure to yield 3.20 
g of a crude, yellow oil, which was purified using vacuum distillation (110 °C, 1.33 millibar) to 
yield 1.57 g (40%) of compound 89 as a colorless oil. 1H NMR (DMSO-d6)  1.08-1.12 (t, 3H, 
CH3, J = 7.0 Hz), 1.21-1.24 (t, 3H, CH3, J = 7.1 Hz), 1.91-2.1 (m, 2H, CH2), 2.22 (s, 3H, CH3), 
3.34-3.41 (m, 4H, CH2), 3.67-3.71 (t, 1H, CH, J = 7.0 Hz), 4.12-4.18 (q, 2H, CH2, J = 7.1 Hz). 
Compound 89 was used in the preparation of compound 90.  
 
5-(2-Ethoxyethyl)-6-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (90) 
Compound 90 was synthesized using a literature procedure for a similar compound.146 Thiourea 
(2.93 g, 38.49 mmol) and a solution of intermediate 89 (1.56 g, 7.71 mmol) in EtOH (22 mL)  were 
added to a stirred solution of sodium ethoxide (3.20 g, 47.03 mmol) in EtOH (25 mL) at 0 ºC (ice-
bath). The reaction mixture was heated at reflux for 4 h, allowed to cool to room temperature and 
concentrated under reduced pressure to yield a crude residue The residue was dissolved in H2O, 
acidified with HCl (1 M, ~ pH 4), and filtered to yield 1.70 g of a pale yellow solid which was 
  192 
purified using column chromatography (silica gel; CH2Cl2/MeOH; 100:0 to 90:10) to afford 0.91 
g (55%) of compound 90 as a pale yellow solid: mp 196-198 ºC (lit.145 mp 203-203.5 ºC). 1H NMR 
(DMSO-d6)  1.10-1.13 (t, 3H, CH3, J = 7.0 Hz), 2.17 (s, 3H, CH3), 3.35-3.45 (m, 6H, CH2), 12.15 
(br s, 1H, NH), 12.36 (br s, 1H, NH). Compound 90 was used in the preparation of compound 91.  
 
5-(2-Ethoxyethyl)-6-methylpyrimidin-4(3H)-one (91) 
Compound 91 was synthesized using a literature procedure for a similar compound.147 NiCl2 (1.62 
g, 12.50 mmol) was added to a stirred solution of 90 (0.90 g, 4.20 mmol) in anhydrous MeOH (70 
mL). This was followed by the slow addition of NaBH4 (1.43 g, 37.66 mmol) at room temperature. 
The reaction mixture was allowed to stir at room temperature for 0.5 h and filtered over celite. The 
filtrate was evaporated under reduced pressure and the residue was washed with CHCl3 (15 mL). 
The CHCl3 was evaporated under reduced pressure to yield 0.46 g (61%) of compound 91 as a 
pale green solid: mp 144-148 °C (lit.145 mp 147.5-148 ºC) 1H NMR (DMSO-d6)  1.10-1.13 (t, 3H, 
CH3,  J = 7 Hz), 2.27 (s, 3H, CH3), 2.66-2.70 (t, 2H, CH2, J = 7.08 Hz), 3.41-3.46 (m, 4H, CH2), 
7.98 (s, 1H, ArH) (-NH of the pyrimidone was not visible). Compound 91 was used in the 
preparation of compound 92.  
 
5-(2-Chloroethyl)-6-methylpyrimidin-4(3H)-one (92)  
Compound 92 was synthesized using a literature procedure for the same compound with a 
modified work-up procedure.145 Compound 91 (0.46 g, 2.52 mmol) was dissolved in HCl (12 N, 
6 mL) and heated in a sealed tube at 150 °C for 3 h, allowed to cool to room temperature, diluted 
with H2O (30 mL) and filtered. The filtrate was neutralized to ~pH 7 using a saturated aqueous 
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NaHCO3 solution and extracted with CHCl3 (3 x 15 mL). The combined organic portion was 
washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure 
to yield 0.31 g of a brown-colored oil which was purified by column chromatography (silica gel; 
CHCl3/MeOH; 100:0 to 90:10) to afford 0.25 g (57%) of compound 92 as an orange-colored oil. 
1H NMR (DMSO-d6)  2.37 (s, 3H, CH3), 3.24-3.28 (t, 2H, CH2, J = 8.32 Hz), 4.64-4.69 (t, 2H, 
CH2, J = 8.7 Hz), 8.46 (s, 1H, ArCH), (-NH of the pyrimidone was not visible). Compound 92 was 
used in the preparation of compound 64.  
 
1-Cyclohexylcyclobutan-1-ol (97) 
Compound 97 was synthesized using a literature procedure for the same compound.148,149 Iodine 
(few crystals) and magnesium turnings (0.16 g, 6.41 mmol) were added to a stirred solution of 
freshly distilled cyclohexyl bromide (96) (1.00 g, 6.13 mmol) in anhydrous Et2O (5 mL) at 0 ºC 
(ice-bath) under an N2 atmosphere. The stirred reaction mixture was heated at 40 ºC for 2 h, cooled 
to 0 ºC (ice-bath), and cyclobutanone (0.43 g, 6.13 mmol) was added dropwise. The reaction 
mixture was allowed to stir at room temperature for 4 h, cooled to 0 ºC (ice-bath) and quenched 
by the careful addition of H2O (~10 mL). The organic portion was separated, and the aqueous 
portion was extracted with Et2O (3 x 10 mL). The combined organic portions were washed with 
H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.31 
g of a colorless oil. The oil was purified using Kugelrohr distillation (72-80 ºC, 1.33 millibar) to 
yield 0.21 g (21%) of compound 97 as a colorless oil 1H NMR (DMSO-d6)  0.96-1.3 (m, 6H, 
CH2), 1.38-1.50 (m, 1H, CH), 1.66-1.79 (m, 6H), 1.83-1.90 (m, 2H, CH2), 2.01-2.08 (m, 2H, CH2). 
Compound 97 was used in the preparation of compound 98. 
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1-Cyclohexyl-4-hydroxybutan-1-one (98) 
Intermediate 98 was synthesized using a literature procedure for the same compound.150 
Phenyliodine diacetate (0.43 g, 1.36 mmol) was added to a stirred solution of 97 (0.2 g, 1.30 mmol) 
in 1,1,1,3,3,3-hexafluoro-2-propanol/H2O (10 mL, 9/1). The reaction mixture was allowed to stir 
at room temperature for 15 min, and was quenched using a saturated aqueous NaHCO3 solution 
(10 mL), and was extracted using EtOAc (3 x 10 mL). The combined organic portion was washed 
with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 
0.18 g of a crude colorless oil. The oil was purified by column chromatography (silica gel; 
hexanes/EtOAc; 3:1) to afford 0.12 g (50%) of compound 98 as a colorless oil. 1H NMR (DMSO-
d6)  1.09-1.26 (m, 5H, CH2), 1.53-1.76 (m, 7H, CH2), 2.32-2.37 (m, 1H, CH), 2.45-2.49 (t, 2H, 
CH2, J = 7.2 Hz), 3.31-3.34 (t, 2H, CH2, J = 6.5 Hz), 4.40-4.42 (t, 1H, OH, D2O ex., J = 4.7 Hz). 
IR (diamond, cm-1) 1700 (-C=O), 3400 (-OH). Compound 98 was used in the preparation of 
compound 99 and 100. 
 
4-Cyclohexyl-4-oxobutyl 4-methylbenzenesulfonate (99) 
Compound 99 was synthesized using a modified literature procedure for a similar compound.151 
Intermediate 98 (0.11 g, 0.65 mmol) was added to a stirred solution of tosyl chloride (0.19 g, 0.98 
mmol) and Et3N (0.20 g, 1.96 mmol) in CH2Cl2 (5 mL). The reaction mixture was allowed to stir 
at room temperature for 48 h, filtered, and the filtrate was evaporated under reduced pressure to 
give 0.15 g of a crude residue. The residue was purified by column chromatography (silica gel; 
hexanes/EtOAc; 8.5:1.5) to afford 0.07 g (33%) of compound 99 as a colorless oil. 1H NMR 
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(DMSO-d6)  1.07-1.26 (m, 5H, CH2), 1.56-1.76 (m, 7H, CH2), 2.26-2.33 (m, 1H, CH), 2.46-2.51 
(m, 5H, CH2, CH3), 3.98-4.01 (t, 2H, CH2, J = 6.4 Hz), 7.48-7.50 (d, 2H, ArH, J = 8.0 Hz) 7.77-
7.79 (dd, 2H, ArH, J = 1.72 Hz, 6.7 Hz). 
 
4-Cyclohexylbutan-1-ol (100) 
Method A: 
Compound 100 is known and was synthesized using a literature procedure for a similar 
compound.215 KOH (0.09 g, 1.61 mmol) and hydrazine hydrate (0.15 g, 4.68 mmol) were added 
to a solution of compound 98 (0.06 g, 0.35 mmol) in diethylene glycol (4 mL) at 0 ºC (ice-bath). 
The stirred reaction mixture was heated at 135 ºC for 2 h, a Dean-Stark apparatus was connected 
to the flask, and the temperature was increased to 200 ºC. The stirred reaction mixture was heated 
at 200 ºC for 6 h, diluted with H2O (~5 mL), and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated 
under reduced pressure to yield 0.03 g (58%) of compound 100 as a colorless oil. 
 
Method B: 
Compound 100 was synthesized using a literature procedure for a similar compound.152 A solution 
of 4-cyclohexylbutanoic acid (101) (1.00 g, 5.87 mmol) in anhydrous THF (5 mL) was added to a 
stirred suspension of LiAlH4 (0.44 g, 11.74 mmol) in anhydrous THF (10 mL) at 0 ºC (ice-bath) 
under an N2 atmosphere The reaction mixture was allowed to stir at room temperature for 6 h, 
cooled to 0 ºC (ice-bath), quenched by addition of H2O (0.5 mL), 15% NaOH (0.5 mL) and H2O 
(1.5 mL). The suspension was filtered over Celite and the residue was washed with THF. The 
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aqueous portion was basified with 15% NaOH (pH ~12) and extracted with Et2O (3 x 10 mL). The 
combined organic portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and 
evaporated under reduced pressure to yield 0.49 g (54%) of compound 100 as a colorless oil. 
Intermediate 100 was used without further purification in the next step.  
IR (diamond, cm-1) 3388 (-OH). 1H NMR (DMSO-d6)  0.83-0.92 (m, 2H, CH2), 1.12-1.24 (m, 
6H, CH2), 1.28-1.35 (m, 2H, CH2) 1.39-1.46 (m, 2H, CH2), 1.63-1.71 (m, 5H, CH2, CH), 3.39-
3.43 (m, 2H, CH) 4.30-4.33 (t, 1H, OH, J = 5.2 Hz). Compound 100 was used in the preparation 
of compound 102. 
 
4-Cyclohexylbutyl 4-methylbenzenesulfonate (102) 
Compound 102 was synthesized using a modified literature procedure for the same compound.151 
Compound 100 (0.48 g, 3.08 mmol) was added to a stirred solution of tosyl chloride (0.88 g, 4.62 
mmol) and Et3N (0.94 g, 9.23 mmol) in CH2Cl2 (15 mL). The reaction mixture was allowed to stir 
at room temperature for 48 h, filtered, and the filtrate was evaporated under reduced pressure to 
give 1.21 g of a crude residue. The residue was purified by column chromatography (silica gel; 
hexanes/EtOAc; 8.5:1.5) to afford 0.29 g (30%) of compound 102 as a white solid: mp 40-42 ºC. 
(lit.151 mp 41.5-42.5 ºC). Intermediate 102 was used without further purification in the next step. 
Compound 102 was used in the preparation of compound 68. 
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3-[2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one Oxalate (103) 
 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.40 g, 
1.76 mmol) was added to a stirred suspension of 4-(4-fluorobenzoyl) piperidine hydrochloride  
(0.43 g,  1.76 mmol), anhydrous K2CO3 (0.49  g, 3.52 mmol) and KI (few crystals) in MeCN (40  
mL) under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 24 h, filtered 
while hot, and the filtrate was evaporated under reduced pressure to give 0.60 g of a yellow, sticky 
solid. The sticky solid was dissolved in H2O, basified with NaOH (3 M to pH ~12), and extracted 
with CHCl3 (3 x 5 mL). The combined organic portion was washed with H2O (3 x 5 mL), brine (5 
mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.51 g of crude free base as 
a yellow-colored solid. The free base was purified using a short column (silica gel; CHCl3/MeOH; 
90:10) to afford 0.36 g of a yellow-colored solid that was dissolved in CHCl3 (2 mL), cooled to 0 
°C (ice-bath) and treated with a saturated solution of (COOH)2/Et2O and then the reaction mixture 
was allowed to stir at room temperature overnight. The precipitate was collected by filtration to 
yield a white solid (0.40 g) which upon recrystallization from EtOH afforded 0.30 g (27%) of 
compound 57 as a white solid: mp 194-198 °C. 1H NMR (DMSO-d6)  1.74-1.85 (m, 6H, CH2), 
1.89-2.01 (d, 2H, CH2, J = 13.2 Hz), 2.23 (s, 3H, CH3), 2.76-2.8 (m, 4H, CH2 ) 2.97-2.99 (m, 4H, 
CH2), 3.46-3.51 (m, 2H, CH2), 3.66-3.68 (m, 1H, CH), 3.78-3.81 (t, 2H, CH2, J = 6.2 Hz), 7.37-
7.41 (t, 2H, ArH, J = 8.8 Hz), 8.07-8.11 (m, 2H, ArH). Anal. Calcd for (C23H28N3O2F•1.5 (COOH)2 
C, 58.64; H, 5.87; N, 7.89. Found C, 58.63; H, 6.03; N, 8.10. 
 
Compound 104 was synthesized by Dr. Supriya A. Gaitonde as previously reported.143 
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Tryptamine Hydrochloride (105) 
Method A: 
Compound 105 was synthesized using a literature procedure for a similar compound.167 BF3•Et2O 
(0.60 mL, 4.40 mmol) was added to a stirred suspension of NaBH4 (0.14 g, 4.00 mmol) in THF 
(10 mL) at 0 ºC (ice-bath), and was allowed to stir at room temperature for 15 min. A solution of 
compound 125 (0.14g, 0.75 mmol) in anhydrous THF (2 mL) was added in a dropwise manner, 
and the reaction mixture was heated at reflux for 2 h, cooled to room temperature and quenched 
with addition of ice-H2O. The reaction mixture was acidified with HCl (1 N, to ~pH 2) and heated 
at 85 °C for 2 h. The reaction mixture was allowed to cool to room temperature and extracted with 
Et2O (3 x 10 mL). The aqueous portion was basified with NaOH (1 N to ~pH 12) and extracted 
with Et2O (3 x 10 mL). The combined organic portion was washed with H2O (10 mL), brine (10 
mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.09 g as a brown-colored 
oil. The oil was dissolved in Et2O (5 mL) and cooled to 0 °C (ice-bath). A gaseous solution of 
HCl/Et2O was added and the reaction mixture was allowed to stir at room temperature for 1 h. The 
precipitate was filtered to yield a beige-colored solid that was recrystallized from EtOH/Et2O to 
yield 0.06 g (40%) of compound 105 as a beige solid: mp 242-244 ºC (lit.168 mp 248-249 °C). 
 
Method B: 
Compound 105 was synthesized using a literature procedure for the same compound.168 LiAlH4 
(0.56 g, 14.75 mmol) was added to a stirred solution of compound 125 (0.14 g, 0.77 mmol) in 
anhydrous Et2O (8.4 mL) at 0 °C (ice-bath) under an N2 atmosphere. The stirred reaction mixture 
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was heated at reflux for 3 h, allowed to stir at room temperature for 12 h, cooled to 0 °C (ice-bath), 
and quenched by addition of H2O (0.6 mL), 15% NaOH (0.6 mL) and H2O (1.8 mL). The 
suspension was filtered and the residue was washed with Et2O. The aqueous portion was extracted 
with Et2O (3 x 10 mL). The combined organic portion was washed with water (3 x 10 mL), brine 
(10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.13 g as a brown-colored 
oil. The oil was dissolved in Et2O (5 mL) and cooled to 0 °C (ice-bath). A gaseous solution of 
HCl/Et2O was added and the reaction mixture was allowed to stir at room temperature for 1 h. The 
precipitate was filtered to yield a beige-colored solid that was recrystallized from EtOH/Et2O to 
yield 0.11 g (80%) of compound 105 as a beige solid: mp 246-248 ºC (lit.168 mp 248-249 °C). 
 
2-(6-Fluoro-1H-indol-3-yl)ethan-1-amine Oxalate (106) 
LiAlH4 (0.58 g, 15.33 mmol) was added to a stirred solution of compound 123 (0.63 g, 3.07 mmol) 
in anhydrous THF (8.5 mL) and anhydrous Et2O (9.5 mL) at 0 °C (ice-bath) under an N2 
atmosphere. The stirred reaction mixture was heated at 60 °C for 1 h, cooled to 0 °C (ice-bath), 
quenched by addition of H2O (0.6 mL), 15% NaOH (0.6 mL) and H2O (1.8 mL). The suspension 
was filtered and the residue was washed with THF. The aqueous portion was extracted with Et2O 
(3 x 10 mL). The combined organic portion was washed with brine (10 mL), dried (Na2SO4), and 
evaporated under reduced pressure to yield 0.42 g as a brown-colored oil. The oil was dissolved 
in Et2O (5 mL) and cooled to 0 °C (ice-bath). A saturated solution of (COOH)2/Et2O was added 
and the reaction mixture was allowed to warm to room temperature and stirred for 1 h. The 
precipitate was filtered to yield a brown-colored solid that was heated at reflux in MeCN for 0.5 
h, and recrystallized from acetone/H2O to yield 0.22 g (27%) of compound 106 as a beige-colored 
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solid: mp 152-154 ºC. 1H NMR (DMSO-d6)  2.99-3.08 (m, 4H, CH2), 6.86-6.91 (m, 1H, ArH), 
7.14-7.17 (d, 1H, ArH, J = 9.6 Hz) 7.24 (s, 1H, ArH), 7.53-7.57 (t, 1H, ArH, J = 7.1 Hz), 11.08 (s, 
1H, NH). Anal. Calcd for (C10H11N2F•1(COOH)2•0.2H2O•0.1CH3COCH3) C, 53.21; H, 5.08; N, 
10.09. Found C, 53.03; H, 5.14; N, 9.99. 
 
2-(1H-Indol-3-yl)-N-methylethanamine (107) 
Compound 107 was synthesized using a literature procedure for the same compound.172 LiAlH4 
(0.86 g, 22.75 mmol) was added to a stirred solution of intermediate 131 (1.76 g, 7.59 mmol) in 
anhydrous THF (16 mL) at 0 ºC (ice-bath) under an N2 atmosphere. The stirred reaction mixture 
was heated at reflux for 1.5 h, cooled to 0 °C (ice-bath), and quenched by addition of H2O (0.9 
mL), 15% NaOH (0.9 mL) and H2O (2.7 mL). The suspension was filtered and the residue was 
washed with THF. The aqueous portion was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic portion was washed with brine (10 mL), dried (Na2SO4), and evaporated under reduced 
pressure to yield 0.83 g (48%) of compound 107 as a white solid: mp 82-84 °C (lit.173 mp 80-84 
°C).  
 
2-(6-Fluoro-1H-indol-3-yl)-N-methylethan-1-amine Hydrochloride (108) 
LiAlH4 (0.23 g, 6.03 mmol) was added to a stirred solution of 127 (0.50 g, 2.01 mmol) in anhydrous 
THF (18 mL) at 0 ºC (ice-bath) under an N2 atmosphere. The stirred reaction mixture was heated 
at reflux for 1.5 h, cooled to 0 ºC (ice-bath), quenched by addition of H2O (0.2 mL), 15% NaOH 
(0.2 mL) and H2O (0.6 mL). The suspension was filtered and the residue was washed with THF. 
The aqueous portion was extracted with CH2Cl2 (3 x 10 mL). The combined organic portion was 
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washed with brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.28 
g of crude free base as an oil. The free base was dissolved in Et2O (3 mL) and cooled to 0 °C (ice-
bath). A saturated solution of gaseous HCl/Et2O was added and the reaction mixture was allowed 
to stir at room temperature overnight. The precipitate was collected by filtration to yield a brown-
colored solid which upon recrystallization from acetone/H2O afforded 0.36 g (78%) of compound 
108 as a brown-colored solid: mp 216-220 ºC. 1H NMR (DMSO-d6)  2.58-2.61 (t, 3H, CH3, J = 
5.48 Hz), 3.01-3.05 (t, 2H, CH2, J = 7.28 Hz), 3.13-3.18 (m, 2H, CH2), 6.87-6.92 (m, 1H, ArH), 
7.14-7.17 (dd, 1H, ArH, J = 2.2, 10.16 Hz), 7.24-7.25 (d, 1H, ArH, J = 2.32 Hz), 7.56-7.60 (m, 
1H, ArH), 8.58 (s, 1H, NH+), 11.01 (s, 1H, NH). Anal. Calcd for (C11H13N2F•1HCl) C, 57.77; H, 
6.17; N, 12.25. Found C, 57.52; H, 6.15; N, 11.98). 
 
3-[2-((2-(1H-Indol-3-yl)ethyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one Oxalate (109) 
 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.20 g, 0.88 
mmol) was added to a stirred suspension of  tryptamine (105) (0.31 g, 1.96 mmol) and anhydrous 
K2CO3 (0.12 g, 0.88 mmol) in MeCN (40 mL) under an N2 atmosphere. The stirred reaction 
mixture was heated at reflux for 17 h. The hot reaction mixture was filtered and the filtrate was 
evaporated under reduced pressure to give 0.32 g of crude free base as a yellow liquid. The free 
base was purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 8.5:1.5:0.1) to yield 
0.06 g of a liquid, that was dissolved in CHCl3 (2 mL), cooled to 0 C (ice-bath). A saturated 
solution of (COOH)2/Et2O was added and the reaction mixture was allowed to stir at room 
temperature overnight. The precipitate was collected by filtration to yield a yellow-colored solid 
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(0.05 g) which upon recrystallization from MeOH afforded 0.03 g (6%) of compound 109 as a 
yellow solid: mp 112-114 ºC. 1H NMR (DMSO-d6)  1.75-1.90 (m, 4H, CH2), 2.24 (s, 3H, CH3), 
2.78-2.82 (m, 4H, CH2 ), 3.03-3.07 (t, 4H, CH2, J = 7.0 Hz), 3.22-3.23 (m, 2H, CH2), 3.78-3.82 (t, 
2H, CH2, J = 6.2 Hz), 7.00-7.04 (t, 1H, ArH, J = 7.0 Hz), 7.09-7.13 (t, 1H, ArH, J = 7.2 Hz ), 7.24 
(s, 1H, ArH), 7.37-7.39(d, 1H, ArH, J = 8.1 Hz), 7.58-7.60 (d, 1H, ArH, J = 7.8 Hz), 8.67-8.76 
(brs, 1H, NH+), 11.0 (s, 1H, NH). Anal. Calcd for (C21H26N4O•2(COOH)2•1H2O•1CH3OH) C, 
53.79; H, 6.25; N, 9.65. Found: C, 53.84; H, 5.95; N, 9.84. 
 
3-(2-((2-(6-Fluoro-1H-indol-3-yl)ethyl)amino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one Oxalate (110) 
 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.22 g, 
0.98 mmol) was added to a stirred suspension of compound 106 (0.35 g, 1.96 mmol) and anhydrous 
K2CO3 (0.12 g, 1.98 mmol) in MeCN (40 mL) under an N2 atmosphere. The stirred reaction 
mixture was heated at reflux for 17 h. The reaction mixture was allowed to cool and evaporated 
under reduced pressure to give 0.66 g of a yellow semi-solid. The semi-solid was dissolved in 
H2O, basified with NaOH (2 M to ~pH 12) and extracted with CH2Cl2 (5 x 5 mL). The combined 
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated 
under reduced pressure to yield 0.40 g of crude free base as a yellow-colored liquid. The free base 
was purified using a short column (silica gel; CHCl3/MeOH/NH4OH; 9:1:0.1) to afford 0.06 g of 
a liquid, that was dissolved in CHCl3 (2 mL) and cooled to 0 ºC (ice-bath). A saturated solution of 
(COOH)2/Et2O was added and the reaction mixture was allowed to stir at room temperature 
overnight. The precipitate was collected by filtration to yield a yellow-colored solid (0.05g) which 
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upon recrystallization from MeOH afforded 0.03 g (17%) of compound 110 as a yellow solid: mp 
188-192 ºC. 1H NMR (DMSO-d6)  1.75-1.90 (m, 4H, CH2), 2.24 (s, 3H, CH3), 2.78-2.81 (t, 4H, 
CH2, J = 6.6 Hz),  3.01-3.05 (m, 4H, CH2), 3.22-3.23 (m, 2H, CH2), 3.78-3.81, (t, 2H, CH2 J = 6.2 
Hz ), 6.86-6.91 (td, 1H, ArH,  J = 2.3 Hz, 7.5 Hz ), 7.14-7.17 (dd, 1H, ArH, J = 2.3 Hz, 7.9 Hz ), 
7.24-7.25 (d, 1H, ArH, J = 1.6 Hz), 7.56-7.59 (m, 1H, ArH), 8.70 (brs, 1H, NH+) 11.01 (s, 1H, 
NH). Anal. Calcd for (C21H25N4OF•2(COOH)2) C, 54.74; H, 5.32; N, 10.21. Found: C, 54.87; H, 
5.50; N, 10.20. 
 
3-[2-((2-(1H-Indol-3-yl)ethyl)(methyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one Oxalate (111) 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.30 g, 
1.32  mmol) was added to a stirred suspension of 107 (0.23 g,  1.32 mmol), anhydrous K2CO3 
(0.18 g, 1.32 mmol) and KI (few crystals) in MeCN (27  mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux for 48 h, and evaporated under reduced pressure to give 0.60 
g of a yellow sticky solid. The sticky solid was dissolved in H2O, basified with NaOH (1 M to ~pH 
12), and extracted with CH2Cl2 (3 x 10 mL). The combined organic portion was washed with H2O 
(5 mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.41 g of a 
crude free base as a yellow-colored solid. The free base was purified using a short column (silica 
gel; CHCl3/MeOH/NH4OH; 9:1:0.1) to afford 0.38 g of a solid, that was dissolved in CH2Cl2 (2 
mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O was added and the 
reaction mixture was allowed to stir at room temperature overnight. The precipitate was collected 
by filtration to yield a white solid (0.40 g) which upon recrystallization from EtOH afforded 0.31 
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g (47%) of compound 111 as a white solid: mp 190-192 ºC. 1H NMR (DMSO-d6)  1.74-1.90 (m, 
4H, CH2), 2.25 (s, 3H, CH3), 2.77-2.88 (m, 4H, CH2 ), 2.95 (s, 3H, CH3), 3.11-3.18 (m, 4H, CH2), 
3.40-3.44 (m, 2H, CH2), 3.78-3.81 (t, 2H, CH2, J = 6.2, 12.3 Hz), 7.00-7.04 (m, 1H, ArH,), 7.09-
7.13 (m, 1H, ArH), 7.26-7.27 (d, 1H, ArH, J = 2.0 Hz), 7.37-7.39 (d, 1H, ArH, J = 8.1 Hz), 7.62-
7.64 (d, 1H, ArH J = 7.8 Hz), 11.00 (s, 1H, NH). Anal. Calcd for (C22H28N4O•1.5(COOH)2) C, 
60.10; H, 6.25; N, 11.21. Found C, 59.92; H, 6.24; N, 11.12. MS calculated [M+H]+: 365.2263 
MS found [M+H]+: 365.2260. 
 
3-[2-((2-(6-Fluoro-1H-indol-3-yl)ethyl)(methyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-4-one Hydrogen Oxalate (112) 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.30 g, 1.31 
mmol) was added to a stirred suspension of  compound 108 (0.30 g, 1.31 mmol), anhydrous K2CO3 
(0.36 g, 2.62 mmol)  and KI (few crystals) in MeCN (20 mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux for 48 h. The hot reaction mixture was filtered and the filtrate 
was evaporated under reduced pressure to give 0.36 g of a yellow liquid. The liquid was dissolved 
in H2O, basified with NaOH (2 M to ~pH 12) and extracted with CH2Cl2 (5 x 5 mL). The combined 
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated 
under reduced pressure to yield 0.22 g of crude free base as a yellow-colored liquid. The free base 
was purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 9:1:0.1) to afford 0.17 g of 
a liquid that was dissolved in CH2Cl2 (2 mL) and cooled to 0 C (ice-bath). A saturated solution of 
(COOH)2/Et2O was added and the reaction mixture was allowed to stir at room temperature 
overnight. The precipitate was collected by filtration to yield a yellow-colored solid (0.19 g) which 
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upon recrystallization from EtOH afforded 0.14 g (16%) of compound 112 as a yellow solid: mp 
78-82 ºC. 1H NMR (DMSO-d6)  1.76-1.90 (m, 4H, CH2), 2.25 (s, 3H, CH3), 2.78-2.87 (m, 4H, 
CH2 ), 2.95 (s, 3H, CH3), 3.11-3.18 (m, 4H, CH2), 3.40-3.46 (m, 2H, CH2), 3.78-3.81 (t, 2H, CH2, 
J = 6.2 Hz), 6.86-6.92 (td, 1H, ArH, J  = 2.32, 9.84 Hz), 7.14-7.17 (dd, 1H, ArH, J = 2.24, 10.12 
Hz), 7.27 (s, 1H, ArH), 7.61-7.65 (q, 1H, ArH, J = 5.4 Hz), 11.01 (s, 1H, NH). Anal. Calcd for 
(C22H27N4OF•1.5 (COOH)2 •0.7CH2Cl2•0.1 C2H5OH) C, 53.49; H, 5.55; N, 9.63. Found: C, 53.46; 
H, 5.47; N, 9.36). MS calculated [M+H]+: 383.2169 MS found [M+H]+: 383.2244. 
 
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-
a]pyrimidin-4-one Oxalate (113) 
3-(2-Chloroethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (136) (0.20 g, 0.90  mmol) was 
added to a stirred suspension of 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (0.20 g, 0.90 mmol), 
anhydrous K2CO3 (0.12 g, 0.90 mmol) and KI (few crystals) in MeCN (20 mL) under an N2 
atmosphere. The stirred reaction mixture was heated at reflux for 20 h, cooled to room temperature 
and filtered. The residue was washed with MeOH (2 x 10 mL) and H2O to yield 0.18 g of a pink-
colored solid: mp 172-174 ºC (lit.174 mp 170.4 ºC). The solid (0.18 g) was dissolved in CH2Cl2 (2 
mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O was added and the 
reaction mixture was allowed to stir at room temperature overnight. The precipitate was collected 
by filtration to yield a white solid (0.25 g) which upon recrystallization from EtOH/H2O afforded 
0.17 g (5%) of compound 113 as a white solid: mp 198-200 ºC. 1H NMR (DMSO-d6)  1.04-1.07 
(t, 3H, CH3 from EtOH), 2.09-2.33 (m, 4H, CH2), 3.04-3.17 (m, 6H, CH2 ) 3.42-3.48 (m, 3H, CH2 
from EtOH, CH), 3.65 (s, 2H, CH2), 7.31-7.36 (m, 2H, ArH), 7.62-7.64 (d, 1H, ArH, J = 8.8 Hz), 
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7.73-7.75 (dd, 1H, ArH, J = 2.1 Hz, 9.1 Hz), 7.90-7.94 (m, 1H, ArH), 8.07-8.10 (m, 1H, ArH), 
8.90-8.92 (d, 1H, ArH, J = 6.6 Hz)), (3H are under the DMSO peak, verified by COSY). Anal. 
Calcd for (C23H23N4O2F
.1(COOH)2•1C2H5OH.0.2H2O) C, 59.38; H, 5.79; N, 10.26. Found C, 
59.11; H, 5.62; N, 10.20. MS calculated [M+H]+: 407.1805 MS found [M+H]+: 407.1883. 
 
4-[4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl]-1-phenylbutan-1-one Hydrochloride 
(114) 
4-Chlorobutyrophenone (137) (1.19 g, 0.82 mmol) was added to a stirred suspension of 6-fluoro-
3-(4-piperidinyl)benz[d]isoxazole (1.43 g, 0.82 mmol), anhydrous K2CO3 (0.90 g, 0.82 mmol) and 
KI (few crystals) in MeCN (50 mL) under an N2 atmosphere. The stirred reaction mixture was 
heated at reflux for 20 h, filtered, and the filtrate was evaporated under reduced pressure to give 
1.9 g of a yellow oil. The yellow oil was dissolved in CH2Cl2 and 1M HCl (10 mL) was added to 
afford a precipitate that was insoluble in H2O. The precipitate was collected by filtration and 
washed with CH2Cl2 (3 x 15 mL) and H2O (3 x 15 mL) to yield a white solid (1.44 g) which upon 
recrystallization from EtOH/H2O afforded 0.42 g (15%) of compound 114 as a white solid: mp 
224-228 °C. 1H NMR (DMSO-d6)  2.05-2.15 (m, 2H, CH2), 2.22-2.25 (d, 2H, CH2, J = 12.4 Hz) 
2.33-2.42 (m, 2H, CH2), 3.11-3.27 (m, 6H, CH2 ) 3.47-3.53 (m, 1H, CH), 3.65-3.68 (d, 2H, CH2, 
J = 11.7 Hz), 7.33-7.38 (m, 1H, ArH), 7.54-7.58 (t, 2H, ArH, J = 7.4 Hz), 7.65-7.69 (t, 1H, ArH, 
J = 7.4 Hz), 7.72-7.75 (dd, 1H, ArH, J = 2, 9.1 Hz), 8.00-8.02 (m, 2H, ArH), 8.20-8.24 (m, 1H, 
ArH)  10.58 (br s, 1H, NH+, D2O ex). Anal. Calcd for (C22H23N2O2F•1HCl) C, 65.59; H, 6.00; N, 
6.95. Found C, 65.29; H, 6.01; N, 6.89. 
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6-Fluoro-3-[1-(4-phenylbutyl)piperidin-4-yl]benz[d]isoxazole Hydrochloride (115) 
1-Chloro-4-phenylbutane (138) (0.14 g, 0.82 mmol) was added to a stirred suspension of 6-fluoro-
3-(4-piperidinyl)benz[d]isoxazole (0.18 g, 0.82 mmol), anhydrous K2CO3 (0.11 g, 0.82 mmol) and 
KI (few crystals) in MeCN (15 mL) under an N2 atmosphere. The stirred reaction mixture was 
heated at reflux for 36 h, filtered, and the filtrate was evaporated under reduced pressure to give 
0.28 g of crude free base as a yellow oil. The free base was unsuccessfully purified using Kugelrohr 
distillation and was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9:1) to afford 
0.20 g of a yellow-colored oil, that was dissolved in EtOAc (2 mL), cooled to 0 C (ice-bath) and 
treated with a saturated solution of gaseous HCl/EtOAc, and then the reaction mixture was allowed 
to stir at room temperature overnight. The precipitate was collected by filtration to yield a white 
solid (0.19 g) which upon recrystallization from EtOH/H2O afforded 0.13 g (40%) of compound 
115 as a white solid: mp 200-204 ºC. 1H NMR (DMSO-d6)  1.62-1.81 (m, 4H, CH2), 2.21-2.36 
(m, 4H, CH2), 2.63-2.67 (t, 2H, CH2, J = 7.4 Hz), 3.05-3.17 (m, 4H, CH2), 3.43-3.51 (m, 1H, CH), 
3.59-3.62 (d, 2H, CH2, J = 12.0 Hz), 7.18-7.38 (m, 6H, ArH), 7.72-7.76 (m, 1H, ArH), 8.17-8.21 
(m, 1H, ArH), 10.38 (br s, 1H, NH+). Anal. Calcd for (C22H25N2OF•1 HCl) C, 67.94; H, 6.74; N, 
7.20. Found C, 67.65; H, 6.81; N, 7.11. 
 
4-[4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl]-1-phenylpentan-1-one Hydrochloride 
(116) 
Compound 141 (0.20 g, 1.01 mmol) was added to a stirred suspension of 6-fluoro-3-(4-
piperidinyl)benz[d]isoxazole  (0.25 g, 1.12 mmol), anhydrous K2CO3 (0.15 g, 1.12 mmol) and KI 
(few crystals) in MeCN (5 mL). The stirred reaction mixture was heated in a sealed tube at 80 ºC 
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for 48 h, filtered, and the filtrate was evaporated under reduced pressure to give 0.29 g of a sticky 
solid. The solid was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9:1)  to yield 
0.13 g of a sticky solid.  The solid was dissolved in EtOH, cooled to 0 °C (ice-bath) and a saturated 
solution of gaseous HCl/EtOH was added. The EtOH was removed under reduced pressure to yield 
a white solid (0.06 g; mp 206-208 ºC) which upon recrystallization from MEOH/H2O afforded 
0.05 g (13%) of compound 116 as a white solid: mp 206-208 ºC. 1H NMR (DMSO-d6)  1.68-1.80 
(m, 4H, CH2), 2.15-2.22.28 (m, 4H, CH2), 3.07-3.20 (m, 6H, CH2), 3.49-3.51 (m, 1H, CH), 3.62-
3.65 (d, 2H, CH2, J = 11.84 Hz), 7.34-7.39 (td, 1H, ArH, J = 2.0, 8.9 Hz ), 7.53-7.57 (t, 2H, ArH, 
J = 7.4 Hz), 7.64-7.68 (t, 1H, ArH, J = 7.32 ), 7.74-7.76 (dd, 1H, ArH, J = 2.1, 9.1 Hz), 7.97-8.01 
(m, 2H, ArH), 8.12-8.15 (m, 1H, ArH), 9.97 (brs, 1H, NH+). Anal. Calcd for 
(C23H25N2O2F•1HCl•0.2CH3OH•0.7H2O) C, 63.92; H, 6.52; N, 6.43. Found C, 63.65; H, 6.14; N, 
6.40. 
 
6-Fluoro-3-[1-(5-phenylpentyl)piperidin-4-yl]benz[d]isoxazole Hydrochloride (117) 
1-Chloro-5-phenylpentane (142) (0.50 g, 2.73 mmol) was added to a stirred suspension of 6-
fluoro-3-(4-piperidinyl)benz[d]isoxazole (0.66 g, 2.97 mmol), anhydrous K2CO3 (0.41 g, 2.97 
mmol) and KI (few crystals) in MeCN (4 mL). The stirred reaction mixture was heated at 80 °C 
in a sealed tube for 96 h, allowed to cool to room temperature, filtered, and the filtrate was 
evaporated under reduced pressure to give 0.90 g of a yellow oil. The oil was purified by column 
chromatography (silica gel; CH2Cl2/MeOH; 9.5:0.5) to afford 0.23 g of a sticky white solid. The 
solid was dissolved in MeOH (2 mL), and cooled to 0 C (ice-bath). A saturated solution of gaseous 
HCl/EtOH was added and the reaction mixture was allowed to stir at room temperature overnight. 
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The solvent was evaporated under reduced pressure to yield a white solid (0.21 g) which upon 
recrystallization from MeOH/H2O afforded 0.14 g (12%) of compound 117 as a white solid: mp 
166 °C. 1H NMR (DMSO-d6)  1.30-1.38 (m, 2H, CH2), 1.59-1.66 (m, 2H, CH2), 1.76-1.84 (m, 
2H, CH2), 2.18-2.21 (d, 2H, CH2, J = 13.3 Hz), 2.33-2.43 (m, 2H, CH2 ), 2.59-2.63 (t, 2H, CH2, J 
= 7.7 Hz), 3.04-3.17 (m, 4H, CH2), 3.40-3.50 (m, 1H, CH), 3.60-3.62 (d, 2H, CH2, J = 11.8 Hz), 
7.16-7.36 (m, 6H, ArCH), 7.71-7.74 (dd, 1H, ArCH, J = 2.0, 9.0 Hz), 8.22-8.25 (m, 1H, ArCH), 
10.84 (br s, 1H, NH+). Anal. Calcd for (C23H27N2OF•1 HCl) C, 68.56; H, 7.00; N, 6.95. Found C, 
68.66; H, 7.10; N, 6.93. 
 
6-Fluoro-3-(2-nitrovinyl)-1H-indole (123) 
Compound 123 was synthesized using a literature procedure for the same compound.165 
Trifluoroacetic acid (3.7 mL) was added to 6-fluoroindole (120) (0.5 g, 3.69 mmol) and 1-
dimethylamino-2-nitroethylene (0.43 g, 3.71 mmol) under an N2 atmosphere. The reaction mixture 
was allowed to stir at room temperature for 1 h, and quenched carefully with a saturated aqueous 
NaHCO3 solution. The residue was collected by filtration, washed with H2O and dried to yield 
0.65 g (85%) of compound 123 as a yellow solid. mp 172-174 ºC (lit.166 mp 170-172 ºC). 
Compound 123 was used in the preparation of compound 106. 
 
3-(2-Nitrovinyl)-1H-indole (125) 
Compound 125 was synthesized using a literature procedure for a similar compound.165 
Trifluoroacetic acid (3.7 mL) was added to indole (124) (0.43 g, 3.69 mmol) and 1-dimethylamino-
2-nitroethylene (0.43 g, 3.71 mmol) under an N2 atmosphere. The reaction mixture was allowed 
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to stir at room temperature for 1 h and quenched carefully with a saturated aqueous NaHCO3 
solution. The residue was collected by filtration, washed with H2O and dried to yield 0.56 g (81%) 
of compound 125 as a yellow solid: mp 164-168 ºC (lit.168 mp 167-168 ºC). Compound 125 was 
used in the preparation of compound 105. 
 
Ethyl (2-(6-fluoro-1H-indol-3-yl)ethyl)carbamate (127) 
Compound 127 was synthesized using a literature procedure for a similar compound.172 Ethyl 
chloroformate (0.37 mL, 3.92 mmol) was added in a dropwise manner at 0 oC (ice-bath) to a stirred 
solution of 106 (0.7 g, 3.91 mmol) and Et3N (0.549 mL, 3.92 mmol) in anhydrous CH2Cl2 (13 mL) 
under an N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 3 h. The 
organic portion was washed with H2O (13 mL), 1M HCl (5 mL), 5% NaHCO3 solution (5 mL), 
H2O (5 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.84 g 
(86%) as an orange-colored oil. An attempt was made to isolate the product using a short column 
(silica gel; Ethyl acetate /Hexanes; 4:6). 0.50 g (51%) of a mixture of 127 and impurities was 
isolated as an orange-colored oil and was used without further purification in the next step. IR 
(diamond, cm-1) 1689 (-NH), 3318 (-C=O). Compound 127 was used in the preparation of 
compound 108. 
 
Indolyl-3-glyoxyl chloride (128) 
Compound 128 was synthesized using a literature procedure for the same compound.169 Oxalyl 
chloride (0.71 mL, 8.17 mmol) was added dropwise to a stirred solution of indole 124 (0.83 g, 7.08 
mmol) in anhydrous Et2O (15 mL) at 0 ºC (ice-bath) under an N2 atmosphere, and was allowed to 
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stir at 0 ºC for 3 h, and at room temperature for 1 h. The reaction mixture was filtered, and the 
residue was washed with cold Et2O, and dried to yield 1.02 g (73%) of compound 128 as yellow 
crystals: mp 120-124 ºC (decomposes) (lit.216 mp 116-117 °C). Compound 128 was used in the 
preparation of compound 129. 
 
Indole-3-yl-N-methylglyoxalylamide (129) 
Compound 129 is known and was synthesized using a literature procedure for the same 
compound.217 A solution of compound 128 (0.60 g, 2.89 mmol) in THF was added to methylamine 
(40% in H2O, 30 mL) at 0 ºC (ice-bath), and the reaction mixture was allowed stirred at room 
temperature for 24 h. The solvent was removed under reduced pressure to yield a crude sticky 
residue that was dried and recrystallized from MeOH to yield 0.4 g (68%) of compound 129 as a 
beige-colored solid: mp 214-216 ºC (lit.217 mp 220-222 ºC). Compound 129 was used in the 
preparation of compound 130. 
 
Hydroxy-indol-3-yl-acetic acid methylamide (130) 
Compound 130 was obtained as a side-product and was synthesized using a literature procedure 
for a compound similar to analog 107.172 A solution of compound 129 (0.30 g, 1.50 mmol) in THF 
(40 mL) was added to a stirred solution of LiAlH4 (0.29 g, 7.50 mmol) in anhydrous THF (50 mL) 
at 0 ºC under an N2 atmosphere. The reaction mixture was heated at reflux for 8 h, cooled to 0 °C 
(ice-bath), and quenched by addition of H2O (0.3 mL), 15% NaOH (0.3 mL) and H2O (1.5 mL). 
The suspension was filtered, and the residue was washed with Et2O. The filtrate was extracted with 
Et2O (3 x 10 mL). The combined organic portion was washed with brine (10 mL), dried (Na2SO4), 
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and evaporated under reduced pressure to yield 0.10 g (33%) of compound 130 as a white solid: 
mp 184-188 °C (lit.171 mp 193-194 °C). IR (diamond, cm-1) 3277 (-OH). 
 
Ethyl 2-(1H-indol-3-yl)ethylcarbamate (131) 
Compound 131 was synthesized using a literature procedure for the same compound.172 Ethyl 
chloroformate (1.48 mL, 15.61 mmol) was added dropwise at 0 ºC (ice-bath) to a stirred solution 
of tryptamine (105) (2.5 g, 15.61 mmol) and Et3N (2.17 mL, 15.61 mmol) in anhydrous CH2Cl2 
(39 mL). The stirred reaction mixture was allowed to warm to room temperature. The organic 
portion was washed with H2O (10 mL), 1M HCl (10 mL), 5% NaHCO3 solution (10 mL), H2O (10 
mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 2.80 g (77%) 
as an orange-colored oil. The oil was purified using column chromatography (silica gel; 
EtOAc/Hexanes; 3:7) to yield 1.76 g (49%) of compound 131 as an orange-colored oil. IR 
(diamond, cm-1) 1689 (-C=O), 3318 (-NH). Compound 131 was used in the preparation of 
compound 107. 
 
N,N-bis(3-(2-Ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-
onyl)tryptamine (132) 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.10 g, 0.4 
mmol) was added to a stirred suspension of  tryptamine (105) (0.079 g, 0.44 mmol), KI (catalytic 
amount) and anhydrous K2CO3 (0.07 g, 0.44 mmol) in MeCN (3 mL) The stirred reaction mixture 
was heated in a sealed tube at 80 ºC for 5 days. The hot reaction mixture was filtered and the filtrate 
was evaporated under reduced pressure to give 0.15 g of a crude residue. The crude residue was 
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purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 8.5:1.5:0.1) to yield 0.03 g 
(13%) of compound 132 as a sticky white solid. 1H NMR (DMSO-d6)  1.73-1.85 (m, 8H, CH2), 
2.21 (s, 6H, CH3), 2.62 (s, 8H, CH2), 2.72-2.76 (t, 4H, CH2 ), 2.83 (s, 4H, CH2), 3.76-3.79 (t, 4H, 
CH2, J = 6.2 Hz), 6.94-6.98 (t, 1H, ArH, J = 7.4 Hz), 7.03-7.07 (t, 1H, ArH, J = 7.5 Hz ), 7.12 (s, 
1H, ArH), 7.31-7.33 (d, 1H, ArH, J = 8.0 Hz), 7.52-7.54 (d, 1H, ArH, J = 7.8 Hz), 10.76 (s, 1H, 
NH). MS calculated [M+H]+: 541.3213 MS found [M+H]+: 541.3313. 
 
N-Benzyltryptamine (133) 
Compound 133 is known and was synthesized using a literature procedure for the same 
compound.218 MgSO4 (0.01 g, 0.1 mmol), tryptamine (105) (0.16 g, 1.00 mmol), and benzaldehyde 
(0.14 g, 1.3 mmol) were added to EtOH (10 mL), and the stirred reaction mixture was heated at 60 
ºC for 1 h. The reaction mixture was filtered and NaBH4 (0.04 g, 1 mmol) was added to the filtrate. 
The reaction mixture was allowed to stir at room temperature for 1.5 h and was quenched by the 
addition of ice-H2O at 0 ºC (ice-bath). The aqueous portion was extracted with CH2Cl2 (3x 5 mL), 
and the combined organic portion was washed with H2O (5 mL), brine (5 mL), dried (Na2SO4), 
and evaporated under reduced pressure to yield 0.18 g (78%) of compound 133 as a brown-colored 
oil. NMR (DMSO-d6)  2.77-2.88 (m, 4H, CH2), 3.74 (s, 2H, CH2), 6.93-6.97 (m, 1H, ArH), 7.03-
7.07 (td, 1H, ArH, J = 1.1, 8.1 Hz), 7.12-7.13 (d, 1H, ArH, J = 2.3 Hz), 7.19-7.23 (m, 1H, ArH), 
7.28-7.34 (m, 5H, ArH), 7.48-7.50 (d, 1H, ArH, J = 7.9 Hz). 10.76 (s, NH). Compound 133 was 
used in the preparation of compound 134. 
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3-(2-((2-(1H-Indol-3-yl)ethyl)(benzyl)amino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one (134) 
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.16 g, 0.73 
mmol) was added to a stirred suspension of intermediate 133 (0.18 g, 0.73 mmol), anhydrous 
K2CO3 (0.10 g, 0.73 mmol)  and KI (few crystals) in MeCN (15 mL) under an N2 atmosphere. The 
stirred reaction mixture was heated at reflux for 48 h. The hot reaction mixture was filtered and 
the filtrate was evaporated under reduced pressure to give 0.24 g of a crude residue. The residue 
was dissolved in H2O (~5 mL), and extracted with CH2Cl2 (3 x 5 mL). The combined organic 
portion was washed with H2O (5 mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced 
pressure to yield 0.20 g of a sticky, yellow-colored liquid that was purified using a short column 
(silica gel; CH2Cl2/MeOH/NH4OH; 9:1:0.1) to afford 0.12 g of a liquid, that was dissolved in 
CH2Cl2 (2 mL), cooled to 0 C (ice-bath), and treated with a saturated solution of gaseous 
HCl/EtOH, and then the reaction mixture was allowed to stir at room temperature overnight. The 
precipitate was collected by filtration to yield 0.07 g (20%) of compound 134 as a sticky, pale 
gray-colored solid. NMR (DMSO-d6)  1.77-1.94 (m, 4H, CH2), 2.36 (s, 3H, CH3), 3.02-3.43 (m, 
10 H, CH2), 3.81-3.84 (t, 2H, CH2, J = 6.3 Hz), 4.55-4.57 (d, 2H, CH2, J = 5.2 Hz), 6.96-7.00 (m, 
1H, ArH), 7.07-7.11 (m, 1H, ArH, J = 1.1, 8.1 Hz), 7.21 (d, 1H, ArH, J = 3.96 Hz), 7.35-7.37 (d, 
1H, ArH, J = 8.1 Hz), 7.48-7.51 (m, 4H, ArH), 7.77-7.79 (m, 2H, ArH, J = 7.9 Hz). 11.01 (s, 1H, 
NH), 11.41 (brs, 1H, NH+). 
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5-Chlorovaleroyl chloride (140) 
Compound 140 was synthesized using a literature procedure for the same compound.175 Thionyl 
chloride (2.0 mL, 28.09 mmol) was added to 5-chlorovaleric acid (139) (2.00 g, 14.64 mmol), and 
heated at reflux for 3 h under an N2 atmosphere. The reaction mixture was allowed to cool to room 
temperature and the thionyl chloride was evaporated under reduced pressure to give 2.04 g (90%) 
of compound 140 as a crude yellow oil. Compound 140 was used without further purification in 
the next step. IR (diamond, cm-1) 1791 (-C=O). Compound 140 was used in the preparation of 
compound 141. 
 
5-Chloro-1-phenyl-1-pentanone (141) 
 Compound 141 was synthesized using a literature procedure for the same compound.176 AlCl3 
(1.89 g, 14.17 mmol) was added to a stirred solution of 140 (2.04 g, 13.16 mmol ) in benzene (3.2  
mL, 35.88 mmol) at 0 ºC (ice-bath). The reaction mixture was stirred at 0 ºC for 1 h, and was 
allowed to cool to room temperature and stirred for an additional hour. It was quenched by pouring 
into ice-H2O, and the organic portion was separated. The aqueous portion was extracted with 
benzene (3 x 10 mL). The combined organic portion was washed with H2O (10 mL), brine (10 
mL), dried (Na2SO4), and concentrated under reduced pressure to yield 2.4 g of a crude pale brown 
solid: mp 42-43 ºC, that  was recrystallized using hexane to give 2.2 g of a pale yellow solid: mp 
43-44 ºC that was further purified by column chromatography (silica gel; hexanes/ EtOAc; 100:0 
to 94:06) to yield 2.1 g (81%) of compound 141 as a pearly white solid: mp 49 ºC (lit.176 mp 50-
51 °C). 1H NMR (DMSO-d6)  1.70-1.84 (m, 4H, CH2), 3.07-3.10 (t, 2H, CH2, J = 6.8 Hz), 3.68-
3.71 (t, 2H, CH2, J = 6.4 Hz), 7.51-7.55 (t, 2H, ArCH, J = 7.4 Hz), 7.62-7.66 (t, 1H, ArCH, J = 7.4 
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Hz), 7.96-7.99 (d, 2H, ArCH, J = 7.1 Hz). Compound 141 was used in the preparation of compound 
116. 
  
4-(4-Phenylpiperidin-1-yl)pyridin-2(1H)-one (150) 
Compound 150 was unknown and was synthesized using a literature procedure for a similar 
compound.204 A solution of 151 (0.11 g, 0.32 mmol) in EtOAc/MeOH (27 mL, 1/2) was 
hydrogenated (30-40 psi) using 10% Pd/C (0.01 g) as a catalyst at room temperature for 2 h. The 
reaction mixture was filtered over Celite and the filtrate was evaporated under reduced pressure to 
yield 0.07 g (86%) of compound 150 as a yellow-colored solid: mp 110-114 ºC. 1H NMR (DMSO-
d6)  1.57-1.68 (m, 2H, CH2), 1.82-1.85 (d, 2H, CH2, J = 11.4 Hz), 2.77-2.83 (m, 1H, CH), 2.91-
2.97 (t, 2H, CH2, J = 11.5 Hz) 3.94-3.97 (d, 2H, CH2, J = 13.3 Hz), 5.53 (s, 1H, ArH), 6.14-6.17 
(dd, 1H, ArH, J = 2.4 Hz, 7.6 Hz), 7.16-7.32 (m, 6H, Ar H). IR (diamond, cm-1) 1611 (-C=O), 
2917 (-NH). Compound 150 was used in the preparation of compounds 153 and 154. 
 
2-(Benzyloxy)-4-(4-phenylpiperidin-1-yl)pyridine (151) 
Compound 151 was not known and was synthesized using a procedure for a similar compound.119 
4-Phenyl piperidine (1.71 g, 10.67 mmol), palladium diacetate (0.79 g, 3.53 mmol), BINAP (0.33 
g, 0.53 mmol) and sodium tert-butoxide (1.38 g, 14.33 mmol) were added to a stirred solution of 
152 (1.5 g, 5.73 mmol) in toluene (15 mL). The reaction mixture was heated in a sealed tube at 
100 ºC for 27 h and filtered over Celite. The filtrate was diluted with water (~20 mL) and extracted 
with EtOAC (3x 20 mL). The combined organic portion was washed with H2O (10 mL), brine (10 
mL), dried (Na2SO4), and concentrated under reduced pressure to yield 2.01 g of a crude, yellow 
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oil that was further purified by column chromatography (silica gel; hexanes/ EtOAc; 100:0 to 
94:06) to yield 0.43 g (22%) of compound 151 as a white solid: mp 106-108 ºC. 1H NMR (DMSO-
d6)  1.62-1.69 (m, 2H, CH2), 1.82-1.85 (d, 2H, CH2, J = 12.12 Hz), 2.75-2.82 (m, 1H, CH), 2.89-
2.96 (m, 2H, CH2), 4.01-4.04 (d, 2H, CH2, J = 13.3 Hz), 5.30 (s, 2H, CH2), 6.23 (s, 1H, ArH), 
6.60-6.62 (dd, 1H, ArH, J = 2.3 Hz, 6.2 Hz), 7.18-7.44 (m, 10H, Ar H), 7.80-7.82 (d, ArH, 1H, J 
= 6.2 Hz). Compound 151 was used in the preparation of compound 150. 
 
2-(Benzyloxy)-4-bromopyridine (152) 
Compound 152 is known and was synthesized using a literature procedure for the same 
compound.203 Sodium hydride (0.93 mg, 38.75 mmol) was added to a stirred solution of benzyl 
alcohol (2.65 mL, 25. 51 mmol) in THF (8 mL) at 0 ºC and was allowed to stir at room temperature 
for 15 min. 4-Bromo-2-chloro pyridine (148) (1.50 g, 7.79 mmol) in THF (2 mL) was added, the 
stirred reaction mixture was heated at reflux for 3 h, and quenched by the addition of H2O (~10 
mL). The aqueous portion was extracted with EtOAC (3x 10 mL). The combined organic portion 
was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under reduced 
pressure to yield 2.20 g of a crude yellow oil that was further purified by column chromatography 
(silica gel; hexanes/ EtOAc; 100:0 to 80:20) to yield 1.5 g (73%) of compound 152 as a colorless 
oil. 1H NMR (DMSO-d6)  5.41 (s, 2H, CH2), 7.26 (s, 1H, ArH), 7.30-7.31 (dd, 1H, ArH, J = 1.6 
Hz, 5.5 Hz), 7.36-7.51 (m, 5H, Ar H), 8.14-8.16 (d, ArH, 1H, 5.5 Hz). Compound 152 was used 
in the preparation of compound 151. 
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2-Butoxy-4-(4-phenylpiperidin-1-yl)pyridine (153) 
Compound 153 was obtained as a side-product instead of compound 147 and was synthesized 
using a literature procedure for a similar compound.219 Sodium hydride was added to a solution of 
compound 150 (0.22 g, 0.85 mmol) in DMF (10 mL) at 0 ºC under an N2 atmosphere and was 
stirred at room temperature for 1 h. n-Butyl bomide (0.1 mL, 0.91 mmol) was added dropwise and 
the reaction mixture was heated at 103 ºC for 3 days. The reaction mixture was diluted with H2O 
(~10 mL) and extracted with EtOAC (3x 10 mL). The combined organic portion was washed with 
H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under reduced pressure to yield 
0.16 g of a crude yellow oil that was further purified by column chromatography (silica gel; 
hexanes/ EtOAc; 100:0 to 80:20) to yield 0.04 g (17%) of compound 153 as a yellow-colored oil. 
1H NMR (DMSO-d6)  0.91-0.95 (t, 3H, CH3, J = 7.4 Hz), 1.25-1.27 (d, 1H, CH, J = 10 Hz), 1.38- 
1.46 (m, 2H, CH2), 1.62-1.69 (m, 4H, CH2), 1.82-1.85 (d, 2H, CH2, J = 10.6 Hz), 2.76-2.81 (m, 
1H, CH), 2.87-2.93 (m, 2H, CH2), 3.99-4.02 (d, 2H, CH2, J = 12.8 Hz), 4.17-4.20 (t, 2H, CH2, J = 
6.6 Hz), 6.12-6.13 (d, 1H, ArH, J = 2.2 Hz), 6.56-6.58 (dd, 1H, ArH, J = 2.2 Hz, 6.2 Hz), 7.16-
7.32 (m, 5H, ArH), 7.77-7.78 (d, 1H, ArH, J = 6.1 Hz).  
 
3-Chloro-4-(4-phenylpiperidin-1-yl)pyridin-2(1H)-one (154) 
Compound 154 was unknown and was synthesized using a literature procedure for a similar 
compound.119 N-Chlorosuccinimide (0.08 g, 0.63 mmol) was added to a stirred solution of 
Compound 150 (0.16 g, 0.63 mmol) in CH2Cl2 (30 mL). The reaction mixture was allowed to stir 
at room temperature for 10 min and was quenched by the addition of a saturated aqueous NaHCO3 
solution. The aqueous portion was extracted with CH2Cl2 (3 x 10 mL) and the combined organic 
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portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under 
reduced pressure to yield 0.12 g of a crude residue that was was further purified by column 
chromatography (silica gel; CH2Cl2/ MeOH; 90:10) to yield 0.05 g (81%) of compound 154 as a 
white solid: mp 274 ºC. 1H NMR (DMSO-d6)  1.67-1.86 (m, 4H, CH2), 2.65-2.73 (m, 1H, CH), 
2.83-2.91 (t, 2H, CH2, J = 11.55 Hz), 3.64-3.68 (d, 2H, CH2, J = 12.3 Hz), 6.08-6.11 (d, 1H, ArH, 
J = 7.2 Hz), 6.14-6.17 (m, 6H, ArH). 
 
(±)6-Fluoro-3-(piperidin-3-yl)benz[d]isoxazole Hydrochloride (155) 
Compound 155 was synthesized using a literature procedure for a similar compound.153 Compound 
161 (0.07 g, 0.27 mmol) was added to a solution of HCl (3N, 1 mL) and EtOH (1 mL), and heated 
at reflux for 3 h. It was allowed to cool to room temperature and evaporated to dryness under 
reduced pressure to yield a crude yellow-colored solid (mp 258-260 °C) that was recrystallized 
from EtOH/H2O to yield 0.05 g (74%) of compound 155 as a yellow-colored solid: mp 262-264 
°C. 1H NMR (DMSO-d6)  1.78-1.92 (m, 3H, CH2), 2.21-2.25 (d, 1H, CH2, J = 13.2 Hz), 3.04 (s, 
1H, CH), 3.27-3.34 (m, 2H, CH2), 3.59-3.72 (m, 2H, CH2), 7.34-7.39 (m, 1H, ArH), 7.75-7.78 (m, 
1H, ArH), 8.13-8.16 (m, 1H, ArH), 9.25 (br s, 2H, NH+) ; Anal. Calcd for (C12H13N2OF•1HCl) C, 
56.15; H, 5.50; N, 10.91. Found C, 56.11; H, 5.52; N, 10.84. 
 
N-Formylpiperidine-3-carboxylic acid (157) 
Compound 157 was synthesized using a literature procedure for a similar compound.143 A solution 
of HCOOH (9 mL, 222.98 mmol) and Ac2O (22 mL, 222.98 mmol) was heated at 60 ºC for 1 h, 
cooled to 0 °C (ice-bath) and nipecotic acid (156) (5.00 g, 38.71 mmol) was added portion-wise. 
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The reaction mixture was allowed to stir at room temperature for 16 h. and concentrated under 
reduced pressure to yield a colorless oil that was crystallized using i-PrOH and diisopropyl ether 
to give a crude white solid (mp 110-112 °C). The solid was recrystallized using i-PrOH to yield 
5.14 g (85%) of compound 157 as a white solid: mp 114 °C and used without further purification 
in the next step. Compound 157 was used in the preparation of compound 158. 
  
N-Formylpiperidine-3-carboxylic acid chloride (158) 
Compound 158 was synthesized using a literature procedure for a similar compound.153 SOCl2 (3 
mL, 41.30 mmol) was added to 157 (2.00 g, 12.72 mmol) at 0 ºC (ice-bath) under an N2 
atmosphere. It was allowed to stir at room temperature for 6 h and the SOCl2 was evaporated under 
reduced pressure to afford 2.18 g (98%) of compound 158 as a crude orange-colored oil that was 
verified spectrally and used without further characterization and purification in the next step. IR 
(diamond, cm-1) 1668 (-C=O). Compound 158 was used in the preparation of compound 159. 
 
N-Formyl-3-(2,4-difluorobenzoyl)piperidine (159) 
Compound 159 was synthesized using a literature procedure for a similar compound.153 Compound 
158 (2.18 g, 12.41 mmol) was added dropwise to a stirred suspension of AlCl3 (3.00 g, 22.50 
mmol) suspended in 1,3-difluorobenzene (13 mL, 132.51 mmol) at 0 °C (ice-bath) under an N2 
atmosphere. The reaction mixture was heated at reflux for 22 h, allowed to cool to room 
temperature, and quenched by pouring into ice-H2O (50 mL). The aqueous portion was extracted 
using CHCl3 (3 x 15 mL) and the combined organic portion was washed with H2O (10 mL), brine 
(10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 2.98 g (95%) of 159 as 
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an orange-colored oil that was used without further purification in the next step. Compound 159 
was used in the preparation of compound 160. 
 
N-Formyl-3-((2,4- difluorophenyl)(hydroxyimino)methyl)piperidine (160) 
Compound 160 was synthesized using a literature procedure for a similar compound.143 
Hydroxylamine hydrochloride (2.37 g, 34.09 mmol) was added to a solution of 159 (2.89 g, 11.41 
mmol) in EtOH (58 mL)and was followed by the addition of  a solution of NaOH (1.39, 34.70 
mmol) in H2O (9 mL). The reaction mixture was heated at reflux for 96 h, allowed to cool to room 
temperature, and filtered. The filtrate was evaporated under reduced pressure to give a crude 
yellow-colored oil that was purified by column chromatography (silica gel; CH2Cl2/CH3OH; 100:0 
to 95:5) to afford 0.60 g (40%) of 160 as a yellow-colored solid: mp 158-160 °C. IR (diamond, 
cm-1) 1639 (-C=N), 2864-3180 (-OH). Compound 160 was used in the preparation of compound 
161. 
 
N-Formyl-3-(6-fluorobenz[d]isoxazol-3-yl)piperidine (161) 
Compound 161 was synthesized using a literature procedure for a similar compound.153 A solution 
of 160 (0.59 g, 2.14 mmol) in DMF (3 mL) was added dropwise to a suspension of NaH (0.09 g, 
3.63 mmol) in THF (5 mL) at 0 °C (ice-bath) under an N2 atmosphere. The reaction mixture was 
heated at 75 °C for 4 h, allowed to cool to room temperature and poured into ice-H2O (30 mL). 
The aqueous portion was extracted with EtOAc (3 x 15 mL) and the combined organic portion was 
washed with H2O (10 mL), brine (10 mL), dried (Na2SO4) and evaporated under reduced pressure 
to give a crude yellow-colored solid that was purified by column chromatography (silica gel; 
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CH2Cl2/MeOH; 100:0 to 95:5) to afford 0.08 g (15%) of compound 161 as a pale yellow-colored 
solid: mp 104-106 ºC. Compound 161 was used in the preparation of compound 155. 
 
B. Radioligand binding studies 
i. For risperidone (14), ketanserin (36), and compounds 60, 61, 65, 66, Ris/Ket (103) and 
Ket/Ris (104) 
Radioligand binding studies of the compounds were conducted in Dr. Javier Gonzalez-Maeso’s 
laboratory as previously reported.141 Binding affinities of risperidone (14), ketanserin (36) and 
compounds 60, 61, 65, 66, Ris/Ket (103) and Ket/Ris (104) were determined by Dr. Jose L. 
Moreno. 
 
ii. For compounds 57, 62, 63, 111, 112 and 155  
Radioligand binding studies of the compounds were conducted in Dr. Javier Gonzalez-Maeso’s 
laboratory. Binding affinities of analogs 62 and 63 were determined by Dr. Supriya A. Gaitonde. 
 
The radioligand binding studies were performed in HEK 293 cells that stably express human 5-
HT2A receptors. The cell pellets were homogenized using a Teflon-glass grinder (50 up-and-down 
strokes) in 5 mL of binding buffer (5 mM Tris-HCl; pH 7.4). The volume was made up to 10 mL 
with binding buffer and the crude homogenate was centrifuged at 3000 rpm for 5 min at 4 °C. The 
supernatant was centrifuged at 18,000 rpm for 10 min at 4 °C. The resultant pellet (P2 fraction) 
was washed with 10 mL of binding buffer (5 mM Tris-HCl pH 7.4) and re-centrifuged at 18,000 
rpm for 15 minutes. Aliquots were stored at -80 °C until assay. Protein concentration was 
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determined using the Bio-Rad protein estimation assay. Curves were carried out by incubating 
each drug (10-10-10-4 M; 13 concentrations) in binding buffer containing 5 nM [3H]-ketanserin. 
Nonspecific binding was determined in the presence of 10 μM methysergide. Incubations were 
terminated by dilution with 200 μL ice-cold incubation buffer, and free ligand was separated from 
bound ligand by rapid filtration under vacuum through GF/C glass fiber filters using a microbeta 
filtermat-96 harvester (PerkinElmer). These filters were then rinsed twice with 200 μL of ice-cold 
incubation buffer, air-dried for 0.5 h, dried at 65 ºC for 1 h and counted for radioactivity by liquid 
scintillation spectrometry, using a MicroBeta2 detector (PerkinElmer). Radioligand binding data 
were analyzed by nonlinear regression by GraphPad PRISM (version 7 for Windows 10, GraphPad 
Software, La Jolla California, US). 
 
C. Functional activity studies 
The TEVC and calcium imaging assays were performed in Dr. Diomedes Logothetis’s laboratory 
by Dr. Jason Younkin, Amr Ellaithy, and Dr. Lia Baki as previously reported.141 
 
D. Molecular modeling studies 
i. Docking studies at 5-HT2A receptors 
The ligands were sketched in and energy minimized using the Tripos Force Field (Gasteiger-
Hückel charges, distance-dependent dielectric constant = 4.0) in SYBYL X-2.1 (Tripos 
International). Docking studies at 5-HT2A receptors were conducted using the genetic algorithm 
docking program GOLD suite 5.4187 (Cambridge Crystallographic Data Centre, Cambridge, UK), 
with ChemPLP as the chosen scoring function. The binding site was defined to include all amino 
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acid residues within a radius of 10 Å from Asp155 The docking poses were clustered (intracluster 
RMSD ≤ 2 Å) using a script that was provided by Dr. Philip Mosier. The top solutions were merged 
into homology models of the 5-HT2A receptor and the receptor-ligand complexes were energy 
minimized using the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric 
constant = 4.0) in SYBYL X-2.1 (Tripos International). HINT188 analysis was performed in 
SYBYL-8.1 to quantify the receptor-ligand interactions observed in molecular modeling studies. 
PYMOL220 was used to generate images. 
 
ii. Homology modeling of mGlu2 receptors 
The amino acid sequences of the crystal structure of the mGlu5 receptor (PDB ID: 4OO9) was 
retrieved as a FASTA file from the Protein Databank (PDB) The sequences retrieved consisted of 
a dimer and only residues from one monomer were retained. The sequence was prepared by 
removal of water molecules, ligand and other molecules. The amino acid sequence of the human 
mGlu2 receptor was (entry code: Q14416), were retrieved as a FASTA files from the Universal 
Protein Resource (UniPort) Database. The amino acid sequences of the TMD of the mGlu5 receptor 
and the mGlu2 receptor were aligned using Clustal X 2.1.
178. Homology models (100) of the TMD 
of the mGlu2 receptor were generated using MODELLER v9.12
179 (University of California San 
Francisco, San Francisco, CA) Hydrogen atoms were added to the homology models and disulfide 
bonds were built using SYBYL-X 2.1 (Tripos International, St. Louis, MO, USA). Ramachandran 
plots using MolProbity197 were generated to examine the models.  
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iii. Docking studies at mGlu2 receptors 
The ligands were sketched in and energy minimized using the Tripos Force Field (Gasteiger-
Hückel charges, distance-dependent dielectric constant = 4.0) in SYBYL X-2.1 (Tripos 
International). Docking studies at mGlu2 receptors were conducted using the genetic algorithm 
docking program GOLD suite 5.2187 (Cambridge Crystallographic Data Centre, Cambridge, UK) 
with ChemPLP as the chosen scoring function. The binding site was defined to include all amino 
acid residues within a radius of 10 Å from Asn735. The docking poses were clustered (intracluster 
RMSD ≤ 2 Å) using a script that was provided by Dr. Philip Mosier. The top solutions were merged 
into homology models of the mGlu2 receptor and the. The receptor-ligand complexes were energy 
minimized using the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric 
constant = 4.0) in SYBYL X-2.1 (Tripos International). 
 
HINT188 analysis was performed in SYBYL-8.1 to quantify the receptor-ligand interactions 
observed in molecular modeling studies. PYMOL220 was used to generate images. 
 
iv. Distance measurements for 5-HT (6) and analogs 61, 63 and 155 
A systematic search was performed on SYBYL-X 2.1 (Tripos International) to determine the 
lowest energy conformation of the molecules. The benzene ring centroid was defined as the 
aromatic center, and the distances of the aromatic centers from the nitrogen atoms (for 5-HT (6), 
analogs 61, 63 and 155) as well as the distances of the hydrogen bond acceptors from the nitrogen 
atom (for analog 61) were measured using SYBYL-X 2.1. 
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APPENDIX A 
 
 
 
 
Analog 155 (Figure A1) has a chiral carbon atom, and can have multiple conformational isomers. 
A systematic search was performed using SYBYL-X 2.1 (Tripos International) to determine the 
lowest energy conformations of analog 155. Figure A1 illustrates the bonds that were set as 
rotatable bonds (RB) as well as the closure bond. The increment value, and the maximum energy 
difference, were set as 10 degrees and 9999 kcal/mol, respectively. Default options were used for 
the other parameters. The benzene-ring centroid was defined as the aromatic center, and the 
distances of the aromatic centers from the nitrogen atoms were also measured as part of the 
systematic search. The systematic search was performed on the S equatorial, R axial, R equatorial, 
and S axial isomers of 155, and the results of the conformational search are tabulated in Tables 
A1, A2, A3 and A4, respectively. In the lowest energy conformations of the S equatorial, R axial, 
R equatorial, and S axial isomers of analog 155, the piperidine ring was in a chair conformation, 
and are shown in Figure A2. 
 
Figure A1. Analog 155. Blue arrows indicate rotatable bonds (RB). 
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Table A1. Results of the systematic search for S equatorial-155. 
*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance. 
 
 
 
Name RB1* RB2* RB3* RB4* RB5* RB6* Energy 
(kcal/mol) 
Distance 
(Å)** 
1. CNF_15 280 56.3 303.6 56.8 302 58 15.5630 5.75 
2. CNF_1 270 56.3 303.6 56.8 302 58 15.6464 5.85 
3. CNF_14 290 56.3 303.6 56.8 302 58 15.6809 5.65 
4. CNF_8 200 56.3 303.6 56.8 302 58 15.7319 6.35 
5. CNF_2 260 56.3 303.6 56.8 302 58 15.7662 5.95 
6. CNF_7 210 56.3 303.6 56.8 302 58 15.7855 6.25 
7. CNF_6 220 56.3 303.6 56.8 302 58 15.8622 6.25 
8. CNF_3 250 56.3 303.6 56.8 302 58 15.8743 5.95 
9. CNF_9 190 56.3 303.6 56.8 302 58 15.8863 6.35 
10. CNF_5 230 56.3 303.6 56.8 302 58 15.9212 6.15 
11. CNF_4 240 56.3 303.6 56.8 302 58 15.9315 6.05 
12. CNF_13 300 56.3 303.6 56.8 302 58 16.9391 5.55 
13. CNF_10 180 56.3 303.6 56.8 302 58 17.2677 6.35 
14. CNF_12 60 56.3 303.6 56.8 302 58 17.3462 5.55 
15. CNF_11 170 336.3 323.6 66.8 332 328 27.2139 5.45 
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Table A2. Results of the systematic search for R axial-155. 
Name RB1* RB6* RB5* RB4* RB3* RB2* Energy 
(kcal/mol) 
Distance 
(Å)** 
1. CNF_1 161.7 303.3 58.5 301.9 56.2 304.4 15.2224 5.75 
2. CNF_62 171.7 303.3 58.5 301.9 56.2 304.4 15.4034 5.75 
3. CNF_60 181.7 303.3 58.5 301.9 56.2 304.4 17.1884 5.65 
4. CNF_37 81.7 23.3 38.5 291.9 26.2 34.4 23.6635 6.05 
5. CNF_41 71.7 23.3 38.5 291.9 26.2 34.4 23.6724 5.95 
6. CNF_33 91.7 23.3 38.5 291.9 26.2 34.4 23.6975 6.15 
7. CNF_36 81.7 33.3 28.5 291.9 36.2 24.4 23.7202 6.05 
8. CNF_32 91.7 33.3 28.5 291.9 36.2 24.4 23.7492 6.15 
9. CNF_29 101.7 23.3 38.5 291.9 26.2 34.4 23.7506 6.25 
10. CNF_40 71.7 33.3 28.5 291.9 36.2 24.4 23.7628 5.95 
11. CNF_28 101.7 33.3 28.5 291.9 36.2 24.4 23.802 6.25 
12. CNF_23 111.7 23.3 38.5 291.9 26.2 34.4 23.8169 6.35 
13. CNF_45 61.7 23.3 38.5 291.9 26.2 34.4 23.8227 5.85 
14. CNF_22 111.7 33.3 28.5 291.9 36.2 24.4 23.8653 6.35 
15. CNF_17 121.7 23.3 38.5 291.9 26.2 34.4 23.8978 6.35 
16. CNF_16 121.7 33.3 28.5 291.9 36.2 24.4 23.9309 6.35 
17. CNF_10 131.7 33.3 28.5 291.9 36.2 24.4 24.0114 6.45 
18. CNF_11 131.7 23.3 38.5 291.9 26.2 34.4 24.0238 6.45 
19. CNF_5 151.7 323.3 68.5 331.9 326.2 64.4 24.0278 6.05 
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20. CNF_2 161.7 323.3 68.5 331.9 326.2 64.4 24.0727 6.05 
21. CNF_44 61.7 33.3 28.5 291.9 36.2 24.4 24.085 5.85 
22. CNF_8 141.7 323.3 68.5 331.9 326.2 64.4 24.0919 6.05 
23. CNF_14 131.7 323.3 68.5 331.9 326.2 64.4 24.2301 6.05 
24. CNF_7 141.7 333.3 68.5 321.9 336.2 64.4 24.2679 6.15 
25. CNF_64 171.7 323.3 68.5 331.9 326.2 64.4 24.2811 5.95 
26. CNF_4 151.7 333.3 68.5 321.9 336.2 64.4 24.2888 6.15 
27. CNF_58 301.7 23.3 38.5 291.9 26.2 34.4 24.3342 5.35 
28. CNF_49 51.7 23.3 38.5 291.9 26.2 34.4 24.3522 5.75 
29. CNF_13 131.7 333.3 68.5 321.9 336.2 64.4 24.3568 6.15 
30. CNF_20 121.7 323.3 68.5 331.9 326.2 64.4 24.4141 5.95 
31. CNF_19 121.7 333.3 68.5 321.9 336.2 64.4 24.5013 6.05 
32. CNF_26 111.7 323.3 68.5 331.9 326.2 64.4 24.6469 5.95 
33. CNF_25 111.7 333.3 68.5 321.9 336.2 64.4 24.6739 6.05 
34. CNF_57 301.7 33.3 28.5 291.9 36.2 24.4 24.7407 5.45 
35. CNF_48 51.7 33.3 28.5 291.9 36.2 24.4 25.2815 5.75 
36. CNF_51 41.7 23.3 38.5 291.9 26.2 34.4 25.5312 5.65 
37. CNF_54 311.7 23.3 38.5 291.9 26.2 34.4 26.7319 5.25 
38. CNF_35 81.7 43.3 18.5 291.9 46.2 14.4 27.2489 6.05 
39. CNF_39 71.7 43.3 18.5 291.9 46.2 14.4 27.2763 5.95 
40. CNF_31 91.7 43.3 18.5 291.9 46.2 14.4 27.3276 6.15 
41. CNF_42 71.7 13.3 48.5 291.9 16.2 44.4 27.3566 5.95 
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42. CNF_46 61.7 13.3 48.5 291.9 16.2 44.4 27.3805 5.85 
43. CNF_38 81.7 13.3 48.5 291.9 16.2 44.4 27.4161 6.05 
44. CNF_27 101.7 43.3 18.5 291.9 46.2 14.4 27.4313 6.25 
45. CNF_34 91.7 13.3 48.5 291.9 16.2 44.4 27.5012 6.15 
46. CNF_21 111.7 43.3 18.5 291.9 46.2 14.4 27.5322 6.25 
47. CNF_30 101.7 13.3 48.5 291.9 16.2 44.4 27.5977 6.25 
48. CNF_15 121.7 43.3 18.5 291.9 46.2 14.4 27.6072 6.35 
49. CNF_9 131.7 43.3 18.5 291.9 46.2 14.4 27.6525 6.45 
50. CNF_50 51.7 13.3 48.5 291.9 16.2 44.4 27.6563 5.75 
51. CNF_6 141.7 43.3 18.5 291.9 46.2 14.4 27.6825 6.45 
52. CNF_3 151.7 43.3 18.5 291.9 46.2 14.4 27.6952 6.45 
53. CNF_24 111.7 13.3 48.5 291.9 16.2 44.4 27.6983 6.35 
54. CNF_43 61.7 43.3 18.5 291.9 46.2 14.4 27.7931 5.85 
55. CNF_53 31.7 23.3 38.5 291.9 26.2 34.4 27.7996 5.55 
56. CNF_18 121.7 13.3 48.5 291.9 16.2 44.4 27.8048 6.35 
57. CNF_63 171.7 43.3 18.5 291.9 46.2 14.4 27.8064 6.45 
58. CNF_12 131.7 13.3 48.5 291.9 16.2 44.4 27.9582 6.45 
59. CNF_59 301.7 13.3 48.5 291.9 16.2 44.4 28.0038 5.15 
60. CNF_56 301.7 43.3 18.5 291.9 46.2 14.4 28.6003 5.65 
61. CNF_52 41.7 13.3 48.5 291.9 16.2 44.4 28.6801 5.65 
62. CNF_55 311.7 13.3 48.5 291.9 16.2 44.4 29.0222 5.15 
63. CNF_61 181.7 43.3 18.5 291.9 46.2 14.4 29.2778 6.45 
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64. CNF_47 51.7 43.3 18.5 291.9 46.2 14.4 30.2279 5.75 
*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance. 
 
Table A3. Results of the systematic search for R equatorial-155. 
Name RB1* RB2* RB3* RB4*  RB5* RB6*  Energy 
(kcal/mol) 
Distance 
 (Å)** 
1. CNF_1 283.2 56.9 301.6 58.2 303.3 56.1 15.558 6.45 
2. CNF_2  273.2  56.9  301.6  58.2  303.3  56.1  15.6152  6.45 
3. CNF_11  203.2 56.9 301.6 58.2 303.3 56.1 15.7263 5.95 
4. CNF_4  263.2  56.9  301.6  58.2  303.3  56.1  15.7295  6.45 
5. CNF_12  193.2 56.9  301.6 58.2 303.3 56.1 15.7835 5.85 
6. CNF_10  213.2  56.9  301.6  58.2  303.3  56.1  15.793  6.05 
7. CNF_16  293.2 56.9 301.6 58.2 303.3 56.1 15.8182 6.45 
8. CNF_6  253.2  56.9  301.6  58.2  303.3  56.1  15.8422  6.35 
9. CNF_9  223.2 56.9  301.6 58.2 303.3 56.1 15.8683 6.15 
10. CNF_7  243.2 56.9  301.6  58.2  303.3  56.1  15.9138  6.25 
11. CNF_8  233.2 56.9 301.6 58.2 303.3  56.1  15.9189 6.25 
12. CNF_13  183.2  56.9 301.6  58.2  303.3 56.1  16.6131  5.85 
13. CNF_14  63.2  56.9  301.6  58.2  303.3  56.1  17.2443  5.75 
14. CNF_15  303.2  56.9 301.6 58.2 303.3  56.1 17.891  6.45 
15. CNF_3  273.2  346.9  311.6  68.2  343.3  316.1 27.2003  6.25 
16. CNF_5  263.2  346.9  311.6  68.2  343.3  316.1  27.3223  6.25 
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*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance. 
 
Table A4. Results of the systematic search for S axial-155. 
Name RB1* RB2* RB3* RB4* RB5* RB6* Energy 
(kcal/mol) 
Distance 
(Å)** 
1. CNF_1 80 54.9 299.7 60.2 304.7 52.2 15.9379 5.85 
2. CNF_3 70 54.9 299.7 60.2 304.7 52.2 15.9942 5.85 
3. CNF_41 90 54.9 299.7 60.2 304.7 52.2 16.0544 5.85 
4. CNF_37 100 54.9 299.7 60.2 304.7 52.2 16.2338 5.85 
5. CNF_33 110 54.9 299.7 60.2 304.7 52.2 16.4354 5.85 
6. CNF_12 170 54.9 299.7 60.2 304.7 52.2 16.4431 5.05 
7. CNF_29 120 54.9 299.7 60.2 304.7 52.2 16.6118 5.75 
8. CNF_25 130 54.9 299.7 60.2 304.7 52.2 16.7173 5.65 
9. CNF_5 60 54.9 299.7 60.2 304.7 52.2 16.8652 5.75 
10. CNF_8 180 54.9 299.7 60.2 304.7 52.2 18.6755 4.85 
11. CNF_18 160 334.9 69.7 320.2 334.7 62.2 23.6483 6.05 
12. CNF_15 170 334.9 69.7 320.2 334.7 62.2 23.7422 5.95 
13. CNF_21 150 334.9 69.7 320.2 334.7 62.2 23.7704 6.15 
14. CNF_24 140 334.9 69.7 320.2 334.7 62.2 23.9774 6.15 
15. CNF_28 130 334.9 69.7 320.2 334.7 62.2 24.1841 6.25 
16. CNF_16 160 34.9 289.7 30.2 34.7 292.2 24.3245 5.55 
17. CNF_32 120 334.9 69.7 320.2 334.7 62.2 24.3255 6.35 
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18. CNF_19 150 34.9 289.7 30.2 34.7 292.2 24.3952 5.65 
19. CNF_36 110 334.9 69.7 320.2 334.7 62.2 24.3987 6.35 
20. CNF_11 180 334.9 69.7 320.2 334.7 62.2 24.4115 5.75 
21. CNF_13 170 34.9 289.7 30.2 34.7 292.2 24.448 5.45 
22. CNF_42 90 34.9 289.7 30.2 34.7 292.2 24.4602 6.15 
23. CNF_40 100 334.9 69.7 320.2 334.7 62.2 24.4681 6.45 
24. CNF_2 80 34.9 289.7 30.2 34.7 292.2 24.4715 6.05 
25. CNF_22 140 34.9 289.7 30.2 34.7 292.2 24.5117 5.85 
26. CNF_38 100 34.9 289.7 30.2 34.7 292.2 24.5393 6.05 
27. CNF_4 70 34.9 289.7 30.2 34.7 292.2 24.6103 6.05 
28. CNF_26 130 34.9 289.7 30.2 34.7 292.2 24.6265 5.95 
29. CNF_34 110 34.9 289.7 30.2 34.7 292.2 24.64 6.05 
30. CNF_30 120 34.9 289.7 30.2 34.7 292.2 24.6809 6.05 
31. CNF_9 180 34.9 289.7 30.2 34.7 292.2 25.7056 5.25 
32. CNF_7 190 334.9 69.7 320.2 334.7 62.2 26.3994 5.65 
33. CNF_14 170 4.9 299.7 60.2 354.7 312.2 26.7008 5.75 
34. CNF_17 160 4.9 299.7 60.2 354.7 312.2 26.7645 5.85 
35. CNF_10 180 4.9 299.7 60.2 354.7 312.2 26.8825 5.65 
36. CNF_20 150 4.9 299.7 60.2 354.7 312.2 26.8877 6.05 
37. CNF_23 140 4.9 299.7 60.2 354.7 312.2 27.0264 6.15 
38. CNF_27 130 4.9 299.7 60.2 354.7 312.2 27.1553 6.15 
39. CNF_31 120 4.9 299.7 60.2 354.7 312.2 27.2394 6.25 
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*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance. 
 
 
 
Figure A2. The lowest energy conformers of S equatorial-155 (CNF_15; pink), R equatorial 155 
(CNF_1; violet), S axial-155 (CNF_1; salmon), and R axial-155 (CNF_1; green).  
 
 
Discussion 
 
The systematic search on S-equatorial 155 and R-equatorial 155 resulted in only 15 (Table A1), 
and 16 (Table A3) isomers, respectively. Hence, we modified the Van der Waals radius scale 
factors general parameter to 0.7, and performed the systematic search as previously described. This 
40. CNF_35 110 4.9 299.7 60.2 354.7 312.2 27.2777 6.35 
41. CNF_39 100 4.9 299.7 60.2 354.7 312.2 27.3496 6.35 
42. CNF_6 190 4.9 299.7 60.2 354.7 312.2 28.1301 5.55 
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change resulted in 123 isomers for both S-equatorial 155 and R-equatorial 155. The lowest energy 
conformer for the S-equatorial isomer had the same energy as CNF_15 (Table A1), however, the 
distance of the aromatic (benzene-ring centroid) center from the amine increased to 5.95 Å. The 
lowest energy conformer for the R-equatorial isomer had the same energy and aromatic center 
(benzene-ring centroid) to amine distance as CNF_1 (Table A3).
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